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i. Abstract 
Parkinson's disease is the second most common neurodegenerative disease, affecting 
0.1 - 0.2% of the population. Incidence of this debilitating disorder rises to 1% of the 
population over the age of 65, posing a substantial socioeconomic burden on the UKs 
aging population. There are currently no disease altering treatments for PD, in part 
due to the incomplete knowledge of the disease mechanism.  
The misfolding and aggregation of the protein alpha-synuclein is associated with a 
range of neurological disorders, including Parkinson's disease. Alpha-synuclein has 
been irrefutably linked to Parkinson's disease through both genetic and pathological 
data, with increasing evidence suggesting prefibrillar oligomeric forms of the protein 
are the toxic species. However, the precise molecular mechanisms through which this 
protein is linked to the disease are currently unknown. Consequently, increasing 
knowledge of alpha-synuclein is of great importance, as new discoveries will 
potentially further the development of new therapeutics for the disease.  
In this thesis the primary aim was to conduct investigations into the structural and 
functional aspects of N-terminally acetylated alpha-synuclein and its oligomers 
through a combination of Electrospray Ionisation – Ion Mobility Spectrometry – Mass 
Spectrometry, biochemical and cell culture assays. Alpha-synuclein is a known metal 
binding protein and the copper binding and subsequent conformational changes and 
aggregation of modified and mutated forms of the protein were investigated. A novel 
loss of metal binding function was found for the N-terminally acetylated H50Q form of 
the protein. The conformational effects of N-terminal acetylation on the oligomeric 
forms of the protein were also investigated. It was demonstrated that this co-
translational modification of alpha-synuclein did not affect oligomer formation or 
function. Low order oligomers were found to be dynamic during the course of 
aggregation, by the use of isotopically labelled forms of the protein. Lastly the 
response of SH-SY5Y cells treated with alpha-synuclein oligomers with the ability to 
seed intracellular aggregation was investigated, demonstrating that this procedure 
evokes a stress response in these cells, highlighting a potential mode of action. 
Together, investigations presented in this thesis have demonstrated the role of a 
constitutive co-translational modification in ligand binding and oligomer assembly. 
Furthermore, the cellular stress response to treatment with these oligomers was also 
determined giving insights into disease progression. Results have highlighted the 
importance of using the biologically relevant form of a protein when performing in 
vitro experiments, validated the cellular effects of previously characterised alpha-
synuclein oligomers when produced from N-terminally acetylated protein, and 
extended knowledge of the cellular response of the SH-SY5Y cell line to treatment with 
a specific class of oligomers. 
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Chapter 1: General Introduction 
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1.1 Parkinson’s disease 
Parkinson's disease (PD) is a progressive, neurological condition estimated to affect 
between 1 and 2 of the population per 1000 in industrialised countries (von 
Campenhausen et al., 2005), meaning there are approximately 65000 - 130000 
individuals in the UK with the condition. The three main symptoms of PD are tremor, 
slowness of movement (bradykinesia) and rigidity. A wide range of other physical and 
psychological symptoms are often experienced, including depression, anxiety, balance 
problems, loss of sense of smell, insomnia, problems with urination and constipation, 
erectile and sexual dysfunction, swallowing difficulties and memory problems 
(Schapira, Chaudhuri and Jenner, 2017). 
The classical motor symptoms of PD are caused by a loss of dopaminergic neurons in 
the brain, leading to a reduction in dopamine levels. Motor difficulties arise as 
dopamine plays a vital role in regulating movement through acting as a 
neurotransmitter. As PD progresses the severity of symptoms escalate, leading it to be 
increasingly difficult for sufferers to live independently. The primary risk factor of PD is 
age, with incidence rising to 1% for the over 60's (de Lau and Breteler, 2006) and 2.6% 
for those between 85 and 89 (de Rijk et al., 2000). Consequently, PD will pose an 
increased social and economic burden on society in the UK, as the population ages. 
Current treatments for PD aim to ease symptoms, maintaining quality of life for as long 
as possible. However, no new classes of drugs have been introduced within the last 30 
years, and symptomatic treatment does not affect the progression of the disease. 
Medication is used to improve the main movement symptoms of PD by increasing 
levels of dopamine in the brain (reviewed by Connolly and Lang, 2014). The three main 
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types of medication commonly used are levodopa, dopamine agonists and monoamine 
oxidase-B inhibitors. Levodopa is absorbed by neurons, where it is converted into 
dopamine. Initially levodopa can have a significant positive effect on motor symptoms; 
however, its effects are gradually reduced as more neurons are lost to the disease, 
leaving fewer to absorb the levodopa. Dopamine agonists act as substitutes for 
dopamine in the brain and have a similar, but milder, effect compared to levodopa. 
Dopamine agonists can have a variety of undesirable side effects, such as 
hallucinations, confusion and the development of compulsive behaviours. Monoamine 
oxidase-B inhibitors increase dopamine by blocking the effect of monoamine oxidase-
B, an enzyme which breaks down dopamine. This improves symptoms of PD, but to a 
lesser degree than levodopa. While these treatments can provide relief from some PD 
symptoms, they lose their effectiveness as the disease progresses, leaving sufferers 
further debilitated as neurodegeneration continues. Despite decades of research, the 
cause of the loss of the dopamine producing neurons is still unknown. Therefore, we 
currently have no treatments to alter the progression of the disease. As such, further 
research to increase understanding of the cellular and molecular aspects of the 
aetiology of PD are required in order to develop disease altering treatments.  
1.1.1 Genetics of Parkinson’s disease 
 While the aetiology of PD is currently unclear, the majority of cases are sporadic, 
occurring in people with no clear family history of the disease. These cases are thought 
to most likely be the result of a complex interplay of environmental and genetic factors 
(Wirdefeldt et al., 2011). However, a small proportion of sufferers present with a 
family history of the disease, with familial instances accounting for approximately 5-
10% of total cases (Lesage and Brice, 2009). Genetic alterations found in these families 
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have given insights into the proteins and cellular pathways which may underlie the 
disease.  
Familial PD can be caused by alterations in several genes, with the most significant 
monogenic causes being highly penetrant mutations in SNCA, LRRK2, DJ-1, PINK1 and 
PRKN, as summarised in Table 1.1. An overarching theme of the function of these 
genes is that they are linked to either the protein degradation system, which when 
disrupted leads to an accumulation of potentially toxic proteins, or to mitochondrial 
quality and function, impairment of which leads to an accumulation of free radicals 
and oxidative stress (OS).  
 
Gene Locus Protein Inheritance Reference 
SNCA 4q21-23 Alpha-synuclein AD 
(Polymeropoulos 
et al., 1996) 
LRRK2 12q12 Leucine rich repeat kinase 2 AD 
(Paisán-Ruıź et 
al., 2004) 
DJ-1 1p36 
Protein/nucleic acid 
deglycase DJ-1 
AR 
(Bonifati et al., 
2003) 
PINK1 1p35-36 
Phosphate and tensin 
homolog-induced putative 
kinase 1 
AR 
(Valente et al., 
2004) 
PRKN 6q25.2-27 
E3 ubiquitin-protein ligase 
parkin 
AR 
(Kitada et al., 
1998) 
Table 1.1: Summary of monogenic alterations causative of familial PD 
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The inheritance pattern of PD is dependent on the affected gene, with SNCA and 
LRRK2 alterations being inherited in an autosomal dominant (AD) fashion and DJ-1, 
PINK1 and PRKN having autosomal recessive (AR) inheritance. A summary of these 
genes and their association with PD is provided below.  
1.1.1.1 SNCA 
The first genetic link to PD occurred in 1996, when Polymeropoulos et al. discovered a 
locus at 4q21-q23 which was associated with AD PD in a large Italian family 
(Polymeropoulos et al., 1996). Shortly after, the SNCA gene, encoding the protein 
alpha-synuclein, was mapped to this locus. Upon sequencing of the SNCA gene a 
mutation causing the substitution of an alanine at amino acid 53 with a threonine 
(A53T) was identified in this Italian family, in addition to three unrelated Greek families 
with high incidence of PD (Polymeropoulos et al., 1997). Subsequently the A53T 
mutation, along with five other point mutations (A30P, E46K, H50Q, G51D, and A53E), 
has been identified in many families of varied origin from around the world (Krüger et 
al., 1998; Zarranz et al., 2004; Lesage et al., 2013; Proukakis et al., 2013; Pasanen et al., 
2014). Copy number variation of SNCA have also been found to be associated with PD 
(La Cognata et al., 2017) displaying a dose-related phenotype, with severity of clinical 
presentation and disease progression correlating to SNCA dosage (Ross et al., 2008).  
In addition to the known, disease causing variants of alpha-synuclein, single nucleotide 
polymorphisms in the SNCA gene have consistently been found to be one of the main 
risk factors for sporadic PD by genome wide association studies (GWAS), with variants 
throughout the 5' region, 3' region and introns having a statistically significant effect 
on PD susceptibility (Loureiro, Campêlo and Silva, 2017). While the function of alpha-
synuclein is not well characterised, studies have shown a role for the protein in the 
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regulation of neurotransmitter release through mediation of vesicular trafficking 
(Vargas et al., 2014) and the maintenance of synaptic function and plasticity of 
dopaminergic neurons (Burré, 2015). Alpha-synuclein is the major constituent of Lewy-
bodies (LBs), amyloid containing structures which are found in surviving cells in PD 
patients on post mortem (Spillantini et al., 1997). 
1.1.1.2 LRRK2 
The first evidence that the LRRK2 gene was associated with PD came in 2002, when a 
locus at 12p11.2-q13.1 was linked to autosomal dominant Parkinsonism in a Japanese 
family (Funayama et al., 2002). In 2004 the LRRK2 gene was mapped to this locus 
(Paisán-Ruıź et al., 2004). LRRK2 mutations are the most common known contributor 
to PD, estimated to account for between 1-5% of sporadic cases and 5-20% of familial 
cases worldwide (Correia Guedes et al., 2010). Mutations in this gene display variable 
penetrance, depending largely on ethnicity (Ross et al., 2010), and usually present as 
mid-to-late onset with slow disease progression. Single nucleotide polymorphisms in 
the LRRK2 gene have also been consistently found as one of the main risk factors for 
sporadic PD by GWAS (Nalls et al., 2014).  
LRRK2 encodes for the highly conserved, multi-domain protein leucine rich repeat 
kinase 2 (LRRK2). Evidence suggests that LRRK2 plays an important role in the 
regulation of autophagy, vesicular trafficking and lysosome function (Roosen and 
Cookson, 2016). Many PD associated LRRK2 mutations affect the protein's enzymatic 
core (Rudenko and Cookson, 2014), with pathogenic mutations leading to altered 
kinase activity (Liao et al., 2014; Cookson, 2015). Mutations in LRRK2 have also been 
linked to mitochondrial impairment, resulting in a loss of mitochondrial function in 
neuronal cells and an increase in OS (Sanders et al., 2014).  
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1.1.1.3 DJ-1 
In 2003 it was discovered that mutations in DJ-1, encoding protein/nucleic acid 
deglycase DJ-1 (DJ-1), were associated with early onset, AR PD (Bonifati et al., 2003). 
DJ-1 has been associated with a number of cellular processes and is most widely 
accepted as having a role in the protection of neuronal cells from OS (Cookson, 2012). 
Mutations in the DJ-1 protein cause a loss of its protective properties against OS and 
DJ-1 knockout increases the vulnerability of cells to oxidative insult (Goldberg et al., 
2005).  
1.1.1.4 PINK1/PRKN 
In 1998 mutations in the PRKN gene were identified in a Japanese family with AR 
juvenile Parkinsonism (Kitada et al., 1998). Mutations in PRKN have since been 
identified in patients of many ethnicities, and are the most common cause of familial, 
early onset PD (Schulte and Gasser, 2011). PRKN encodes the E3 ubiquitin-protein 
ligase parkin (parkin) which plays a role in the proteasome degradation system through 
the ubiquitination of proteins, targeting them for degradation. PD associated parkin 
mutations result in a loss of E3 ligase function and subsequent toxic accumulation of 
proteins which cannot be degraded by the parkin dependent ubiquitin/proteasome 
pathway (Shimura et al., 2000). 
In 2004 mutations in the PINK1 gene were identified in an Italian family with AR, early 
onset PD (Valente et al., 2004). PINK1 encodes the phosphate and tensin homolog-
induced putative kinase 1 (PINK1), which is believed to work together in a common 
pathway with parkin to regulate mitochondrial quality control. PINK1 accumulates on 
the outer membrane of damaged mitochondria, recruiting and activating parkin, which 
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ubiquitinates proteins on the outer membrane of the mitochondria, triggering 
autophagy (Pickrell and Youle, 2015).  
In addition to the five well characterised PD causative genes described here, 
polymorphic variants in many additional genes have been linked to PD susceptibility, 
with GWAS highlighting new associations as more studies are carried out. A recent 
meta-analysis of GWAS identified 41 risk loci for PD, many of which encoded genes 
involved in lysosomal biology, mitochondrial biology and autophagy (Chang et al., 
2017). Overall, mutations associated with PD mainly appear to disrupt the protein 
degradation system or affect mitochondrial quality and function. The genetics of PD is 
complex but has contributed to understanding of the pathogenesis of the disease, 
which may by extension ultimately be leveraged for therapeutic benefit. 
1.1.2 Pathophysiology of Parkinson’s disease 
While external examination of the PD brain is typically unremarkable, two major 
neuropathological findings are most commonly found (Mackenzie, 2001). The first is a 
loss of pigmented dopaminergic neurons in the substantia nigra pars compacta (SNpc), 
found upon examination of brain sections, an example of which is shown in Figure 1.1 
(a). It is thought that around 50% of nigral neurons are lost before the motor 
symptoms of PD begin to appear, and on autopsy a loss of over 80% is typically seen 
(Hartmann, 2004). The significant loss of neuromelanin-pigmented neurons in the 
SNpc, and subsequent dopamine deficit in the nigrostriatal system, represent the most 
important hallmark of PD, leading to the major motor symptoms observed in patients. 
The second major neuropathological finding in PD is the presence of LBs, metal rich 
proteinaceous inclusions found in surviving neurons which are comprised mainly of 
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alpha-synuclein in the form of amyloid fibrils (Spillantini et al., 1997). A variety of other 
proteins are detectable in LBs, most notably ubiquitin, neurofilament protein, heat 
shock proteins and tau (Goedert et al., 2012). The presence of ubiquitin is indicative of 
LBs representing a structural manifestation of a protective cellular response. Classical 
LBs are spherical, intracytoplasmic neuronal inclusions with a typical diameter 
between 8 µm and 30 µm. Upon H&E staining they have an eosinophilic hyaline core 
and a pale peripheral halo, as shown in Figure 1.1 (b).  
 
 
Figure 1.1: Example images of typical PD pathology. Shown in (a) is horizontal sections 
of midbrain from a patient with PD (P) and a normal control (C), where a loss of 
pigmentation in the SN in PD can be seen. Shown in (b) is H&E staining of a pigmented 
neuron from a PD patient (nucleus highlighted with an arrow), containing two Lewy 
bodies, highlighted with arrowheads. Image adapted from Mackenzie (2001).
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The presence of alpha-synuclein in LBs has warranted significant attention, particularly 
as the protein is strongly linked to PD through genetic evidence, as described in 
Section 1.1.1.1. Therefore, both genetic and pathological evidence point towards 
alpha-synuclein playing a key role in the pathogenesis of PD. Research into alpha-
synuclein has been an extremely active field over the past 20 years and investigations 
of this protein are the focus of this thesis.  
1.2 Proteins 
Proteins constitute the major building blocks of the cell, being fundamental 
components of almost every function involved in life. Proteins are biological polymers 
of amino acids linked by an amide bond. Amino acids are small, organic molecules 
consisting of an amino group (-NH2), a carboxyl group (-COOH), a hydrogen atom and a 
variable R group, as shown in Figure 1.2. It is this variable R group which defines the 
properties of an amino acid. Proteins have innumerable cellular functions, and typically 
adopt a unique structure which determines this function. There are four levels of 
protein structure, as shown in Figure 1.3. 
 
Figure 1.2: Diagram of an amino acid. The common structure of amino acids, 
consisting of an amino group, a carboxyl group, a hydrogen atom and a variable R 
group.
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Figure 1.3. Illustration of the various levels of protein structure. Adapted from (Wijaya, 
Wijaya and Mehta, 2015). 
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Primary structure refers to the order of amino acids which make up the polypeptide 
chain of a protein. It is this sequence of amino acids which determines a protein's 
ultimate structure, with the variable R groups of the amino acids interacting and 
forming non-covalent bonds. Secondary structure refers to stretches of proteins 
adopting distinct, characteristic local conformations dependent on hydrogen bonding, 
with the two main types being α-helices and β-sheets. Tertiary structure refers to the 
three dimensional (3D) arrangement of these local structural conformations, with the 
protein adopting a conformation to achieve maximum stability or lowest energy state. 
In a protein made up of multiple polypeptide chains, quaternary structure is the 3D 
arrangement of these protein subunits. Most proteins require a complex folding 
process after they are synthesised to be able to acquire their correct tertiary or 
quaternary structure. Proteostasis, the management of this folding procedure, 
comprises a quality control network of hundreds of proteins (Hartl, Bracher and Hayer-
Hartl, 2011). If this process becomes impaired, protein folding is compromised, which 
can lead to abnormal aggregation or mislocalisation of proteins (Schneider and 
Bertolotti, 2015). 
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1.2.1 Intrinsically disordered proteins 
Challenging the traditional model that protein structure governs its function, many 
biologically active proteins possess substantial regions lacking a stable secondary 
structure, which are termed Intrinsically Disordered Proteins (IDPs). Alpha-synuclein is 
an example of such a protein. Despite lacking significant secondary structure, IDPs 
have been shown to be involved in many biological functions (Uversky, 2011) such as 
cell signalling (Iakoucheva et al., 2002) and transcription (Minezaki et al., 2006), often 
gaining structure on the binding of ligands. IDPs typically contain a low proportion of 
hydrophobic and order promoting amino acids, and a high proportion of charged and 
disorder promoting amino acids (Dyson, 2016; Uversky, 2016), leading to flexible and 
highly heterogenic conformations. Numerous IDPs have been implicated in disease, 
such as p53 in cancer, amyloid beta in Alzheimer’s disease and alpha-synuclein in 
Parkinson’s disease (reviewed by Babu, 2016). 
1.2.2 Protein aggregation 
Protein aggregation is a common feature in nature, with functional amyloids playing 
important roles in processes such as structure and protection, cell-cell recognition and 
epigenetic inheritance (Pham, Kwan and Sunde, 2014). However, the misfolding and 
subsequent aggregation of proteins is known to be implicated in the pathogenesis of 
many disease states, termed protein misfolding diseases.  
A common feature of protein misfolding diseases is the presence of amyloid fibrils 
found deposited in various organs and tissues. Amyloid fibrils are protein aggregates, 
formed from normally soluble proteins which assemble to form insoluble fibers which 
are resistant to degradation. Despite being made from various different proteins, 
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amyloid fibrils share many characteristics, including a common structure, a typical X-
ray diffraction pattern and common histological characteristics. The common structure 
of amyloid fibrils consists of a regular cross beta structure, with beta sheets stacked 
parallel to the fibril axis. The fibrils are unbranching assemblies, many μm in length and 
typically 5 - 15 nm wide under electron microscopy (Toyama and Weissman, 2011). A 
variety of possible protein species can be populated during the aggregation pathway, 
as described in Figure 1.4. 
 
 
Figure 1.4: Illustration of the possible species adopted by proteins during the 
aggregation process. Image taken from (Invernizzi et al., 2012). 
 
Many neurodegenerative diseases are associated with abnormal protein aggregation 
and the proteins implicated in such disease states are frequently IDPs. Understanding 
the aggregation process of proteins implicated in these diseases is an important area 
of research, in order to facilitate the design of therapeutics capable of disrupting the 
aggregation process. However, the precise mechanisms by which aggregation occurs 
and triggers disease remain largely unknown (Eisele et al., 2015). 
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1.3 Alpha-synuclein 
1.3.1 Physiological role of alpha-synuclein 
Alpha-synuclein is a highly abundant protein in the brain. Accounting for 
approximately 1% of total protein in neuronal cells (Mizuno et al., 2012), alpha-
synuclein is mainly localised to the presynaptic terminals of neurons (Iwai et al., 1995). 
While the precise physiological function of alpha-synuclein is largely unknown, it is 
believed to contribute to activity at the synapse (reviewed by Burré, 2015). Specifically, 
it is thought to be involved in the regulation of neurotransmission through 
participation in vesicular trafficking and neurotransmitter release (Clayton and George, 
1998), and has been demonstrated to interact with various components of the SNARE 
complex (Burré et al., 2010). In addition to being abundant in the brain, alpha-
synuclein is found in many other tissues, including the skin (Rodríguez-Leyva et al., 
2014), heart (Iwanaga et al., 1999) and gastrointestinal tract (Shannon et al., 2012), 
suggesting its function may be more varied than purely the regulation of 
neurotransmission. Animal and cellular models have implicated a possible involvement 
of alpha-synuclein in many biological functions, including dopamine biosynthesis 
(Perez et al., 2002), metal binding (Tavassoly et al., 2014), mitochondrial function 
(Pozo Devoto and Falzone, 2017) and microtubule organisation (Cartelli et al., 2016).  
1.3.2 Alpha-synuclein structure 
Structurally, alpha-synuclein is generally agreed to be an intrinsically disordered, 
negatively charged protein comprised of 140 amino acids. However, in recent years 
alpha-helical tetrameric forms of the protein have been reported (Bartels, Choi and 
Selkoe, 2011; Wang et al., 2011). However this theory remains to be confirmed, as 
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other groups report an intrinsically disordered structure when the protein is purified 
under similar conditions (Fauvet et al., 2012). In addition, in-cell nuclear magnetic 
resonance spectroscopy (NMR) has shown the protein remains in an intrinsically 
disordered state when introduced to the cell by electroporation (Theillet et al., 2016). 
Alpha-synuclein can be split into three main regions as shown in Figure 1.5; the N-
terminal region (amino acids 1-65), the central region (amino acids 66-95) and the C-
terminal region (amino-acids 96-140). The N-terminal region contains seven series of 
11 amino acid imperfect repeats, with a conserved KTKEGV hexameric motif, which is 
similar to repeats found in the alpha-helical domain of apolipoproteins (George et al., 
1995). This region of alpha-synuclein is known to be able to bind to lipids, forming 
amphipathic alpha-helices (Bussell and Eliezer, 2003). The alpha-helical form of alpha-
synuclein has been found to have a reduced tendency to aggregate in vitro (Zhu and 
Fink, 2003) and these repeats have been linked to inhibition of this protein adopting a 
beta-sheet structure (Kessler, Rochet and Lansbury, 2003). Interestingly, all six of the 
familial alpha-synuclein mutations (A30P, E46K, H50Q, G51D, A53T and A53E) reside 
within this N-terminal region, and it has been suggested that the KTKEGV motif plays 
an important role in maintaining the intrinsically disordered structure of the protein 
(Sode et al., 2007). The central region of alpha-synuclein contains the non-amyloid-β 
component (NAC) sequence between residues 71 and 82, which has been shown to be 
essential to the protein's aggregation (Giasson et al., 2001). The C-terminal region is 
largely unfolded and rich in acidic residues, giving the protein its overall negative 
charge. This region of the protein is known to be important in the inhibition of alpha-
synuclein assembly through interfering with molecular interactions of the NAC region 
(Murray et al., 2003). The C terminus of the protein contains the most common post-
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translational modification site of the protein; the phosphorylation of the serine residue 
at position 129. This modification is highly associated with PD, with approximately 90% 
of the alpha-synuclein found in LBs being phosphorylated at this site compared to 
approximately 4% which is found to be phosphorylated within the cytosol (Walker et 
al., 2013).  
 
 
Figure 1.5: The structure of alpha-synuclein. Alpha-synuclein is a 140-residue protein 
comprised of three distinct regions; the highly conserved N-terminus, containing a 
series of imperfect KTKEGV repeats involved in lipid binding, the central non amyloid- 
β component (NAC) which is essential for the protein's aggregation, and the largely 
unfolded, negatively charged C-terminus. Known familial mutations are shown in pink 
and acetylation/phosphorylation sites are shown in blue.  
 
1.3.3 Alpha-synuclein aggregation 
Alpha-synuclein is thought to be natively unfolded at neutral pH due to its low intrinsic 
hydrophobicity and high net negative charge, evidence for which has been provided by 
a number of techniques including far-UV circular dichroism and NMR (Eliezer et al., 
2001). However, there has been debate regarding its in vivo conformational state as 
described above, with some believing the physiological form of the protein to be the 
tetramer. What is clear is that the highly ordered fibrillar form of alpha-synuclein 
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found in LBs in not the normal state of the protein in healthy individuals. However, the 
exact mechanism of alpha-synuclein aggregation is still uncertain, and currently it is 
not known whether the aggregation of the protein is a cause or a consequence of PD.  
It is thought that alpha-synuclein is involved in PD through misfolding of the usually 
disordered monomer into highly structured, beta-sheet rich amyloid fibrils via a 
population of potentially transient toxic soluble oligomers and protofibrils (discussed 
in detail in Section 4.1.1). The formation of these oligomers is preceded by the collapse 
of extended forms of the protein into a partially folded intermediate (Uversky, Li and 
Fink, 2001a). Further fibrillation of alpha-synuclein is a nucleation dependent process 
(Conway, Harper and Lansbury, 2000), where the disordered monomer first assembles 
into soluble oligomers during an initial lag phase until a nucleus is formed. Aggregates 
then form rapidly around this nucleus during an elongation phase, until a 
thermodynamic equilibrium between fibrillar aggregates and monomer is established. 
The familial PD mutations have been shown to alter alpha-synuclein oligomerisation 
and subsequent aggregation (Winner et al., 2011), demonstrating a probable role for 
alpha-synuclein misfolding and aggregation in PD. Ligand binding has also been 
demonstrated to effect alpha-synuclein aggregation, with binding of some compounds 
such as divalent metal cations (Han, Choi and Kim, 2018) and biological polyamines 
(Krasnoslobodtsev et al., 2012) increasing aggregation, and others such as squalamine 
(Perni et al., 2017) and curcumin (Herva et al., 2014) decreasing aggregation. 
1.4 Mass spectrometry 
Mass spectrometry (MS) is a powerful analytical technique used to identify the 
molecular mass and relative abundance of ions within a sample and is particularly 
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suited to the study of diverse and transient non-covalent complexes such as amyloid 
oligomers. Mass spectrometers consist of three fundamental components; an 
ionisation source, analyser and detector. Samples are introduced into the mass 
spectrometer via an ionisation source, which generates gas phase ions from the 
analyte. Ions are then separated by one or more mass analysers, based on their mass 
(m) to charge (z) ratios (m/z). The separated ions then reach a detector which 
measures the relative abundance of each ion of a particular m/z, converting it to an 
electrical signal and presenting this information in the form of a mass spectrum. 
Many different configurations of mass spectrometers are commercially available, with 
diverse combinations of ionisation source, mass analysers and detectors. MS data 
presented in this thesis were predominantly obtained on a Waters SynaptTM G2 HDMS 
instrument (Waters Corporation, Wilmslow, Manchester, UK), using a TriVersa 
NanoMate electrospray ionisation (ESI) source (Advion, Ithaca, USA). The ESI process is 
described in detail below.   
1.4.1 Electrospray Ionisation 
ESI is an atmospheric pressure ionisation technique, well suited to the analysis of polar 
molecules of a wide range of molecular mass. It is a soft ionisation technique, meaning 
a sample is ionised by the addition or removal of a proton with little extra energy 
remaining. This allows the sample to be analysed with little or no fragmentation and, 
depending on the conditions used, can preserve sample conformation and non-
covalent interactions (Gaskell, 2009). As such, ESI is one of the main ionisation 
methods used in the analysis of biomolecules. ESI commonly uses samples dissolved in 
a polar, volatile solvent such as ammonium acetate (AA). The sample passes through a 
fine needle to which a high voltage is applied. In positive ion mode (which is frequently 
 37 
used for protein analysis, and used exclusively in this thesis) a positive voltage is 
applied to the needle and a negative voltage applied to the counter-electrode in the 
instrument. This leads to a build-up of protons at the tip of the needle. As a 
consequence of this strong electric field the sample emerging from the tip is dispersed 
into an aerosol of highly charged droplets, aided by introducing nitrogen as a 
nebulising gas flowing around the outside of the capillary. This flow of gas directs the 
Taylor cone towards the mass spectrometer. As the charged droplet travels towards 
the sample cone, evaporation of the solvent occurs. This results in a reduction of 
droplet size, which becomes unstable as it reaches its Raleigh limit, where the surface 
tension is balanced by Coulombic repulsion. At this stage the droplet undergoes 
Coulombic explosion, resulting in many smaller, more stable droplets which in turn 
undergo desolvation and consequently more Coulombic explosion events.  
NanoElectroSpray Ionisation (nESI) is a variant of conventional ESI developed by Wilm 
and Mann (Wilm and Mann, 1994) where needle tip openings of only a few µm are 
used rather than the ~100 µm openings seen in conventional ESI. In nESI a reduced 
flow rate is used (<10 nL per minute versus ~1-10 µL per minute typically utilised in 
conventional ESI), resulting in lower sample consumption. nESI is a softer ionisation 
mechanism than conventional ESI, requiring lower capillary voltages and gas flows. The 
initial nESI droplet size is smaller than ESI and therefore droplets undergo fewer 
solvent evaporation and Coulombic explosion cycles prior to ion production. This soft 
ionisation mechanism makes nESI ideal for acquiring mass spectra of intact, 
noncovalent complexes. nESI also allows improvements in sensitivity and ionisation 
efficiency (Karas, Bahr and Dülcks, 2000; Konermann et al., 2013). 
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Gas phase ions are formed when the ion is released from the droplet and the charge is 
transferred onto the analyte (Figure 1.6). It is believed that the exact mechanism 
through which an analyte is released from the droplet is dependent on the properties 
of the analyte. Three main models by which ions may be released from the charged 
droplet have been proposed; the ion evaporation model (IEM), the charged residue 
model (CRM) and the chain ejection model (CEM). In the IEM, low molecular weight 
charged species are emitted from nanometer-sized droplets, which have shrunk by 
evaporation until the field strength at the surface of the droplet is large enough for 
ions to be expelled (Nguyen and Fenn, 2007). In the CRM a solvent droplet containing a 
single analyte fully evaporates, with the residual charge being transferred to the 
analyte inside (Fernandez de la Mora, 2000). The most recently proposed model is the 
CEM, in which a disordered polymer is partially ejected from the droplet after 
migrating to the surface of the droplet due to the exposure of hydrophobic residues. 
This leads to protons attaching to the exposed portion of the ion, followed by further 
extrusion and ultimate ejection of the extended chain (Konermann et al., 2013). Much 
of the current evidence suggests that folded proteins formed by ESI from buffered 
aqueous solution ionize by the CRM, small ions by the IEM, and unfolded, disordered 
proteins by the CEM (Donor et al., 2017). A schematic illustrating these three models 
of ion formation by ESI is shown in Figure 1.7.  
The ESI process gives rise to multiply charged protein ions, with the number of charges 
transferred onto an analyte being dependent on its accessible surface area and 
presence of ionisable functional groups. During acquisition a range of different charge 
states of the same protein may be observed, referred to as the proteins charge state 
distribution (CSD). The CSD is largely influenced by the folded state of the solution 
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phase protein. Folded proteins are known to display a narrow CSD with lower average 
charge, due to a limited number of charged residues on their surface. An unfolded 
protein will display a wide CSD with higher average charge, due to a higher number of 
charged ionisation sites being accessible (Vahidi, Stocks and Konermann, 2013).  
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Figure 1.6: Schematic of electrospray ionisation. Multiply charged droplets are expelled from the needle. Solvent evaporation occurs followed by 
columbic explosion, resulting in protonated analyte ions which enter the mass spectrometer in the gas phase. 
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Figure 1.7: Summary of electrospray ionization mechanisms. Schematic of the three main proposed mechanisms of ESI. In the IEM small ions are 
emitted from droplets which have shrunk until the field strength at the surface is large enough for ions to be expelled. In the CRM a droplet 
containing a single analyte evaporates with the residual charge being transferred to the analyte. In the CEM a disordered polymer is partially ejected 
from the droplet where protons attach to the exposed portion, followed by further extrusion and ultimate ejection of the extended chain. 
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Based on the CRM, the number of charges that a protein will obtain can be estimated 
based on the mass of the protein when acquired from aqueous ammonium acetate at 
neutral pH (Peschke, Blades and Kebarle, 2002). The calculated charge can be 
estimated by the Rayleigh limit, with the size equivalent to the protein in question as 
follows. 
 
𝑧𝑅 = 8𝜋/𝑒(𝛾𝜀0𝑅
3)
1
2 
Equation 1: Predicted charge calculation, where γ is the surface tension of the aqueous 
solution droplet, ε0 is the empirical permittivity of the vacuum, e is the elementary 
charge and R is the radius of the droplet. 
 
Making the assumption that the radius of the protein correlates to its mass, and its 
density is similar to water, a simplified equation can be created as shown below: 
 
𝑧𝑅 = 0.078 𝑀
1
2 
Equation 2: Calculated charge of a protein (zR), in which M is the Mass in Da. 
 
Therefore an 18.4 kDa folded globular protein for example would be expected to have 
11 charges and a 36.9 kDa globular dimer would accommodate 15 charges and a 72.7 
kDa heptamer would possess 21 charges (Heck and Van Den Heuvel, 2004). If the 14 
kDa alpha-synuclein monomer had a folded, globular conformation it would be 
expected to acquire 9 charges if ionised by the CEM.   
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1.4.2 Overview of the Synapt G2 HDMS 
Following ionisation of the sample, resulting ions were analysed using a SynaptTM G2 
HDMS on the basis of both their m/z values and their arrival time through a drift tube, 
from which collisional cross sectional area (Ω) was calculated.  Figure 1.8 shows an 
overview of the transit of the ions through the SynaptTM G2 HDMS used within this 
thesis. Analyte ions in the gas phase first pass through the sample cone where they 
enter an intermediate vacuum region, and from here pass into the mass spectrometer, 
which is held under high vacuum to prevent ions being hindered by air molecules on 
their journey through the instrument. Ions travel through a stacked ring ion guide 
towards the quadrupole mass analyser, where ions of a certain m/z can be selected if 
required for tandem MS analysis. Ions subsequently enter the tri-wave region of the 
instrument, where ion mobility spectrometry (IMS) is carried out, allowing the 
detection of an ions arrival time, and subsequent calculation of Ω. The tri-wave region 
consists of three cells; the trap cell, IMS cell and transfer cell. Ions enter the trap cell, 
which is pressurised by argon, where pockets of ions are collected before entering the 
IMS cell. The IMS cell consists of a helium pressurised gate region where ions are 
pulsed into the nitrogen pressurised section of the IMS cell, where ion mobility 
separation occurs. The process of IMS is described in detail in Section 1.4.3. Ions then 
enter the argon pressurised transfer cell, where ions are collected before being pushed 
as packets of ions into the time-of-flight (TOF) mass analyser. TOF analysers are based 
on the principle that the time taken for an ion to travel a known distance under high 
vacuum is directly related to its m/z ratio. A reflectron at the end of the flight tube aids 
in the correction of the difference in kinetic energy distributions of ions of the same 
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m/z, reducing peak broadening and therefore increasing resolution (Wollnik and 
Przewloka, 1990). 
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Figure 1.8: Schematic of the Waters SynaptTM G2 HDMS instrument. Image reproduced from The University of Warwick showing the main 
components of the Synapt G2 HDMS; the ionisation source, the quadrupole mass analyser, the triwave ion mobility separation region and the 
QuanTOF mass analyser. 
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1.4.3 Ion mobility spectrometry 
IMS is a widely used technique which separates gas phase ions based on differences in 
their mobility through a buffer gas under a weak electric field. Mobility is quantified as 
the time taken for an ion to traverse through a drift tube of a given length. The time an 
ion will take is dependent on its charge, mass and conformation. IMS provides 
structural information in the form of calculated rotationally averaged Ω, providing a 
valuable structural biology tool for characterising co-populated protein conformations 
under varying conditions. The Ω of an ion is a calculation of the momentum transfer of 
its average area as it tumbles through a gas, and is typically measured in Angstroms 
squared (Å2). Ω is related to the chemical structure (mass and size) and three-
dimensional conformation (or shape) of an ion. Ω is not an intrinsic property of an 
analyte, as measured Ω is additionally dependent on the identity of drift gas used, 
experimental temperature and the electric field used during the measurements (May, 
Morris and McLean, 2017).   
Coupled to MS, IMS is capable of separating isobaric species in complex samples, 
enabling structural information about a given ion to be gained often in comparison to 
model structures whose Ω has been determined in silico. IMS is able to distinguish 
isobaric species as the mobility of an ion is dependent on its conformation (in addition 
to its m and z). If two given ions have identical m and z, but different conformations, 
the ion with the smaller Ω will traverse the length of a drift tube more rapidly than the 
ion with larger Ω. This occurs as the larger ion is slowed due to increased collisions 
with the buffer gas (Cumeras et al., 2015).   
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1.4.3.1 Drift time ion mobility 
There are two main types of drift tubes commonly used for IMS of proteins, traditional 
drift time ion mobility (DTIMS) and travelling wave ion mobility (TWIMS). DTIMS 
measures the time taken for an ion to traverse through a drift tube filled with a buffer 
gas (typically nitrogen or helium), in the presence of a uniform electric field. Ω can be 
directly measured from DTIMS using the Mason-Schamp equation (Mason and 
Schamp, 1958), described below.  
𝐾 =  
𝑣𝐷
𝐸
 
Equation 3 
 
The mobility of a gas phase ion (K) is defined by its drift velocity (vD) divided by the 
electric field (E). As the drift velocity (vD) is related to the drift time (tD) taken to 
traverse the length (L) of the drift tube, the mobility of an ion can be experimentally 
determined from its observed drift time as shown in Equation 4: 
𝐾 =  
𝑣𝐷
𝐸
=  
𝐿
𝑡𝐷𝐸
 
Equation 4 
 
As the density of the buffer gas influences the mobility of an ion, reduced mobility (K0) 
is generally used, where P is the pressure of the buffer gas and T is the temperature of 
the buffer gas, which are normalised to a standard buffer gas pressure of 760 torr and 
temperature of 273.2K to provide a basis for comparison of results: 
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𝐾0 =  𝐾 ×  
273.2
𝑇
 × 
𝑃
760
 
𝐾    0  =  
𝐿
𝑡𝐷𝐸
 ×  
273.2
𝑇
 ×  
𝑃
760
 
Equation 5 
 
Once the mobility of an ion (K) has been established, Ω can then be calculated using 
the following equation, where z is the number of charges on the analyte ion, e is the 
charge on an electron (1.6022 × 10–19 C), kb is the Boltzmann constant, T is the 
temperature and N is the number density of the buffer gas and [
1
𝑚𝐼
+
1
𝑚𝑁
] is the 
reciprocal of the reduced mass between the analyte ion (mI) and the buffer gas (mN): 
𝐾 =  
(18𝜋)
1
2
16
 
𝑧𝑒
(𝑘𝑏𝑇)
1
2
[
1
𝑚𝐼
+
1
𝑚𝑁
]
1
2 1
𝑁
1
Ω
 
Equation 6 
 
Substituting the definition for K in terms of K0 and rearranging the equation to make Ω 
the subject describes the proportionality between Ω and average drift time (tD): 
Ω =  
(18𝜋)
1
2
16
 
𝑧𝑒
(𝑘𝑏𝑇)
1
2
[
1
𝑚𝐼
+
1
𝑚𝑁
]
1
2 760
𝑃
𝑇
273.2
1
𝑁
𝑡𝐷𝐸
𝐿
 
Equation 7 
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From this equation the Ω of an ion can be determined by recording its drift time 
through a buffer gas filled conventional ion mobility cell at a range of electric fields. 
1.4.3.2 Travelling wave ion mobility 
Ion mobility data presented in this thesis was acquired by TWIMS. This technique is 
similar to DTIMS, but rather than the ions being under the influence of a constant, 
uniform electric field they are subject to a voltage pulse, creating a travelling wave of 
electric potential that varies with both time and the length of the mobility device. The 
drift tube of the TWIMS cell in the SynaptTM G2 HDMS is composed of a series of 
stacked ring ion guides (SRIG) which carry opposite radio frequency (RF) voltages on 
adjacent rings, providing a radially confining potential barrier for the ions. Ion mobility 
separation occurs due to the combination of a SRIG with a travelling voltage wave 
superimposed on the confining RF voltage, causing ions to roll over the top of the 
travelling waves as they traverse the cell, with lower mobility ions rolling over more 
times than the higher mobility ions, giving a longer drift time, as illustrated in Figure 
1.9 (Giles et al., 2004). Unlike DTIMS, it is not possible to directly measure Ω from 
TWIMS as the traveling-wave transport of ions is not well characterised. Although the 
arrival time obtained from a TWIMS device cannot be used to directly derive Ω, it can 
be accurately estimated through calibration of the T wave against standards of known 
Ω, protocols for which have been described in detail by a number of groups (Ruotolo et 
al., 2008; Smith et al., 2009; Thalassinos et al., 2009; Bush et al., 2010).  
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Figure 1.9: Schematic of ion mobility separation via a stacked-ring ion guide. Schematic 
of the SRIG carrying opposite RF voltages on adjacent rings found in the TWIMS cell of 
the Synapt G2 HDMS shown in (a). An illustration of the motion of the travelling wave 
superimposed on the confining RF voltage, causing ions of lower mobility to roll over 
the top of the travelling waves as they traverse the cell, allowing separation on the 
basis of mobility shown in (b).  
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In order to calculate Ω from TWIMS, correction factors must be incorporated into the 
conventional ion mobility equations developed for linear drift tubes to take into 
account the non-linear effects of the TWIMS instruments. These correction factors can 
be determined empirically through experimental calibration once acquisition 
parameters have been optimised. In the following equation, A is the correction factor 
for the electric field parameters (E and L in conventional ion mobility equations) and B 
is a compensatory factor for the non-linear effect of the TWIM instrumentation: 
Ω =  
(18𝜋)
1
2
16
 
𝑧𝑒
(𝑘𝑏𝑇)
1
2
[
1
𝑚𝐼
+
1
𝑚𝑁
]
1
2 760
𝑃
𝑇
273.2
1
𝑁
𝐴𝑡𝐷
𝐵 
Equation 8 
Ω can be defined as a charge and mass independent measure, reduced Ω (Ω'), by 
dividing the above equation by the absolute charge (ze) and reduced mass as shown in 
equation 9: 
Ω′ =  
(18𝜋)
1
2
16
 
1
(𝑘𝑏𝑇)
1
2
760
𝑃
𝑇
273.2
1
𝑁
𝐴𝑡𝐷
𝐵 
Equation 9 
These parameters can then be incorporated into one constant, A’ as shown in equation 
8. A’ is a correction factor for the temperature, pressure and electric field and B is a 
correction factor for the non-linear effects of the TWIMS device: 
Ω′ =  𝐴′𝑡𝐷
𝐵
 
Equation 10 
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Ω can therefore be expressed as equation 11: 
Ω =   𝑧𝑒 [
1
𝑚𝐼
+
1
𝑚𝑁
]
1
2
𝐴′𝑡𝐷
𝐵
 
=   𝑧𝑒 [
1
𝑚𝐼
+
1
𝑚𝑁
]
1
2
Ω′ 
Equation 11 
It is also necessary to compensate for the mass dependent transit time of an ion 
outside of the mobility region of the instrument, which is achieved by use of equation 
12: 
𝑡′𝐷 =  𝑡𝐷 − (𝐶√𝑚 𝑧⁄  /1000) 
Equation 12 
Where t'D is the corrected drift time (msec), tD is the measured drift time (msec) and C 
is a constant, found in the control software as the enhanced duty cycle delay 
coefficient.  
Given a known charge, mass and Ω, the Ω' of an ion can be determined empirically. A’ 
and B can be determined experimentally from drift times (tD) obtained from a range of 
multiply charged ions of known protein standards with known Ω. Ω can then be 
plotted against tD, an example of which is shown in Figure 1.10. A calibration curve can 
then be obtained from fitting these data to the equation y = A'xB, giving empirically 
determined values for A' and B. From this calibration curve the calculation of Ω of an 
analyte of interest can be determined from its drift time (Smith et al., 2009).  
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Figure 1.10: Example calibration curve of denatured standards of known Ω. Ω' versus 
drift time (msec) for multiply charged ions of cytochrome c, myoglobin and ubiquitin 
under denaturing solution conditions. 
 
1.4.4 ESI-IMS-MS of biological systems 
The study of proteins by IMS-MS was enabled through the development of ESI, 
allowing intact proteins and protein complexes to be transferred into the gas phase. 
ESI-MS and ESI-IMS-MS have emerged as useful tools for the study of many biological 
systems, with applications in many areas, such as the study of protein subunit 
stoichiometry, protein modifications and ligand binding and protein-metal interactions 
(reviewed by Sharon and Robinson, 2007). 
ESI-MS and ESI-IMS-MS have also proved to be key techniques in the study of protein 
structure. In order to apply MS based techniques to the study of protein structure, 
successful retention of structure must be maintained on transition from solution phase 
to the gas phase. Early papers within the field reported that experimentally observed 
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Ωs were in good agreement with measurements obtained from more traditional 
analysis techniques such as X-ray crystallography and NMR, or from theoretical values  
(Scarff et al., 2008; Smith et al., 2009; Leney et al., 2014). Growing evidence supports 
the retention of solution structures in the gas phase (Ruotolo et al., 2002; Ouyang et 
al., 2003; Florance et al., 2011), providing experimental design and instrumental 
conditions have been carefully considered (Breuker and McLafferty, 2008; Chen and 
Russell, 2015).  
Gross structural information of a protein can be inferred from MS alone through 
assessment of its CSD. Typically, compact proteins will present with few charge states 
due to limited ionisable sites being present on their surface, while more disordered or 
unfolded proteins have more exposed ionisable sites, and therefore a wider CSD (Testa 
et al., 2013). Gaussian fitting of a protein’s CSD can aid in the investigation of different 
conformers present in the sample, and in this way the effect of variables such as 
solution conditions or ligand binding on gross conformation can be analysed.  
However, such analysis is complicated by multiple species presenting at the same m/z, 
either through overlapping conformational families of the presence of oligomeric 
species. The presence of such species can be resolved through the addition of IMS, 
which enables their separation and interrogation, providing another dimension to 
conformational analysis. Pivotal examples where IMS and MS have been utilised in the 
study of protein structure include studies from the Robinson group into the self-
assembly of insulin aggregates, demonstrating that MS can identify the solution states 
of oligomeric proteins (Nettleton et al., 2000), studies from the Bowers group 
investigating the conformation of biological molecules such as Bradykinin 
(Wyttenbach, von Helden and Bowers, 1996) and trinucleotides (Gidden and Bowers, 
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2003), studies from the Jarrold group investigating the conformations of bovine 
pancreatic trypsin inhibitor and cytochrome C (Shelimov et al., 1997), and studies from 
the Clemmer group investigating the effect of experimental conditions on ubiquitin 
conformers (Li et al., 1999).  
The study of amyloid formation is one biological system which has benefited greatly 
from the advances in ESI-IMS-MS, as understanding the morphological transitions 
which occur at early stages of protein aggregation is of critical importance for 
developing diagnostic and therapeutic strategies for amyloid diseases. This technique 
has been used extensively in the study of early stages of aggregation of proteins 
implicated in protein misfolding diseases, providing valuable information on the co-
existing, transient conformations which often exist during this process. Key examples 
include investigations into the Alzheimer's disease associated amyloid-β (Bernstein et 
al., 2009; Gessel et al., 2012) and tau (Larini et al., 2013), dialysis-related amyloidosis 
associated β-2-microglobulin (Smith et al., 2011; Woods et al., 2011; Leney et al., 
2014) and type 2 diabetes mellitus associated amylin (Bernstein et al., 2009; Young et 
al., 2014). This body of work has increased knowledge of the process of protein 
aggregation through structural characterization of intermediate, oligomeric species of 
aggregate formation, differentiation of isobaric peaks in the mass spectrum and 
investigation of the binding mode and subsequent conformational changes of 
enhancers and inhibitors of aggregation.  
1.4.4.1 ESI-IMS-MS of alpha-synuclein 
The focus of this thesis is the investigation of the structural changes and aggregation of 
alpha-synuclein, with one of the main techniques utilised being ESI-IMS-MS. Due to 
alpha-synuclein’s lack of well-defined secondary structure and structural heterogeneity 
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it has proved challenging to investigate the conformation of this protein using 
conventional structural biology tools such as X-ray crystallography or NMR. In an 
attempt to overcome these challenges, alpha-synuclein has been studied using MS 
methods by a number of groups. Areas of interest included attempts to characterise 
the structure of alpha-synuclein, investigations into the effect of solution conditions 
and ligand binding on alpha-synuclein conformation, and studies of oligomeric species 
of the protein and its aggregation. Summaries of findings from key studies in these 
areas are provided below.  
1.4.4.1.1 Alpha-synuclein structure as determined by MS 
The intrinsic structure of alpha-synuclein has been investigated using MS methods, 
with varying results. Alpha-synuclein has been extensively analysed in both positive 
and negative ionisation mode by several groups. Table 1.2 summarises findings from 
key studies into the structure of alpha-synuclein under native conditions using ESI-MS.  
 
Table 1.2: Summary of key ESI-MS studies of alpha-synuclein 
  
Ionisation 
mode 
Protein 
conc. 
Buffer CSD (mon) CSD (dimer) Reference 
Negative 50 µM 5 mm AA pH 7 6 ≤ z ≤ 16 17 ≤ z ≤ 21 
(Bernstein et al., 2004) 
Negative 12 µM 10 mm AA pH 7.4 6 ≤ z ≤ 18 - 
(Natalello et al., 2011a) 
Positive 10 µM 10 mm AA 6 ≤ z ≤ 22 13 ≤ z ≤ 26 
(Frimpong et al., 2010) 
Positive 40 µM 50 mm AA pH 6.8 6 ≤ z ≤ 18 13 ≤ z ≤ 21 
(Illes-Toth et al., 2013) 
Positive 70 µM 50 mm AA pH 6.8 5 ≤ z ≤ 20 - 
(Beveridge et al., 2015) 
Positive 70 µM 50 mm AA pH 7 5 ≤ z ≤ 21 10 ≤ z ≤ 23 
(Phillips et al., 2015) 
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For studies in positive ion mode, Frimpong et al. (2010), Illes-Toth et al. (2013), 
Beveridge et al. (2015) and Phillips et al. (2015) all found a wide CSD of the protein, 
with +5 being the lowest CSI detected and +22 being the highest, providing supporting 
evidence to alpha-synuclein being a disordered protein. A wide CSD of dimers was also 
noted in several of the studies, ranging from the +10 to the +26 ion, while a range of 
dimers, trimers and tetramers was detected by Phillips et al. (2015). The presence of 
dimeric species in the spectra demonstrates that alpha-synuclein is capable of self-
association under native conditions. Another common finding of these investigations is 
indications of the presence of multiple conformational families of alpha-synuclein, 
within its wide CSD. A characteristic, multimodal distribution of monomeric ions is a 
common feature across all studies, with Frimpong et al. (2010) detecting maxima at 
the +19, +14 and +8 CSIs and Illes-Toth et al. (2013) detecting maxima at the +13 and 
+7 CSIs. Meanwhile, Beveridge et al. (2015) noted significant variation in the CSD in 
terms of peak intensities, highlighting the variability and plasticity of this protein. 
Deconvolution of the CSD by Frimpong et al. (2010) identified four conformational 
envelopes within the +6 ≤ z ≤ +22 CSD, with a degree of overlap. IMS data also 
supports the notion of multiple conformational families of alpha-synuclein, with Illes-
Toth et al. (2013) detecting two distinguishable conformations at the +6, +11, +12 and 
+13 CSIs, three distinguishable conformations at the +7 CSI and four distinguishable 
conformations at the +8 CSI. Upon converting the IMS data to Ω, the most compact 
conformations were found to correspond to expected values for a globular protein of 
alpha-synuclein's mass, while the conformations with largest Ω corresponded to values 
expected from an expanded/alpha-helical conformation. Multiple conformational 
families were also detected using IMS by Beveridge et al. (2015), who found two 
distinguishable conformations between +8 and +16 CSIs, and one conformation at CSIs 
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above and below this range. A minimum Ω of 1043 Å2 and a maximum Ω of 2742 Å2 
was observed, comparable to those observed by Illes Toth et al. (2013). A high level of 
variance in measured Ω was noted, indicating conformational inconsistency, which 
they theorised could be due to either unresolved species or interconversion of species 
within the timescale of the experiment. Phillips et al. (2015) utilised IMS to investigate 
conformations of alpha-synuclein present following chemical crosslinking, which 
identified three distinct conformational families, compact (∼1200 Å2), extended 
(∼1500 Å2) and unfolded (∼2350 Å2). These measurements correlated to those 
observed in solution and correspond well to IMS findings for the non-crosslinked 
protein.  
Due to alpha-synuclein being a negatively charged protein under physiological 
conditions, several investigations into this protein have been conducted using negative 
mode ESI, with results mirroring those seen in positive ionisation mode. An early study 
by Bernstein et al. (2004) found the alpha-synuclein monomer to have a CSD of -6 ≤ z ≤ 
-16, with a CSD of dimers from -17 ≤ z ≤ -21, and a study by Natello et al. (2011) 
bimodal CSD cantered at the -14/-15 and -7/-8 CSIs. Consistent with positive mode 
studies, these reports indicate the protein is intrinsically disordered.  
Although a certain degree of inconsistency is found in the various reports of the 
CSD/conformational families of alpha-synuclein, all investigations have noted the 
presence of coexisting conformational families with both compact and more extended 
species present. The discrepancies seen are likely due to a combination of differences 
in instrumentation, sample acquisition, buffer composition and starting material, as 
well as a result of the natural fluctuation of the protein. Indeed, the conformational 
heterogeneity of alpha-synuclein when studied by ESI-IMS-MS has been highlighted in 
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reports by Phillips et al. (2015) and Beveridge et al. (2015), where spectra obtained 
from identically prepared alpha-synuclein samples taken under highly similar source 
conditions displayed significant differences in the relative population of different 
charge states, as well as differences in the distribution between monomeric and 
oligomeric CSIs.  
1.4.4.1.2 Solution conditions 
In addition to looking at the native structure of alpha-synuclein, investigations into the 
effect of solution conditions on structure have been an active area of research, due to 
the known link between solution condition and alpha-synuclein aggregation. 
The effect of altered pH has been investigated in a number of studies. Bernstein et al. 
(2004) found that reducing the pH from neutral to 2.5 resulted in a significant 
narrowing of CSD, from -6 ≤ z ≤ -16 to -6 ≤ z ≤ -11, suggesting the presence of 
predominantly compact conformations in acidic conditions.  Using IMS the average Ω 
across all CSIs was calculated to be 2530 Å2 at pH 7, which reduced to 1690 Å2 at pH 
2.5, corresponding to a more globular, compact structure. It was also found that the 
acidic conditions employed altered dimer formation, as the CSD of dimers from -17 ≤ z 
≤ -21 found when ionised from a pH 7 solution was not detected in the pH 2.5 solution. 
Studies by Frimpong et al. (2010) and Beveridge et al. (2015) produced similar results, 
with an increase in low CSIs found with decreasing pH. Frimpong et al. (2010) also 
looked at the effect on dimers, which were found clustered around the +11 CSI at pH 
2.5, broadening at pH greater than 4 to +13 ≤ z ≤ +26. These results demonstrate the 
enrichment of particular conformations in response to solution pH.  
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The effect of various alcohols has also been investigated, which has further 
demonstrated the enrichment of particular conformations in response to solution 
conditions. Frimpong et al. (2010) found an abundance of compact forms upon 
addition of 10% - 60% alcohol while Natello et al. (2011) found methanol stabilised 
compact forms and hexafluoro-2-propanol and tetrafluoroethylene promoted partially 
folded, intermediate forms.  
1.4.4.1.3 Ligand binding 
Another key area of interest has been research into the effect of various ligands on 
alpha-synuclein. As with altered solution conditions, it is known that binding of certain 
ligands can enhance or inhibit alpha-synuclein aggregation, and as such investigations 
into early conformational changes which occur upon binding to these ligands is of 
great interest due to the insights it could potentially give into alpha-synuclein 
pathology. 
The effect of metal ion binding on alpha-synuclein conformation has been the subject 
of much research, with a particular emphasis on copper binding, due to its known 
ability to promote oligomerisation and aggregation of alpha-synuclein (discussed in 
detail in Section 2.1.3). A study employing negative mode QTOF-MS to investigate 
conformational transitions following copper binding found a decrease of the 
disordered conformer and a shift towards the compact conformer. A substantial shift 
was seen, with the dominant CSI changing from -15 to -8 (Natalello et al., 2011b). The 
role of copper in its ability to induce aggregation and alter the conformation of alpha-
synuclein will form the central focus of Chapter 2. 
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The binding of many other small molecules has been investigated using IMS-MS, 
including investigations into spermine (Grabenauer et al., 2008), calcium (Han, Choi 
and Kim, 2018), dopamine (Illes-Toth, Dalton and Smith, 2013), epigallocatechin gallate 
(EGCG) (Konijnenberg et al., 2016) and gallic acid (Liu et al., 2014). A common finding 
of these studies was an increase in compact conformations upon binding of 
compounds known to increase alpha-synuclein aggregation, such as spermine 
(Grabenauer et al., 2008), and prevention of the formation of compact conformations 
by compounds which inhibit aggregation, such as gallic acid (Liu et al., 2014).   
1.4.4.1.4 Aggregation 
Various studies have utilised ESI-IMS-MS in an attempt to further understanding of the 
early stages of alpha-synuclein aggregation. Vlad et al., (2011) reported specific 
autoproteolytic truncation and degradation products of alpha-synuclein which arose 
during aggregation. A fragment with high aggregation tendency was identified and 
aggregation studies of the carboxy-terminal fragment (72-140) showed increased 
fibrillisation compared to the intact protein. Philips et al. (2015) saw an increase in 
dimer to monomer ratio following aggregation, but no gross conformational change, 
while Illes-Toth et al., (2015) characterised a specific population of oligomers, from 
dimers through to hexamers, which were able to induce intracellular alpha-synuclein 
aggregation. While some progress has been made in this area, characterising the early 
stages of alpha-synuclein using this technique has lagged behind progress made for 
other amyloidogenic proteins (discussed in Section 1.4.4), and such knowledge is vital 
to develop potential PD treatments to directly target the aggregation process. An 
investigation of the structure and dynamics of these oligomeric species will be the 
central focus to Chapter 3. 
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1.5 Thesis overview  
The overall aim of this thesis was to investigate the structural and functional aspects of 
alpha-synuclein and its oligomers. In Chapter 2 investigations into the copper binding 
and subsequent alterations to conformation and aggregation propensity of alpha-
synuclein were performed. Specifically, the effects of a familial PD mutation and a co-
translational modification on these factors were characterised. In Chapter 3 
investigations into the aggregation of alpha-synuclein, both into specific oligomers of 
known function and into amyloid fibrils were conducted. Chapter 4 set out to further 
characterise the effect of alpha-synuclein oligomers with the ability to seed 
intracellular aggregation on an SH-SY5Y cell culture model. 
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Chapter 2: The effect of N-terminal acetylation and 
H50Q mutation on copper binding of alpha-synuclein 
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2.1 Introduction 
Various metal ions are known to bind to alpha-synuclein and are found in LBs along 
with aggregated forms of the protein. Characterising the metal binding ability and 
subsequent conformational changes of alpha-synuclein can give important insights into 
the association between metal binding and protein aggregation. In this chapter, the 
effect of the H50Q familial mutation and N-terminal acetylation on the copper binding 
of alpha-synuclein was investigated. 
2.1.1 Environmental factors and PD 
Epidemiological studies have linked various environmental factors to increased 
incidence of PD. Well established factors include exposure to pesticides and herbicides 
(Elbaz et al., 2009; Tanner et al., 2011), metals (Gorell et al., 1999; Willis et al., 2010), 
solvents (Goldman et al., 2012) and Polychlorinated Biphenyls (Caudle et al., 2012).   
2.1.2 Metals in PD 
High metal exposure is known to be a potential risk factor in certain non-familial forms 
of PD (Gorell et al., 2004), and alterations in metal homeostasis have been associated 
with many neurodegenerative diseases (Chen, Miah and Aschner, 2016). The 
maintenance of metal homeostasis is vital for biological function, as metals play 
essential roles as co-factors in many biological processes (Tapiero, Townsend and Tew, 
2003). One example relevant to PD is that in dopaminergic neurons the enzyme 
tyrosine hydroxylase (TH), responsible for catalysing the first step in the conversion of 
tyrosine to dopamine, requires ferrous iron as a cofactor (Fitzpatrick, 1989). 
Accumulation and abnormal distributions of various metals (including iron, copper and 
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zinc) in the SNpc and striatum of PD patients has been widely reported (Kozlowski et 
al., 2012; Dusek et al., 2015; Gardner et al., 2017). However, it remains to be 
established whether these alterations in metal homeostasis are a cause or 
consequence of PD (for a review see Rasheed et al., 2017). 
2.1.3 The association between alpha-synuclein and metals 
Due to the established link between alpha-synuclein and PD, the interaction of this 
protein with various metals has been investigated (reviewed by Carboni and Lingor, 
2015). As discussed in Section 1.3.2, alpha-synuclein is known to exhibit significant 
conformational heterogeneity, undergoing considerable conformational transitions 
depending on environmental conditions. Collapsed conformers of alpha-synuclein have 
been linked to its aggregation (Uversky, Li and Fink, 2001b). Certain environmental 
conditions have been demonstrated to be capable of inducing such collapsed 
conformational states, including the presence of various divalent metal ions (Santner 
and Uversky, 2010). While most interactions between alpha-synuclein and metals 
occur at the C-terminus of the protein and appear to be low-specificity (Binolfi et al., 
2006), high affinity binding sites for Cu2+ have been reported (Han, Choi and Kim, 
2018). Evidence suggests alpha-synuclein is capable of binding Cu2+ at three specific 
sites, shown in Figure 2.1; a high-affinity N-terminal site where copper is anchored by 
the freely available amino-terminal nitrogen, a site anchored by the imidazole ring of 
the histidine at residue 50, and a low-affinity site at the C-terminus of the protein 
(Binolfi et al., 2012). Mapping studies employing circular dichroism, calorimetric 
titrations, NMR and electron paramagnetic resonance spectroscopy have all 
demonstrated the population of a collapsed species of alpha-synuclein in the presence 
of this metal (Drew et al., 2008; Binolfi et al., 2010; Natalello et al., 2011b).  
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Figure 2.1: Illustration of proposed localisation of alpha-synuclein metal binding sites. 
Alpha-synuclein has a high affinity for copper, with two main binding sites at the N-
terminus. A third, lower affinity copper binding site exists at the C-terminus, which can 
bind other divalent metals, including Fe(II) Cu(II) and Mn(II). Figure adapted from 
Carboni and Lingor (2015). 
 
In addition to being a known metal binding protein, recent reports have also linked 
alpha-synuclein to the maintenance of cellular iron homeostasis; a carefully regulated 
process crucial for correct biological functioning. An important component of iron 
homeostasis is achieved by iron regulatory proteins (IRPs); cytosolic proteins which 
post-transcriptionally regulate the expression of iron metabolism genes in response to 
cytosolic iron levels (Wang and Pantopoulos, 2011). As illustrated in Figure 2.2, 
through binding to iron response elements (IREs), motifs of around 30 nucleotides 
found within mRNA, which form hairpin-loop structures, IRPs can enhance or inhibit 
translation of a gene, depending on the location of the IRE. In conditions of low iron, 
IRPs bind to IREs. If the IRE is located in the 5'-UTR the IRPs prevent translation of that 
gene by blocking the mRNA from binding to the ribosome. If the IRE is located in the 3'-
UTR, binding of IRPs protect these genes from endonuclease cleavage, making them 
more stable and promoting translation. In conditions of high iron, IRPs do not bind to 
IREs, resulting in translation of mRNAs with IREs in the 5'-UTR, and degradation of 
mRNAs with IREs in the 3'-UTR. IREs are commonly found in proteins involved in iron 
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homeostasis, such as transferrin receptor protein 1 and ferritin. A predicted IRE has 
been identified in the 5'-UTR of SNCA, and it has been demonstrated that alpha-
synuclein translation can be regulated by iron (Febbraro et al., 2012).  
 
 
Figure 2.2: Illustration of IRP regulation of translation and stability of IRE-containing 
mRNAs. IRPs bind to IREs located in either the 5′ or 3′ untranslated regions of specific 
mRNAs. When iron is limited, IRPs bind with high affinity to 5′ IRE mRNAs and repress 
translation, and to 3′ IRE mRNAs, stabilize these mRNAs. When iron is abundant, IRPs 
do not bind IREs, resulting in the translation of 5′ IRE-containing mRNAs and 
degradation of 3′ IRE-containing mRNAs. Figure taken from Anderson et al. (2012). 
 
A further link between alpha-synuclein and iron homeostasis comes from data showing 
the protein is able to act as a ferrireductase. Enzymes with ferrireductase activity 
reduce iron from its ferric form to its ferrous form, a vital function to ensure sufficient 
availability of Fe2+ for a range of cellular processes. It has been demonstrated that both 
recombinant alpha-synuclein and the lysate of cells overexpressing alpha-synuclein are 
capable of reducing Fe3+ to Fe2+, requiring NADH as an electron donor and copper 
bound to the protein to cycle between its oxidized and reduced forms (Davies, Moualla 
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and Brown, 2011). Further research has implied that the major catalytically active form 
of alpha-synuclein is a membrane-associated tetramer (McDowall, Ntai, Hake, et al., 
2017a) and the associated ferrireductase activity is also detectable in vivo (McDowall, 
Ntai, Honeychurch, et al., 2017b). These studies provide substantial evidence for 
alpha-synuclein being involved in iron homeostasis, and points to a physiological 
function for alpha-synuclein as a metalloprotein. Therefore a paradoxical situation 
exists between the ability of alpha-synuclein to undergo metal induced aggregation in 
vitro and its potential role as a metal binding protein in vivo.  
2.1.3.1 Alpha-synuclein mutations and metals 
As discussed in Section 1.1.1.1, several point mutations in SNCA which cause AD forms 
of PD have been identified. The recently identified H50Q missense mutation in SNCA 
exon 4 was reported by two research groups in 2013 (Appel-Cresswell et al., 2013; 
Proukakis et al., 2013). This mutation has been shown to accelerate fibril formation of 
the protein (Ghosh et al., 2013), reduce its solubility (Porcari et al., 2015) and increase 
its secretion and toxicity in cell culture (Khalaf et al., 2014). This mutant is of particular 
interest in relation to copper binding, as the loss of the histidine imidazole ring would 
presumably affect alpha-synuclein's copper binding ability. However, studies 
investigating copper binding of alpha-synuclein in vitro where the H50 residue was 
mutated to an alanine found negligible effects on copper binding; contrary to what 
would be predicted upon the removal of a copper anchoring site (Davies et al., 2011). 
The effect of the H50Q familial mutation on copper binding was investigated by 
Proukakis et al. (2013) who found the mutant was able to bind to copper, but in a 
different manner to the WT protein, with binding mainly involving the N-terminus site.  
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2.1.3.2 Alpha-synuclein modifications and metals 
The diversity of the human proteome is much greater than would be predicted by the 
genome. A large part of this diversity is due to protein modifications; alterations to 
proteins which occur co- or post-translationally, allowing a protein to act in multiple 
ways. In vitro studies of alpha-synuclein have historically used recombinant protein 
obtained from bacterial overexpression. Such expression produces unmodified alpha-
synuclein. However, in vivo alpha-synuclein has been shown to be constitutively 
acetylated at its N-terminus (Anderson et al., 2006), a common co-translational 
modification of nascent polypeptides, particularly those which retain their initiating 
methionine residue such as alpha-synuclein (Bradshaw, 1989).  
Acetylation is one of the most common modifications in eukaryotes, in which the 
acetyl group from acetyl coenzyme A is transferred onto a protein's N-terminus (Fig. 
2.3). In mammalian cells, N-terminal acetylation is carried out by the N-
acetyltransferase (NAT) group of enzymes which catalyse the transfer of an N-acetyl 
group from acetyl-coA to the alpha-amino group of a protein's N-terminus (Varland, 
Osberg and Arnesen, 2015). This process neutralizes the positive charge of the free 
alpha-amino group, blocking it from further modifications. The NatB complex is 
responsible for N-terminal acetylation of alpha-synuclein as it has substrate specificity 
for proteins with starting N-termini Met-Glu-, Met-Asn- and, as is the case with alpha-
synuclein,  Met-Asp- (Van Damme et al., 2012). A method of producing acetylated 
recombinant proteins was established in 2010 (Johnson et al., 2010). This technique 
utilised co-expression of the protein of interest with its corresponding NAT enzyme, 
which has allowed in vitro studies of acetylated, recombinant alpha-synuclein to be 
performed.  
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Figure 2.3: Schematic of N-terminal acetylation. N-acetyltransferase enzymes catalyse 
the transfer of an N-acetyl group from acetyl-coA to the alpha-amino group of a 
protein's N-terminus. 
 
Alpha-synuclein was first identified as being acetylated when purified from Lewy 
bodies using LC-MS/MS (Anderson et al., 2006), which has since been confirmed in 
alpha-synuclein isolated from brain tissue homogenate (Ohrfelt et al., 2011) and 
erythrocytes (Fauvet et al., 2012). In recent years a number of in vitro studies have 
aimed to elucidate the effect of acetylation on alpha-synuclein structure and function. 
Such studies have shown that acetylation results in an increase in lipid binding affinity 
(Dikiy and Eliezer, 2014), altered transient secondary structure (Kang et al., 2013) and 
decreased aggregation rates (Kang et al., 2012). N-terminal acetylation is also an 
important modification in relation to its Cu2+ binding as the transfer of an acetyl group 
to the copper anchoring amino-terminal nitrogen has the potential to alter the 
protein's Cu2+ binding ability. Indeed, it has been demonstrated that N-terminally 
acetylated alpha-synuclein lacks this high affinity N-terminal Cu2+ binding site and 
undergoes altered fibril formation in the presence of this metal (Moriarty et al., 2014).  
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2.2 Aims and Objectives 
Prior studies investigating wild type N-terminally acetylated alpha-synuclein have 
successfully used ensemble based spectroscopy techniques to probe structural 
changes brought about by metal binding (Moriarty et al., 2014). However, changes to 
individual conformational states of alpha-synuclein have not been investigated. To 
date, the effect of the familial H50Q mutation on Cu2+ binding of biologically relevant 
N-terminally acetylated alpha-synuclein has not been investigated. In this chapter, ESI-
IMS-MS has been employed to observe the copper binding and subsequent 
conformational transitions of individual conformational states of unmodified and N-
terminally acetylated forms of wild type (WT) and H50Q alpha-synuclein, using 
conditions suitable to maintain protein-metal complexes in the gas-phase. ESI-IMS-MS 
has been utilized due to its ability to interrogate dynamic ensembles of the same mass 
by separating extended and collapsed conformations (Jenner et al., 2011), with 
changes in solution conformation detected in the gas phase as changes in Ω.  This 
method also allows the binding of ligands to specific conformational states to be 
determined (Hopper and Oldham, 2009). 
The specific aims of this chapter were: 
1. To produce N-terminally acetylated and H50Q mutated recombinant forms of 
alpha-synuclein. 
2. To establish whether N-terminal acetylation or H50Q mutation alter the 
conformational state of alpha-synuclein. 
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3. To establish whether N-terminal acetylation or H50Q mutation alter the 
aggregation propensity of alpha-synuclein. 
4. To establish the effect of N-terminal acetylation in the context of the H50Q 
mutation on the copper binding affinity, conformation states and aggregation 
propensity of alpha-synuclein. 
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2.3 Materials and Methods 
2.3.1 Molecular biology of pET23a-ASYN expression plasmid 
A modified pET23a expression plasmid containing the nucleotide sequence for the 
expression of alpha-synuclein was provided by Dr David Smith (Sheffield Hallam 
University, UK). Throughout this thesis this plasmid will be referred to as pET23a-ASYN.  
2.3.2 pACYCduet-naa20-naa25 plasmid purification 
In order to produce acetylated alpha-synuclein the pNatB (pACYCduet-naa20-naa25) 
plasmid, allowing expression of the fission yeast NatB complex, was obtained from 
Addgene in the form of an agar stab. E.coli from the stab was streaked onto an agar 
plate containing 25 mg/mL chloramphenicol and incubated overnight at 37 °C/5% CO2. 
A 500 mL starter culture was grown from a single colony from the agar plate, and 
plasmid DNA purified using an OriGene PowerPrep HP® Plasmid Maxiprep kit, 
following manufacturer guidelines. Briefly, the starter culture was pelleted and 
resuspended in Cell Suspension Buffer. Cells were lysed through addition of Cell Lysis 
Solution before addition of Neutralisation Buffer. The lysate was centrifuged at 15000 
xg for 10 minutes at room temperature, and the supernatant added to a pre-
equilibrated column provided with the kit. The column was washed with Wash Buffer 
and bound DNA eluted with Elution Buffer. Eluted DNA was subjected to isopropanol 
precipitation and the DNA pellet resuspended in TE Buffer. Glycerol stocks from excess 
overnight culture were produced by the addition of an equal volume of 50% glycerol to 
the culture, and storage at -80 °C. 
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2.3.3 Site directed mutagenesis of pET23a-ASYN 
H50Q mutant alpha-synuclein was created by modification of the pET23a-ASYN 
plasmid via site directed mutagenesis, using a QuikChange® II XL Site-Directed 
Mutagenesis Kit by Stratagene following manufacturer's instructions.  
Briefly, two complimentary oligonucleotides containing the desired mutation, flanked 
by unmodified nucleotide sequence were designed in house and synthesized by Sigma 
Aldrich LTD. Primers used were: 
Forward: 5' GCGTTGTCCAAGGGGTTGCG 3'  
Reverse: 5' CGCAACCCCTTGGACAACGC 3' 
Oligonucleotide primers, each complementary to opposite strands of the vector, were 
extended during temperature cycling by PfuUltra HF DNA polymerase without primer 
displacement. Extension of the oligonucleotide primers generated a mutated plasmid 
containing staggered nicks. Following temperature cycling, the product was treated 
with Dpn I endonuclease to digest the parental DNA template and to select for 
mutation containing synthesized DNA. The nicked vector DNA incorporating the 
desired mutations was then transformed into XL10-Gold ultracompetent cells. 
Mutated plasmids were then isolated using a QIAprep Spin Miniprep Kit, following 
manufacturer's instructions. Throughout this thesis this mutated plasmid will be 
referred to as pET23aH50Q-ASYN. 
2.3.4 Production of chemically competent cells 
Stocks of chemically competent BL21 (DE3) E.coli cells were prepared for use in 
transformations and subsequent overexpression of proteins. E.coli were streaked from 
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glycerol stocks onto an agar plate containing 100 mg/mL ampicillin and incubated 
overnight at 37 °C/5% CO2. A single colony was used to inoculate a 5 mL starter culture 
of LB (containing 10 g/mL Tryptone, 10 g/mL NaCl, 5 g/mL yeast extract and 100 
mg/mL ampicillin). 500 µL of starter culture was transferred to 50 mL pre warmed LB 
and cultured at 37 °C until the OD600 reached between 0.5 and 0.7. The culture was 
then aliquoted into chilled 50 mL falcon tubes and centrifuged at 4000 rpm for 5 
minutes at 4 °C. The supernatant was discarded, the pellet resuspended in 30 mL TBFI 
(30 mM KOAc, 100 mM RbCl, 50 mM MnCl, 10 mM CaCl2, pH 5.8) and incubated on ice 
for one hour. They were then centrifuged again at 4000 rpm for 5 minutes at 4 °C and 
the pellet resuspended in 4 mL TBFII (10 mM MOPS, 10 mM RbCl, 75mM CaCl2, 15% 
Glycerol, pH 7.0). 200 µL aliquots of chemically competent cells were flash frozen in 
liquid nitrogen and stored at -80 °C.  
2.3.5 Transformation of competent cells 
100 µL of BL21 (DE3) chemically competent cells were transformed with 1 µL of the 
appropriate plasmids required to express each protein, as shown in Table 2.1, with the 
addition of β-mercaptoethanol to a final concentration of 24 mM. 
 pET23a-ASYN pET23aH50Q-ASYN pNatB 
Unmodified, WT    
Acetylated WT    
Unmodified H50Q    
Acetylated H50Q    
Table 2.1: Plasmids required to produce the various forms of recombinant alpha-
synuclein. 
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Reaction mixtures were incubated for 30 minutes on ice. The mixture was then 
exposed to 45 second heat shock in a 42 °C water bath and returned to ice for 2 
minutes. 900 µL of preheated, sterile SOC medium (2% tryptone, 0.5% yeast extract, 10 
mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose) was added 
and the reactions incubated at 37 °C with aggitation at 200 rpm for one hour to allow 
the bacteria to express antibiotic resistance. 100 µL of the reaction was spread onto 
agar plates containing 100 mg/mL ampicillin (for those transformed with the pET23a 
plasmids only) or 100 mg/mL ampicillin and 25 mg/mL chloramphenicol (for those 
transformed with both pET23a and pNatB plasmids) to select for bacteria which had 
been successfully transformed. Agar plates were incubated at 37 °C/5% CO2 overnight.  
2.3.6 Agarose gel electrophoresis 
Plasmid DNA was separated on a 1% agarose gel to check quality and purity. A 1% 
agarose gel was prepared by dissolving 400 mg of agarose in 40 mL of TAE buffer (89 
mM Tris-HCL pH 7.8, 89 mM borate, 2 mM EDTA), followed by heating in a microwave 
until agarose was dissolved. The solution was then allowed to cool before the addition 
of 0.5 µg/mL ethidium bromide and the gel poured into a Bio-Rad gel tray sealed with 
a Bio-Rad gel caster. An 8 well comb was inserted into the agarose solution and the gel 
allowed to set at room temperature. Agarose gels were then placed in a Bio-Rad 
horizontal electrophoresis tank and submerged in TAE buffer. DNA samples were 
mixed with loading dye and loaded into the wells. exACTGene Mid Range DNA Ladder; 
300 to 5000bp (Fisher BioReagents), was added into a separate well to aid DNA size 
estimation. The electrophoresis tank was connected to an electrical power pack and 
100 volts applied to the gel for 40 minutes. Gels were imaged on a UVP epi dark room 
trans-illuminator under ultra violet light.  
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2.3.7 Expression of recombinant proteins 
Single colonies from agar plates were incubated in 100 mL LB media (containing 100 
mg/mL ampicillin or 100 mg/mL ampicillin and 25 mg/mL chloramphenicol as 
appropriate) overnight at 37 °C with agitation at 200 rpm. Expression was induced by 
inoculating 15 mL of this overnight culture into 1 L of auto induction media 
(Formedium, UK) containing 100 mg/mL ampicillin or 100 mg/mL ampicillin and 25 
mg/mL chloramphenicol. This was incubated for 18 hours at 28 °C with agitation at 180 
rpm. Cells were then harvested by centrifugation at 8,000 rpm, 4 °C for 20 minutes.   
2.3.8 Protein purification 
The cell pellets were resuspended in a lysis buffer containing 10 mM Tris-HCl, pH 8.0, 
100 µg/mL lysozyme, 20 µg/mL DNase, 20 µg/mL RNase, one bacterial protease 
inhibitor cocktail tablet (Sigma Aldrich) and 2 mM phenylmethylsulfonyl fluoride 
(PMSF). The lysate was incubated on ice for 30 minutes before the addition of 1 mM 
ethylenediaminetetraacetic acid (EDTA) and then further lysed by sonication. The 
lysate was centrifuged at 10000 xg, 4 °C for 40 minutes to remove debris and the 
supernatant acidified to pH 4.5, centrifuged again at 10000 xg, 4 °C for 30 minutes to 
remove precipitated proteins and the lysate neutralised to pH 8.0. This crude lysate 
was passed through a 0.2 μm filter and loaded on to a 50 mL Q-Sepharose column (GE 
Healthcare) for anion exchange at 4 °C. Prior to this the column was equilibrated with 
two column volumes of buffer A (25 mM Tris-HCl, 10 mM NaCl pH 8.0) and the protein 
eluted with a 0-100% linear gradient of buffer B (25 mM Tris-HCl, 1M NaCl pH 8.0). 
SDS-PAGE analysis of Q-Sepharose fractions was performed and the fractions enriched 
with alpha-synuclein were pooled, dialysed at 4 °C against ultrapure water and 
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lyophilised. Lyophilised protein was dissolved in buffer A and injected onto a HiLoad® 
26/600 SuperdexTM 200 Prep Grade size exclusion column (Amersham Biosciences) 
using 25 mM Tris-HCl, 10 mM NaCl pH 8.0 as running buffer. SDS-PAGE analysis of size 
exclusion fractions was performed and purified fractions containing only alpha-
synuclein were pooled, dialysed at 4 °C against ultrapure water, re-lyophilised and 
stored at -20 °C for further experiments. Protein concentration was measured by 
absorbance at 280 nm using an extinction coefficient of 5960 M-1cm-1 on a nanodrop 
spectrophotometer.  
2.3.9 SDS-PAGE 
Separating and stacking gels were prepared as shown in Table 2.2. Glass plates were 
assembled according to manufacturer's instructions. The separating gel was cast and 
allowed to polymerise, followed by casting of the stacking gel and insertion of a comb 
to form sample wells.  
 
 Separating gel (mL) Stacking gel (mL) 
ddH2O 3.4 2.9 
40% acrylamide 2.4 0.75 
1.5 M Tris-HCL pH 8.8 2 - 
0.5 M Tris-HCL pH 6.8 - 1.25 
10% SDS 0.08 0.05 
10% APS 0.08 0.05 
TEMED 0.008 0.005 
Table 2.2: Composition of 12% SDS-PAGE gel. 
 
10x running buffer of 250 mM Tris-HCL, 1920 mM glycine and 1% w/v SDS, pH 8.3 was 
diluted to 1x before use. Samples were diluted with 4x Laemmli protein sample buffer 
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(Bio-rad) and electrophoresed in 1x running buffer at 100 V. To aid molecular weight 
determination 5 µL protein marker (broad range, P7702S, New England Biolabs) was 
loaded into one well. On completion of electrophoresis, gels were stained with 
InstantBlue Protein Stain (Expedeon) and visualised using a LI-COR Odyssey and 
Odyssey Infrared Imaging software (LI-COR, Nebraska, USA).  
2.3.10 Sample preparation for mass spectrometry analysis 
Protein samples were prepared for MS analysis by dissolving lyophilized protein and 
CuCl2 to a final concentration of 20 μM in 50 mM ammonium acetate pH 7.0. Protein 
to metal ratios of 1:0 and 1:1 were prepared and mixed immediately prior to analysis. 
2.3.11 ESI-IMS-MS analysis 
All experimentation was performed on a Synapt G2 HDMS instrument (Waters, 
Manchester, UK) equipped with a Triversa (Advion Biosciences) automated nano-ESI 
interface in positive mode. Positive ESI was used with a capillary voltage of 1.7 kV and 
nitrogen nebulizing gas pressure of 0.7 psi. The following instrument parameters were 
used unless stated otherwise: cone voltage 45 V, source temperature 60 °C, backing 
pressure 3.0 mbar, trap collision energy 4 V, transfer 20 V, IMS wave velocity 600 m/s, 
IMS wave height 4 V, IMS gas flow 90 mL/min. Mass calibration was carried out by an 
infusion of CsI cluster ions. For attaining denatured spectra, calibrants were prepared 
before injection at 10 μM dissolved in 50% acetonitrile, 10% formic acid and 40% 
ultrapure water (v/v/v). A calibration curve for collision cross-sectional areas was 
obtained based on of multiple charge states of cytochrome C from equine heart, 
myoglobin from equine heart and ubiquitin from bovine erythrocytes as described in 
detail in Section 1.4.3.2. Drift times were corrected for both mass-dependent and 
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independent time of flight (Ruotolo et al., 2008). Arrival time distributions (ATD) were 
determined using the Mass Lynx v4.1 software (Waters, Manchester, UK). ATD for each 
charge state at its respective m/z value were extracted from the Driftscope plots 
available within the MassLynx suite of software. Plots were then fitted with Microsoft 
Excel using least square regression to a minimum number of Gaussian distributions 
using multiples of the following equation: 
𝑦 =  
𝐴
𝑤√𝜋/2
𝑒
−(𝑥−𝑥𝑜)
2
2.𝑤2  
Where A = total area under the curve from the baseline, x0 = center of the peak, and w 
= width of the peak at half height. This model describes a normal (Gaussian) probability 
distribution function. 
2.3.12 Thioflavin T (ThT) fluorescence 
Lyophilized alpha-synuclein was reconstituted to a final concentration of 70 μM with 
10 μM ThT, with and without equimolar CuCl2. 100 l of sample was placed into a black 
walled 96 well plate with a 4 mm diameter glass bead, which has been shown to 
increase the reproducibility of ThT assays (Giehm, Lorenzen and Otzen, 2011). The 
plate was incubated at 37 °C with agitation at 300 rpm using a BMG Labtech 
CLARIOstar plate reader. ThT fluorescence readings (excitation 440 nm/emission 488 
nm) were taken at 60 minute intervals over the course of an aggregation experiment. 
Lag time was determined from raw data by calculating the intercept between the 
maximum derivative and the pre-transitional base line as shown in Figure 2.4. 
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Figure 2.4: Illustration of lag time calculation from ThT data. An increase in aggregates 
over time results in a characteristic sigmoidal curve for amyloid fibril formation. Fmax = 
fluorescence intensity of final aggregates. t50 = the time at which half of the plateau 
aggregates are formed. tm = the time at which the growth rate reaches its maximum, 
vmax. tlag is estimated by extending the tangent at tm down to the time axis. Figure 
taken from Shoffner and Schnell, (2016).   
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2.4 Results and discussion 
In order to determine the effect of protein modification and mutation of a key metal 
binding residue on alpha-synuclein, recombinant protein was produced with and 
without N-terminal acetylation, with and without the histidine at residue 50 mutated 
to the PD associated glutamine. 
2.4.1 Site directed mutagenesis of pET23a-ASYN 
In order to produce mutated alpha-synuclein site directed mutagenesis was 
performed. The H50Q mutant was successfully produced as confirmed by sequencing, 
shown in Figure 2.5. Highlighted in red, it can be seen that the usual CAT codon at 
residue 50 (encoding a histidine) has been successfully replaced by a CAA codon 
(encoding a glutamine) using the primers described in Section 2.3.3. 
 
 
 
 
 
Figure 2.5: Sequencing results of the mutated pET23a-ASYN plasmid. The DNA 
sequence (a) and amino acid sequence (b) of the alpha-synuclein coding region of the 
pET23a-ASYN plasmid, mutated via site directed mutagenesis. The mutated amino acid 
to which primers were designed is highlighted in red.  
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2.4.2 Co-transformation of BL21 (DE3) cells 
To achieve N-terminal acetylation of recombinant alpha-synuclein produced in E. coli 
cells, co-transformation with both the pNatB plasmid (encoding the catalytic subunit 
(Naa20) and auxiliary subunit (Naa25) of the NatB complex) and the pET23a-ASYN 
plasmid was performed, as described by Johnson et al. (2013). Successful co-
transformation was confirmed by agarose gel electrophoresis, shown in Figure 2.6. In 
lanes 2 and 3, containing the product of plasmid prep from E.coli cells transformed 
with either pET23a-ASYN or pNatB alone, three bands are seen, corresponding to the 
nicked, linear and supercoiled forms of the individual plasmids. Conversely in lane 4, 
containing the product of plasmid prep from E. coli cells transformed with both the 
pET23a-ASYN and the pNatB plasmids, six bands are present, corresponding to the 
nicked, linear and supercoiled forms of both plasmids. This demonstrates that the 
E.coli cells were successfully co-transformed with both plasmids.  
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Figure 2.6: 1% Agarose gel electrophoresis of plasmid DNA purified from transformed E. 
coli cells. Agarose gels containing ethidium bromide for DNA visualisation used to 
analyse plasmids purified from transformed E. coli cells. Lane 1 contains DNA Ladder to 
aid DNA size estimation. Lane 2 contains the product of plasmid prep from E. coli cells 
transformed with pET23a-ASYN, lane 3 the product from E. coli cells transformed with 
pNatB and lane 4 the product from E. coli cells transformed with both pET23a-ASYN 
and pNatB. 
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2.4.3 Expression and purification of alpha-synuclein recombinant 
proteins 
Unmodified and N-terminally acetylated forms of WT and H50Q alpha-synuclein were 
produced via transformation of E.coli with the appropriate plasmids, overexpression of 
the target protein via auto induction, and purification using column chromatography 
as described in Section 2.3.8. Typical chromatograms and SDS-PAGE results obtained 
from this purification process can be found in Appendix Figure 1. Following the 
purification procedure a single band corresponding to overexpressed alpha-synuclein 
is seen with no visible contaminants, demonstrating that the protein is suitably pure. 
2.4.4 Mass spectrometry confirmation of successful protein production  
In order to confirm modified and mutated forms of the alpha-synuclein protein had 
been produced, protein samples were analysed by ESI-MS to confirm they were of the 
expected mass. Example spectra of the +10 charge state ions are shown in Figure 2.7, 
with theoretical and experimental m/z shown in Table 2.3.   
 Theoretical m/z Experimental m/z 
WT unmodified 1447.0114 1446.9948 
H50Q unmodified 1446.1150 1446.1312 
WT acetylated 1451.2197 1451.3160 
H50Q acetylated 1450.3187 1450.3348 
Table 2.3: Theoretical vs experimental m/z at the +10 charge state ion of recombinant 
alpha-synuclein proteins.  
 
As shown in Table 2.3, all four proteins were found to be of the expected mass. The 
H50Q mutation resulted in a decrease in molecular mass of 9 Da (due to the 
substitution of a glutamine (146 Da) for a histidine (155 Da)) and N-terminal 
acetylation resulted in an increase in molecular mass of 42 Da (due to the replacement 
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of one of the hydrogens from the amine group with an acetyl group). Also observable 
in the spectra of acetylated proteins in Figure 2.7 is a peak of lower intensity 
corresponding to the non-acetylated protein, demonstrating that the acetylation 
process in our experimental set up was not 100% efficient. This is thought to be due to 
the pET23a-ASYN and pNatB plasmids making use of the same induction system, 
meaning they will both start being expressed at a similar time. Due to N-terminal 
acetylation being a co-translational modification this means that for the alpha-
synuclein protein expressed early following induction may not have the NatB complex 
present to carry out the modification. An improved system utilising a sequential 
induction system with improved acetylation efficiency has recently been described 
(Eastwood et al., 2017). Despite the acetylation procedure not being 100% efficient, 
the majority of the protein did undergo this modification. Therefore, MS results 
confirm that all four versions of the protein had been successfully produced. 
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Figure 2.7: ESI-MS spectra of recombinant alpha-synuclein proteins. Representative 
spectra of the +10 charge state of unmodified and N-terminally acetylated WT and 
H50Q mutant alpha-synuclein, acquired in 50 mM ammonium acetate (pH 7) in 
positive ion mode, with the x-axis representing mass to charge ratio and the y-axis 
representing normalised relative intensity. 
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2.4.5 ESI-IMS-MS analysis of recombinant alpha-synuclein reveals a 
disordered protein with two distinct populations 
Although alpha-synuclein is predominantly described as a natively unstructured 
protein, it is known to co-populate a range of conformational families under 
equilibrium, which have been investigated using ESI-IMS-MS by various groups 
(Bernstein et al., 2004; Frimpong et al., 2010; Natalello et al., 2011b; Phillips et al., 
2015). Positive mode ESI-MS of the recombinant alpha-synuclein used in this thesis is 
indicative of an intrinsically disordered protein. As shown in Figure 2.8, the spectrum 
displays a wide CSD of monomeric alpha-synuclein of +5 ≤ z ≤ +15. As discussed in 
Section 1.4.1, a protein with a defined tertiary structure will typically display a narrow 
CSD, while a wider distribution of charge states, as seen here, is characteristic of a 
disordered protein. Also notable in the spectra is the presence of at least two major 
distinct populations of alpha-synuclein, with some degree of overlap. This bi-modal 
distribution consists of an extended conformational state (with corresponding high 
charge states) centred on the +11 ion and a compact conformational state (with 
corresponding lower charge states) centred on the +7 ion, shifted in favour of the 
extended conformational state. The presence of these two major conformational 
families is equivalent to those previously reported by our group (Illes-Toth et al., 2013) 
and others (discussed in Section 1.4.4.1). Ion mobility analysis further supports the 
presence of two major distinct populations, shown in the drift scope plot in Figure 2.8. 
Here, two distinct populations can be distinguished; a primarily extended 
conformation between the +15 and +8 CSIs with longer drift times, and a more 
compact conformation between the +8 and +5 ions, with comparatively shorter drift 
times.
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Figure 2.8: Drift scope plot and corresponding ESI-MS spectra of unmodified, WT alpha-synuclein. Representative drift scope plot and mass spectra of 
unmodified, WT alpha-synuclein, acquired in 50 mM ammonium acetate (pH 7) in positive ion mode. 
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2.4.6 Ion mobility analysis of recombinant alpha-synuclein reveals 
multiple conformations present at each charge state 
In addition to the two major populations distinguishable in Figure 2.8, numerous 
conformational families, with multiple populations of both extended and compact 
conformations, can be observed on deeper analysis of the individual ATD of each CSI. 
Figure 2.9 (a) shows the ATDs extracted from each CSI and fitted to the minimum 
number of Gaussian distributions required to resolve the multiple conformations 
present. Drift time has been converted to Ω through calibration with standards of 
known Ω following the method described in Section 1.4.3.2. The calibration curve used 
for the conversion of drift time to Ω is shown in Figure 1.10, with the celebrants' used 
chosen to bracket the arrival times of all alpha-synuclein species identified under the 
experimental conditions used in this thesis. Figure 2.9 (b) shows the Ω value from the 
peak top of each resolvable conformational family, plotted against its respective z. In 
addition, theoretical values of alpha-synuclein modelled to a globular or all helical 
conformation (Bernstein et al., 2004) have been superimposed onto the experimental 
data to aid in visualisation of the differing conformations.  
A total of eight resolvable conformational families spanning a wide range of Ω were 
detected, which have been assigned a letter from A to H as outlined in Table 2.4, with 
A representing the most compact of the states and H the most extended. In the 
majority of cases each conformational family is seen across multiple CSIs, with a slight 
increase in Ω within the same conformational family observed as charge state 
increases, presumably as a result of Coulombic repulsion. A primarily extended 
population (F - H) is seen between the +8 and +15 charge state ions and a 
subpopulation of more compact conformations (A - E) seen predominantly between 
 91 
the +5 and +9 charge state ions, with multiple overlapping features in both series. Ω 
ranged from the most compact value of 1339 Å2 at the +5 CSI to the most extended of 
3221 Å2 at the +15 CSI. The most compact conformation corresponded to a predicted 
globular conformation and the most extended corresponded to the predicted random 
coil conformation. It can be seen that the various conformational families occupy Ω 
values throughout the full range between these theoretical values, demonstrating 
again the conformational heterogeneity of this protein.  
 
 
Table 2.4: Lettering system of alpha-synuclein conformational families. Conformational 
families determined through Gaussian fitting of ATDs of each CSI from ESI-IMS-MS 
spectrum of 10 µM unmodified WT alpha-synuclein (50 mM ammonium acetate)
 Conformational 
family 
Chromatogram 
colour 
CSI  
range 
Average 
 Ω 
Compact 
 
 
Extended 
A 
 
Yellow +5 1339 
B Green +5 to +9 1681 ± 142 
C Purple +6 to +9 1930 ± 115 
D Black +7 to +12 2269 ± 118 
E Red +8 to +12 2511 ± 104 
F Blue +8 to +15 2749 ± 178 
G Lilac +11 to +15 2916 ± 167 
H Orange +13 to +15 3121 ± 91 
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Figure 2.9: ATDs for each CSI of unmodified WT alpha-synuclein. (a) The peak area of 
each alternate population of differing Ω was calculated from Gaussian distributions. 
The raw ATD is displayed in pink and the sum of the fitted Gaussians is shown as a 
black broken line. (b) The peak top of resolvable conformational families as presented 
in (a) plotted against charge state, with dotted lines representing theoretical Ω 
calculated for structures having an all helical or compact globular structure, as 
reported by Bernstein et al. (2004). 
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2.4.7 Investigating the effect of N-terminal acetylation and H50Q 
mutation on alpha-synuclein conformation by ESI-IMS-MS  
In order to address the effect of N-terminal acetylation and the H50Q mutation on 
alpha-synuclein conformation, these modified proteins were also analysed by ESI-IMS-
MS, enabling comparison to the unmodified, WT protein. The driftscope plot and 
corresponding mass spectrum of each of the four proteins are shown in Figure 2.10.  
The spectra of all four versions of the protein are similar, with a CSD of +5 ≤ z ≤ +15, a 
bi-modal distribution centered on the +7 and +11/+12 CSI's, and a similar pattern of 
relative peak intensities. The driftscope plots are also similar, with two distinct 
populations being observed for each of the proteins.  
When looking in detail at the eight conformational families described in Section 2.4.6, 
some slight differences are apparent. These differences are presented in Figure 2.11, a 
bar chart plotting the percentage population of protein attributed to each 
conformational family (A to H) at each CSI. The percentage population in differing 
conformational families at each CSI was obtained through Gaussian fitting of the ATD 
and calculation of the area under the curve for each resolvable conformation. The 
extracted driftscope plots and Gaussian fitting for each individual protein can be seen 
in Appendix Figure 2. While a degree of variability is to be expected, there are some 
notable differences between the WT and H50Q proteins in the percentage of protein 
populating each family at the +15 CSI. This CSI contains three resolvable 
conformations, F, G and H. The proportion of protein in the most extended state (H) is 
lower in the H50Q mutants than the WT proteins. Conversely the percentage of 
protein in the less extended states (F and G) is higher in the H50Q mutants than the 
WT proteins. These differences are summarised in Table 2.5.  
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 WT H50Q 
Unmodified Acetylated Unmodified Acetylated 
F 14% 1113%41 25% 19% 
G 26% 34% 59% 79% 
H 60% 53% 16% 2% 
Table 2.5: The percentage population of protein at the +15 CSI in each conformational 
family, calculated from the area under the fitted curves shown in Appendix Figure 2. 
 
These results suggest that, compared to unmodified WT alpha-synuclein, neither N-
terminal acetylation nor the H50Q mutation result in significant changes in CSD, 
conformational families, Ωs or abundance of each CSI. This demonstrates that the 
unbound metal free conformational states of these proteins are largely comparable, 
and therefore the introduction of the point mutation and modification has not altered 
the gross gas phase conformation of this protein. However, some slight differences 
were observed in the proportion of protein in each conformational family at specific 
CSIs. 
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Figure 2.10: Driftscope plot and overlaid mass spectrum of each of the four proteins. Driftscope plot/spectra obtained from 50 mM ammonium 
acetate (pH 7) solution of 10 μM unmodified, acetylated, H50Q and acetylated H50Q alpha-synuclein in positive ion mode.  
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Figure 2.11: Bar chart showing the percentage conformation of protein in each conformational family at each CSI. Percentage in each conformation 
calculated through fitting the ATD of 10 μM unmodified and acetylated WT and H50Q alpha-synuclein (50 mM ammonium acetate (pH 7)) of each CSI 
to the minimum number of Gaussians and calculating the area under the curve. 
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2.4.8 Copper binding to alpha-synuclein is observed by ESI-MS 
As discussed in Section 2.1.3.1, alpha-synuclein is known to be a copper binding 
protein (Binolfi et al., 2010; De Ricco et al., 2015). However, while techniques such as 
NMR and electron paramagnetic resonance allow the detection of copper binding, 
they do not allow the detection of conformational change to specific protein species in 
the detail achieved by ESI-IMS-MS. To determine the degree of Cu2+ binding to alpha-
synuclein, mass spectra were acquired at a 1:1 protein to metal ratio, immediately 
upon the addition of CuCl2. 
Figure 2.12 shows the ESI spectra of the +10 CSI of alpha-synuclein, alone and in the 
presence of equimolar CuCl2. It is clear that alpha-synuclein is binding to copper, with 
an increase in mass equivalent to the addition of one or two copper ions (an increase 
of the overall mass of 61.5 Da per copper bound, given that each ion repels two 
protons from the protein to conserve charge) being detected. Virtually the entire 
population of monomeric alpha-synuclein can be seen to bind to copper, with the 
majority of the protein found bound to one ion and a smaller proportion bound to 
two. This pattern of binding is seen across all charge state of the protein, 
demonstrating that all CSIs, and hence conformational states, of monomeric alpha-
synuclein are able to bind to copper (shown in Figure 2.17). 
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Figure 2.12: Spectra of the +10 CSI of unmodified, WT alpha-synuclein alone and in the 
presence of equimolar Cu2+. Spectra acquired at a protein concentration of 10 µM 
with a CuCl2 ratios of 1:0 and 1:1. The x axis represents m/z and the y axis represents 
relative abundance.  
 
The CSD of alpha-synuclein alone or in the presence of equimolar copper is shown in 
Figure 2.13. Here, a change in CSD can be seen, with a broadening from the +5 ≤ z ≤ 
+15 seen in the absence of copper to +5 ≤ z ≤ +17 in the presence of copper. The most 
abundant ion also differs, from the +11 CSI in the absence of copper to the +13 CSI in 
the presence of copper. This would indicate an alteration in the conformation 
distribution on metal binding, with higher CSIs, and therefore more extended forms of 
the protein, being observed in the presence of copper.
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Figure 2.13: CSD of unmodified recombinant alpha-synuclein alone (bottom) and in the presence of equimolar Cu2+ (top). Spectra acquired at a protein 
concentration of 10 µM with a CuCl2 ratios of 1:0 and 1:1. The x axis represents m/z and the y axis represents relative abundance.  
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2.4.9 Copper binding to alpha-synuclein results in altered populations of 
conformations detectable by ESI-IMS-MS 
Compact conformations of alpha-synuclein are known to be aggregation prone, and 
the equilibrium of conformations can be shifted towards compact states under certain 
conditions. Polyvalent metal ions have the propensity to shift the conformational 
equilibrium and trigger structural rearrangements (Santner and Uversky, 2010). Ion-
mobility spectra were acquired in order to investigate changes in alpha-synuclein 
conformations that occur upon Cu2+ binding.  
Figure 2.14 shows the ATD of each CSI of alpha-synuclein alone (a) or bound to one 
copper ion (b). It can be seen that the same conformational families (A-H) are present 
in both the apo- and holo- conditions, demonstrating that binding of a copper ion does 
not result in monomeric alpha-synuclein adopting any new conformations detectable 
by this method. However, what can be noted is the proportion of protein populating 
these conformations being altered upon copper binding. A shift to the more compact 
conformations of the protein can be seen at the majority of CSIs, most notably at +7, 
+8, +9, +14 and +15. Figure 2.15 summarises these data, showing the percentage 
population of protein in each conformational family at all CSIs, for alpha-synuclein 
alone or bound to 1 or 2 copper ions. A clear pattern of an increase in the more 
compact conformations at each charge state can be seen. The data also demonstrates 
that alpha-synuclein bound to two copper ions undergoes a greater conformational 
shift than the protein bound to one copper ion or the apo protein. As an example, the 
+10 CSI contains 3 conformations: D, E and F, which occupy 9%, 12% and 79% of the 
protein at the CSI respectively. Upon binding to copper the proportion of protein in the 
most compact of these three conformations, D, increases to 24% when one copper ion 
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is bound and further to 30% when two copper ions are bound. On the contrary, the 
proportion of protein in the most extended conformation at this CSI, F, decreases to 
58% when one copper ion is bound and further to 47% when two copper ions are 
bound. This demonstrates that, compared to the unbound protein, a greater 
proportion of the protein is in a compact conformation at these CSIs when copper is 
bound. 
Also of note are the CSIs detectable in the presence (but not the absence) of copper at 
+16 and +17 (shown in Figure 2.14). The conformations detected at these CSIs do not 
represent new conformations of the protein, but rather a continuation of the most 
extended conformational families present in the unbound spectra, F, G and H.  
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Figure 2.14: ATDs for each charge state ion of unmodified WT alpha-synuclein in the 
absence and presence of equimolar copper. The peak area of each alternate 
population of differing Ω was calculated from Gaussian distributions using a least 
square fitting method. Spectra were acquired at protein to CuCl2 ratios of 1:0 (a) and 
1:1 (b) in 50 mM ammonium acetate. The x axis represents Ω values and the y axis 
represents relative abundance at each charge state. 
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Figure 2.15: Bar chart showing the percentage conformation of apo (c) and copper bound (1 & 2) unmodified, WT alpha-synuclein in each 
conformational family at each CSI. Percentage in each conformation calculated through fitting the ATD of 10 μM unmodified WT alpha-synuclein 
(with and without equimolar copper) of each CSI to the minimum number of Gaussians and calculating the area under the curve. 
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2.4.10 Copper binding to alpha-synuclein increases the rate of protein 
aggregation 
As discussed in Section 1.3.3, alpha-synuclein is a protein which can aggregate into 
amyloid fibrils, and certain environmental conditions, including the presence of various 
metals, are known to alter the rate of aggregation. It is thought that one or more 
species of alpha-synuclein that arises during the aggregation pathway may be the toxic 
form of the protein, and conditions which increase aggregation rate are known to be 
associated with incidence of PD (Manning-Bog et al., 2002; Munishkina, Fink and 
Uversky, 2009). The aggregation propensity of alpha-synuclein in the presence and 
absence of Cu2+ was investigated using ThT fluorescence, a conventional method used 
to probe the emergence of beta-sheet rich protein structures on the amyloid fibril 
forming pathway (LeVine, 1999). ThT is used to monitor in vitro amyloid fibril 
formation as upon binding to amyloid fibrils it emits a strong fluorescence signal at 
approximately 482 nm when excited at 450 nm (Naiki et al., 1989).  
Results are displayed in Figure 2.16, with individual traces of five replicate aggregation 
experiments shown in (a) and the median and standard deviation aggregation lag time 
of the repeats shown in (b). Lag time was determined by calculating the intercept 
between the maximum derivative and the pre-transitional base line as described in 
Figure 2.4. When alpha-synuclein was incubated in the presence of copper, the lag 
time was significantly decreased from a lag time of 677 minutes for alpha-synuclein 
incubated alone to a lag time of 323 minutes in the presence of copper, indicating that 
material rich in beta-sheet material was being formed at an earlier time point. These 
results demonstrate that Cu2+ increases the rate at which unmodified, WT alpha-
synuclein forms amyloid fibrils.  
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Figure 2.16: Copper induced aggregation of alpha-synuclein as monitored by Thioflavin T fluorescence. Alpha-synuclein was incubated at 70 µM alone 
(black) or in the presence of equimolar CuCl2 (blue) and aggregation monitored by ThT fluorescence assay. Shown in (a) are the individual traces of 5 
replicates experiments for each condition. Shown in (b) is the calculated median of these replicates. Statistical significance determined by the 
Kruskall–Wallis with Conover–Inman post hoc analysis test (P < 0.05).  
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2.4.11 Copper binding to alpha-synuclein is altered by N-terminal 
acetylation and H50Q mutation 
Once the pattern of copper binding to unmodified, WT alpha-synuclein and 
subsequent conformational change and aggregation propensity had been established, 
the effect of N-terminal acetylation and H50Q mutation on these factors was 
investigated. To determine the degree of Cu2+ binding to the modified and mutated 
proteins, ESI-MS mass spectra were again acquired at a 1:1 protein to metal ratio 
immediately upon the addition of CuCl2. Figure 2.17 shows resulting spectra for the +6 
to the +14 charge state ions of all 4 proteins in the absence and presence of equimolar 
CuCl2. 
As shown in the spectra in Figure 2.17, in contrast to the unmodified protein, in the 
presence of equimolar Cu2+ the majority of N-terminally acetylated alpha-synuclein 
remained in its apo form with this being the base peak in the spectra of each CSI. The 
N-terminally acetylated protein does bind to copper, with peaks of lower intensity 
being present corresponding to the protein being bound to either one or two copper 
ions. These results in agreement with previous studies (Moriarty et al., 2014) indicate 
that acetylation reduces the ability of alpha-synuclein to bind Cu2+, likely as a result of 
the high-affinity N-terminal copper binding site becoming inaccessible upon 
acetylation.  
In agreement with previous studies (Davies et al., 2011), it was found that the 
unmodified H50Q mutant protein (i.e. the non-acetylated version of H50Q alpha-
synuclein) displayed no alterations in binding of Cu2+ by ESI-MS. As with the 
unmodified WT protein, the base peak at every CSI of the protein corresponded to the 
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binding of one copper ion and the entire population of monomeric H50Q alpha-
synuclein was found bound to either one or two copper ions. The lack of alterations 
seen with this protein implies that the H50Q mutation does not hinder copper binding, 
indicating that the H50 residue does not play a prominent role in copper binding to the 
unmodified protein under the conditions investigated here.  
In contrast, the previously unstudied N-terminally acetylated H50Q mutant showed 
greatly impaired copper binding, with only a negligible proportion of protein binding to 
one Cu2+ ion, and the vast majority remaining in its unbound form. This can clearly be 
seen at every CSI shown in Figure 2.17. This indicates that, although the histidine at 
residue 50 does not appear to play a prominent role in copper binding to the 
unmodified protein, it does play a major role in copper binding to the acetylated H50Q 
mutant. This novel finding is of great interest, as in PD families with the H50Q 
mutation the N-terminally acetylated H50Q mutant would be the form found in vivo. 
Therefore the data presented here implies that the form of alpha-synuclein found in 
these PD patients would have greatly impaired ability to bind to copper.  
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Figure 2.17: Alpha-synuclein spectra in the absence and presence of equimolar Cu2+. Binding of Cu2+ to unmodified and acetylated WT and H50Q 
alpha-synuclein at the +6 to +14 CSIs. Spectra were acquired at protein to CuCl2 ratios of 1:0 and 1:1 in 50 mM ammonium acetate (pH 7). The x axis 
represents m/z values and the y axis represents relative abundance.  
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2.4.12 Addressing the effect of N-terminal acetylation and H50Q 
mutation on copper induced conformational change to alpha-synuclein  
In order to investigate the effect of N-terminal acetylation and H50Q mutation on the 
conformational changes which occur following copper binding, IMS experiments were 
performed. ATDs were extracted for each CSI of unmodified and N-terminally 
acetylated WT and H50Q alpha-synuclein, in the presence and absence of equimolar 
Cu2+. The data were converted to Ω and fitted to the minimum number of Gaussian 
distributions. The area under each curve was then used to gain estimates of the 
population of each conformational state. Results are presented in summarised form in 
Figure 2.18, a bar chart plotting the percentage population of protein attributed to 
each conformational family (A to H) at each CSI. The Gaussian fitting of the extracted 
ATDs used for the production of Figure 2.18 can be seen in Appendix Figure 2. 
The copper induced conformational change to the unmodified WT protein is as shown 
previously in Figure 2.15, with an overall shift to the more compact conformational 
families seen across the majority of CSIs. In the case of the N-terminally acetylated WT 
alpha-synuclein, it can be seen that the unbound form of the protein (in the presence 
of copper) does not undergo any notable conformational changes compared to the 
protein in the absence of copper, indicating that the majority of the acetylated protein 
is indeed unable to interact with the copper. The N-terminally acetylated WT protein 
which is bound to copper undergoes similar conformational change to the unmodified 
protein, with an increase in protein occupying the more compact conformations seen 
at the majority of CSIs. However at some of the higher CSIs the opposite affect is seen, 
with an increase in the more extended conformational families being observed which 
is particularly evident at the +13 and +14 CSIs in Figure 2.18. This demonstrates that 
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acetylation is not only altering alpha-synuclein's affinity for copper, but also altering 
the conformational changes which occur when copper is bound.  
The unmodified H50Q mutant form of the protein displays a pattern of conformational 
change similar to that of the unmodified WT protein. This would indicate in the 
absence of acetylation H50 is not required for binding and the conformational changes 
which occur as a result of this. A significant proportion of acetylated H50Q alpha-
synuclein was unable to bind to copper and hence no conformational changes 
occurred with this protein when copper is present in solution.  
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Figure 2.18: Bar chart showing the percentage conformation of apo (c) and copper bound (1 & 2) unmodified and acetylated WT and H50Q alpha-
synuclein in each conformational family at each CSI. Percentage in each conformation calculated through fitting the ATD of 10 μM unmodified WT 
alpha-synuclein (with and without equimolar copper) of each CSI to the minimum number of Gaussians and calculating the area under the curve. 
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2.4.13 Addressing the effect of N-terminal acetylation and H50Q 
mutation on copper induced aggregation of alpha-synuclein by 
Thioflavin T fluorescence 
The effect of acetylation and the H50Q mutation on alpha-synuclein aggregation 
propensity, in the presence and absence of Cu2+, was investigated using Thioflavin-T 
fluorescence as shown in Figure 2.19.  
In agreement with previous reports (Kang et al., 2012) it was found that the N-
terminally acetylated WT alpha-synuclein had an increased average lag time (tlag = 886 
minutes) compared to that of the unmodified WT protein (tlag = 677 minutes). 
Therefore acetylation of the protein reduces its tendency to aggregate. The H50Q 
mutant displayed a higher aggregation propensity than the WT protein, with a reduced 
average lag time of 228 minutes, which again has been reported in the literature 
(Khalaf et al., 2014). This lag time was further reduced with the addition of Cu2+ (tlag = 
159 minutes). The previously unstudied N-terminally acetylated H50Q mutant 
displayed the same increased aggregation propensity as the unmodified H50Q mutant 
(tlag = 181 minutes), but in this case no further decrease in lag time was observed upon 
the addition of Cu2+ (tlag = 186 minutes). This is consistent with the impaired Cu
2+ 
binding and lack of conformational change seen with this protein by ESI-IMS-MS. 
Hence, N-terminal acetylation decreases and the H50Q mutation increases the intrinsic 
rate of aggregation of alpha-synuclein. This aggregation rate is increased by the 
presence of copper, with the exception of the acetylated H50Q mutant, where copper 
binding is ablated and therefore no further increase in aggregation is observed. 
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Figure 2.19: Copper induced aggregation of modified and mutated alpha-synuclein as 
monitored by Thioflavin T. Alpha-synuclein was incubated at 70 µM alone (black) or in 
the presence of equimolar CuCl2 (blue). Statistical significance determined by the 
Kruskall–Wallis with Conover–Inman post hoc analysis test (P ≤ 0.05).  
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2.5 Conclusions and future work 
The aim of this chapter was to ascertain whether N-terminal acetylation or H50Q 
mutation of alpha-synuclein resulted in alterations to, firstly, the conformation of the 
protein, and secondly, the copper binding and subsequent changes in conformation 
and aggregation propensity. To facilitate these investigations, N-terminal acetylation of 
recombinant alpha-synuclein was achieved through co-transformation and H50Q 
mutation was achieved through site directed mutagenesis. Resulting proteins were 
then investigated via ESI-MS, IMS and ThT fluorescence. 
Results presented in this chapter demonstrate that the alpha-synuclein monomer 
presents as a heterogeneous, dynamic protein; existing simultaneously in a number of 
conformational states. This is evidenced in both its wide, bi-modal CSD and the 
multiple conformational families co-populating each CSI. These findings are in keeping 
with previous investigations utilising ESI-IMS-MS in the study of alpha-synuclein, as 
discussed in detail in Section 1.4.4.1.  
In comparison to the unmodified, WT protein, neither N-terminal acetylation nor H50Q 
mutation appeared to significantly alter the overall conformation of alpha-synuclein. 
However some slight differences were observed in the percentage of protein 
populating the most extended conformational family, H. The H50Q mutants (both 
unmodified and N-terminally acetylated) displayed a reduced proportion of protein in 
this most extended conformation at the +15 CSI compared to their WT counterparts. It 
would be of interest to investigate other familial PD mutants known to alter alpha-
synuclein aggregation, to see if a common pattern emerges. 
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The copper binding characteristics of unmodified, WT alpha-synuclein under our 
experimental set up was first established to allow comparison of the modified 
proteins. It was seen that at a 1:1 ratio of protein to Cu2+, the entire population of 
alpha-synuclein monomer bound to either 1 or 2 copper ions, demonstrating a high 
affinity for this metal. Binding was seen across all CSIs, in agreement with alpha-
synuclein peptide binding studies (Brown, 2009). These results indicate that initial Cu2+ 
binding is determined at the primary structural level, as the extended, disordered state 
was capable of binding Cu2+ ions without a pronounced conformational change.  
ESI-IMS-MS data presented here provides evidence for two concurrent events 
occurring when alpha-synuclein binds to copper. The first is a shift to more compact 
forms of the protein, which is evident when looking at the ATDs of individual CSIs. This 
result is in agreement with previous reports of the protein shifting to a partially folded 
conformation in the presence of this metal, which is thought to be associated with an 
increased tendency to aggregate (Natalello et al., 2011b). The second observation is 
the somewhat contradictory finding of an increased CSD in the presence of copper, 
with an increase in the higher CSIs in particular. This suggests an increase in extended 
forms of alpha-synuclein upon copper binding, which has recently been reported in the 
literature by Ranjan et al. (2017), who found a resultant destabilisation of long-range 
tertiary interactions of alpha-synuclein, exposing the highly amyloidogenic NAC region, 
with a resultant increase in the rate of fibril formation. 
N-terminal acetylation of alpha-synuclein reduced copper binding ability, with the 
majority of the protein remaining in an unbound state. This is in agreement with 
previous studies (Moriarty et al., 2014), and is not surprising when taking into account 
that the initiating methionine residue which is altered upon N-terminal acetylation is a 
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key anchor of alpha-synuclein highest affinity copper binding site. The H50Q mutant 
was found to have the same copper binding affinity as the WT protein, with the entire 
monomeric population binding to either 1 or 2 copper ions. This is in contrast to what 
would be anticipated from the loss of the histidine residue, which is involved in the 
second highest affinity main copper binding site, but is in agreement with previous 
studies on the topic (Davies et al., 2011). Lastly, the previously unstudied N-terminally 
acetylated H50Q mutant was investigated. Here it was found that copper binding was 
drastically impaired, with virtually all of the protein remaining unbound in the 
presence of copper. This result suggests that in the unmodified H50Q mutant the N-
terminus site is largely responsible for the copper binding seen here by ESI-MS.  
In vivo the N-terminus of alpha-synuclein is known to be acetylated; this implies that 
the familial H50Q mutation would result in impaired copper binding. This finding is of 
great importance if the ability of alpha-synuclein to bind copper is important for its (as 
yet uncertain) physiological role. As discussed in Section 2.1.3, one proposed function 
of alpha-synuclein is the protein having ferrireductase activity, requiring copper bound 
to carry out this function. Results presented here would imply that the H50Q mutation 
would leave alpha-synuclein impaired in its ability to act as a ferrireductase, as the 
acetylated form of this protein (the form that would be found in vivo) is not able to 
bind to copper. Copper is required for many reactions in cellular metabolism, which is 
particularly true in the brain due to this organ having a high respiratory rate and being 
prone to OS. Copper is involved in many vital functions in the brain, including the 
control of reactive oxygen species (ROS), neurotransmitter synthesis and metabolism 
and extracellular matrix formation (reviewed by Tapiero, Townsend and Tew, 2003). In 
addition to being vital for many cellular processes, copper can also participate in the 
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cascade of free radical generation as a catalyst in Fenton chemistry. The Fenton 
reaction, Cu(I) + H2O2 ↔ Cu(II) + OH- +OH ͘ converts relatively stable hydrogen 
peroxide into the highly reactive hydroxyl radical. This is important in brain areas 
metabolising biological amines (such as dopamine), as hydrogen peroxide is a by-
product of monoamine oxidase (MAO) metabolism. Damaging aspects of copper are 
present when this metal exists as a free ion, and therefore alterations to a protein's 
copper binding ability has the potential to alter the equilibrium of free copper ions, 
resulting in a possible increase in ROS. Therefore it would be pertinent to assess the 
ability of N-terminally acetylated H50Q alpha-synuclein to act as a ferrireductase in 
vivo, and if alterations are found to assess cellular metal homeostasis and ROS balance.  
Through all experiments presented in this chapter the H50A mutant was also 
investigated in parallel to the H50Q mutant, with identical results seen (data not 
shown). This demonstrates that it is the loss of the histidine residue, rather than the 
presence of the glutamine residue, which is responsible for the loss of copper binding 
seen in the acetylated H50Q mutant.  
Results presented in this chapter are the first to describe the effect of a familial 
mutation on the copper binding ability of the biologically relevant, N-terminally 
acetylated alpha-synuclein protein. Data presented in this chapter highlight the need 
to take into account N-terminal acetylation when conducting in vitro investigations of 
alpha-synuclein. 
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Chapter 3 – Investigating alpha-synuclein aggregation 
using ESI-MS and ESI-IMS-MS 
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3.1 Introduction 
Protein misfolding diseases arise from a protein's inability to retain its native 
conformation. Many neurodegenerative diseases such as Alzheimer's, Huntington's 
and PD share the common feature of a usually soluble protein aggregating and forming 
amyloid deposits in the brain. The proteins implicated in these three diseases (amyloid 
beta in Alzheimer's disease, huntingtin in Huntington's disease and alpha-synuclein in 
PS) are IDPs, with reported levels of disorder of > 80%, > 81% and > 75% respectively 
(Raychaudhuri et al., 2009). Understanding the aggregation process involved in protein 
misfolding diseases is critical to be able to develop therapeutics designed to inhibit 
aggregation as a whole or to inhibit the formation of or dissociate toxic species which 
arise during the aggregation process.  
The aggregation of alpha-synuclein into amyloid fibrils is thought to be associated with 
PD pathogenesis, with evidence pointing towards one or more of the oligomeric 
species which arises during the aggregation process being the pathogenic form. The 
protein's ability to self-assemble has been investigated by numerous techniques, 
including ThT assay (Buell et al., 2014), dynamic light scattering (Dusa et al., 2006), 
small-angle X-ray scattering (Rekas et al., 2010), transmission electron microscopy 
(Anderson and Webb, 2011) and atomic force microscopy (AFM) (Fink, 2006). 
Disadvantages of such techniques include low sensitivity, low throughput nature and, 
in some cases, their inherent biased nature (Giehm, Lorenzen and Otzen, 2011). 
However, these investigations have identified multiple intermediate oligomeric 
species, including spherical and ring-shaped structures populated during assembly 
(Conway et al., 2000; Lashuel et al., 2013). Consequently, it has been theorised that 
the transition from the native, soluble form of alpha-synuclein into amyloid fibrils is 
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not a single step process, or even one single pathway, making it of great importance to 
characterise the individual species populated during the aggregation process.  
ESI-MS is able to provide a high throughput, high sensitivity, unbiased technique which 
is capable of characterising oligomeric species present in the early stages of protein 
aggregation. ESI-IMS-MS emerged in the 1990's as an alternative to more traditional 
techniques such as X-ray crystallography and NMR for the investigation of protein 
structure (Shelimov et al., 1997). While ESI-IMS-MS is not able to provide the atomistic 
resolution of these techniques it offers the valuable advantage of the ability to study 
both the conformational dynamics of a protein and the interrogation of multiple 
overlapping conformers and oligomeric species. This makes ESI-IMS-MS an invaluable 
tool for the study of aggregating proteins, allowing the frequently diverse array of 
species which arise during early aggregation to be investigated. A further benefit of 
ESI-IMS-MS is the lower sample concentrations required compared to techniques such 
as NMR and X-ray crystallography. This is an important advantage for proteins such as 
alpha-synuclein, where concentration is known to affect aggregation (Uversky et al., 
2001). Consequently, ESI-MS and ESI-IMS-MS have been used to investigate a range of 
aggregating proteins and peptides. However, investigations into the aggregation of 
alpha-synuclein using these techniques have been lacking, particularly when compared 
to the progress which has been made for other amyloidogenic proteins, most notably 
β2-microglobulin (Lim and Vachet, 2004; Smith et al., 2006; Mendoza et al., 2010, 
2011; Smith et al., 2011; Woods et al., 2011; Dong et al., 2014; Leney et al., 2014; Hall, 
Schmidt and Politis, 2016) and amyloid-β (Bernstein et al., 2005, 2009; Murray et al., 
2009; Gessel et al., 2012; de Almeida et al., 2017; Jin Lee et al., 2018). Although ligand 
binding studies have been performed with alpha-synuclein little has been published on 
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the oligomeric conformations by mass spectrometry. Several modes of action have 
been proposed as to how alpha-synuclein oligomers can elicit cytotoxicity, with 
protocols established to enable the formation of oligomers with known cellular effects. 
Exogenous application of Type C alpha-synuclein oligomers characterised by Danzer et 
al. (2007) are known to increase cytosolic alpha-synuclein aggregation, as described in 
detail in Section 4.1.1.2. The production of these oligomers has been adapted for MS 
analysis by Illes-Toth et al. (2015). ESI-IMS-MS revealed that in preparations of Type C 
oligomers the unmodified protein is capable of forming species from dimers to 
hexameters that are accessible by this technique. These oligomers, through 
comparison with model structures, were shown to be consistent with ring-like 
assemblies. In parallel, MS compatible Type C oligomers were demonstrated to be able 
to induce intracellular aggregation in neuronal cell lines via a prion-like mechanism 
(Illes-Toth et al., 2015). However, the assembly and dynamics of alpha-synuclein 
oligomers has not yet been investigated. It is also unknown if N-terminally acetylated 
versions of the protein are able to form these oligomeric species in the same manner 
as the unmodified protein. 
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3.2 Aims and Objectives 
ESI-MS and ESI-IMS-MS have proved to be valuable tools for the investigation of 
protein aggregation. The aim of this chapter was to apply MS methods to investigate 
the species present of alpha-synuclein during the early stages of aggregation. The 
presence of low order oligomers, most commonly dimers, of alpha-synuclein in non-
aggregated samples has been a common finding in studies utilising MS, as discussed in 
Section 1.4.4.1. Here, the low order oligomeric species present in samples of the 
unmodified and N-terminally acetylated protein were investigated to determine their 
oligomeric state and the dynamics of these low order oligomers in MS experiments 
was investigated using isotope labelling. 14N and 15N versions of the protein were 
created and through mixing at various time points used to determine the extent of 
inter conversion between the oligomers. Such approaches have been previously for 
other amyloidogenic proteins, showing alterations in oligomer dynamics over time 
(Smith et al., 2011).   
The specific aims of this chapter were: 
1. To characterise the species and dynamics of low order oligomers of unmodified 
and N-terminally acetylated alpha-synuclein present in samples prior to 
aggregation. 
2. To determine if Type C oligomers of alpha-synuclein assembled from both 
unmodified and N-terminally acetylated recombinant protein share a common 
structure.  
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3. To monitor the aggregation of alpha-synuclein under MS compatible 
conditions, looking at the oligomeric species present and their dynamics over 
the aggregation time course. 
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3.3 Materials and Methods 
3.3.1 Production of recombinant alpha-synuclein 
Unmodified and N-terminally acetylated alpha-synuclein were produced as described 
in Section 2.3.7/2.3.8. 
3.3.2 Production of 15N labelled recombinant alpha-synuclein 
15N labelled alpha-synuclein was produced in the manner described in Section 2.3.1, 
with the alteration of culturing transformed E. coli in ¹⁵N Overnight Express™ 
Autoinduction NMR Medium (Novagen), following manufacturer guidelines, rather 
than the autoinduction media used for unlabelled protein production.  
3.3.3 Production of MS compatible Type C alpha-synuclein oligomers 
In order to produce MS-compatible Type C oligomers protocols described by Illes-Toth 
et al. (2015) were followed. Alpha-synuclein was reconstituted to a final concentration 
of 7 μM in 50 mM AA (pH 7.0) containing 20% ethanol, followed by overnight 
incubation at 21 °C with continuous shaking. The following day solutions were 
concentrated 1:14 using ultracentrifugation (VivaSpin 500 columns, MWCO 30 kDa, GE 
Healthcare) allowing the separation of oligomeric species from monomeric protein. 
Type C oligomeric species were then analysed immediately following production. 
3.3.4 Aggregation of alpha-synuclein 
Lyophilised alpha-synuclein was reconstituted in 50 mM AA (pH 7) to a final 
concentration of 70 µM and incubated at 37 °C in a 96 well plate, with agitation at 300 
rpm. A 4 mm diameter glass bead was added to each well. Samples were taken at 0, 
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3.5, 19.5, 46.5 and 71.5 hour time points and an aliquot used immediately for MS 
analysis and the remainder snap frozen and stored at -80 °C for western blot, dot blot 
and ThT analysis. All samples endured the same number of freeze-thaw cycles.  
3.3.5 Mass spectrometry 
Mass spectrometry was performed as described in Section 2.3.11 with the following 
alterations; cone voltage 70 V, backing pressure 6.45 mbar. 
3.3.6 Western blot 
For western blot analysis 5 µL of sample from each time point of the aggregation 
experiment were subjected to SDS-PAGE using a homemade 12% SDS gel and 
transferred to a polyvinylidene fluoride membrane for 90 minutes at 75 V. The 
membrane was then blocked in TBS-T containing 5% (w/v) non-fat milk (NFM) for 1 
hour at room temperature, followed by overnight incubation with mouse monoclonal 
anti-alpha-synuclein antibody [syn211] (1:5000, abcam, ab80627) in TBS-T with 1% 
(w/v) NFM at 4 oC under gentle shaking. Following primary antibody incubation, 
membranes were washed 3 times for 10 minutes with TBS-T before incubation with 
IRDye® 680LT Goat anti-Mouse IgG antibody (H + L) (1:15,000, Licor, 925-68070) in 1% 
(w/v) NFM for 1 hour at room temperature. Visualisation was performed using the LI-
COR Odyssey and Odyssey Infrared Imaging software (LI-COR, Nebraska, USA). 
3.3.7 Dot blot procedure 
Nitrocellulose membranes (0.45 µM, GE Healthcare, Sweden) were spotted with 1 µL 
of sample from each aggregation time point, allowed to air dry and blocked for 1 hour 
in 5 % (w/v) NFM TBS-T. Primary antibody (Anti-Amyloid Fibrils LOC Antibody (1:2000, 
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Merk, AB2287)) was diluted in 1% (w/v) NFM TBS-T and incubated with the membrane 
overnight under continuous gentle shaking at 4 °C. Three wash steps were performed 
with TBS-T before incubation with secondary antibody (IRDye® 800CW Goat anti-
Rabbit IgG (H + L) (1:15,000 dilution, LI-COR)) diluted in 1 % (w/v) NFM TBS-T for one 
hour under continuous gentle shaking at room temperature. Visualisation was 
performed using the LI-COR Odyssey and Odyssey Infrared Imaging software (LI-COR, 
Nebraska, USA). 
3.3.8 Thioflavin T (ThT) fluorescence 
For ThT analysis 20 µL of sample from each time point of the aggregation process were 
mixed with 100 µL of 100 µM ThT and fluorescence intensity between 474 and 594 was 
measured using a CLARIOstar plate reader (BMG LABTECH, Buckinghamshire, UK).    
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3.4 Results and discussion 
3.4.1 Low order oligomeric species of alpha-synuclein are detected in 
both the unmodified and acetylated protein immediately following 
reconstitution 
Chapter 2 details how alpha-synuclein is a highly dynamic protein which exists in 
multiple conformations including a dynamic equilibrium between the monomeric form 
of the protein and low order oligomers. In this chapter low order oligomers of 
unmodified and N-terminally acetylated alpha-synuclein were investigated using ESI-
IMS-MS to ascertain whether any differences were observable between the oligomeric 
forms of the protein.  
Figure 3.1 (a) shows the mass spectra of freshly reconstituted, unmodified and N-
terminally acetylated alpha-synuclein (70 μM, 50 mM AA, pH 7.0) prior to incubation. 
In both the unmodified and N-terminally acetylated preparations, low abundance 
dimers, trimers and tetramers can be observed in addition to the more abundant 
monomer CSIs. The alpha-synuclein dimer peaks display a wide range of CSIs from 10 ≤ 
z ≥ 23, suggesting that the dimer, like the monomer, is dynamic and flexible and that 
N-terminal acetylation has had no effect on this structure. The observed CSD for the 
trimeric forms of the protein was 15 ≤ z ≥ 29 and 20 ≤ z ≥ 31 for the tetramers. This 
decrease in the width of the CSD would suggest that the oligomers of both forms of 
the protein become more compact on assembly. Figure 3.1 (b) shows mass spectra in 
the 1400 - 3000 m/z range where the majority of low order oligomer CSIs reside. The 
inset in (b) shows an expanded view of the 1840 - 2035 m/z region, where the +15 
dimer, +22 and +23 trimer and +29 and +31 tetramer peaks can be seen for both 
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proteins. Driftcope plots of these species are shown in Figure 3.2 (c) where again 
dimers, trimers and tetramers are detectable in both preparations, as highlighted on 
the figure, with the intensity of species decreasing as mass increases.  
Comparison of spectra acquired for unmodified and N-terminally acetylated alpha-
synuclein indicates that acetylation does not affect the formation of low order 
oligomers, as both versions of the protein produced very similar spectra. These results 
are in keeping with a previous investigation of N-terminally acetylated alpha-synuclein 
by ESI-IMS-MS by Kang et al. (2012), where no differences from the unmodified 
protein were found. However, in this previous study the largest species found for both 
forms of the protein was the dimer, whereas here the trimer and tetramer were 
additionally observed. Slight variations in the low order oligomer species present in 
different alpha-synuclein solutions were however commonly found in ESI-MS 
experiments conducted throughout this thesis, with the monomer dimer and trimer 
being found in all protein solutions and the tetramer frequently being detectable, but 
occasionally being absent. This is in keeping with the known variability found when 
analysing this protein using MS methods (Phillips et al., 2015).   
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Figure 3.1: ESI-IMS-MS analysis of unmodified and acetylated alpha-synuclein. Mass 
spectra in the 800 - 3000 range of recombinant proteins (70 µM, 50 mM AA pH 7) 
shown in (a), with the extremes of the CSD of monomeric, dimeric, trimeric and 
tetrameric species labelled. Mass spectra in the 1400 - 3000 range containing low 
order oligomers shown in (b), with CSIs of dimers highlighted in green, trimers in 
purple and tetramers in blue. Inset shows the expanded region of 1840 - 2035 m/z. 
Driftscope plots of both proteins in the 1400 - 3000 range is shown in (c), with one 
example of a dimer, trimer and tetramer CSI highlighted on each. 
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3.4.2 Low order oligomeric species of alpha-synuclein are dynamic 
In order to gain insight into the stability of the low order oligomers of alpha-synuclein 
described above, isotopic labelling of proteins was utilised. 15N alpha-synuclein was 
produced using 15N as the sole source of nitrogen for the E.coli cells during the 
recombinant protein expression process, resulting in a form of the protein with a mass 
shift sufficient to detect by MS. Through incubating equal concentrations of 14N and 
15N labelled alpha-synuclein separately and then mixing samples immediately prior to 
ESI-MS analysis, the rate of subunit exchange of oligomeric species can be determined. 
If the subunits are in rapid exchange the oligomers detected will be formed 
indiscriminately from the protein pool. For a dimer CSI this would result in three peaks 
in a 1∶2∶1 ratio, corresponding to dimers comprised of two 14N subunits, one 14N and 
one 15N subunit, or two 15N subunits respectively. However, if the dimer did not 
interconvert, a ratio of 1:1 between the 14N and 15N peaks would be seen.  
Figure 3.2 shows spectra from 14N and 15N alpha-synuclein reconstituted to equal 
concentrations and either analysed alone or mixed immediately prior to acquisition. 
Full spectra are shown in (a), where two peaks can be seen for each monomeric CSI in 
the mixed sample. Spectra of the +11 monomer CSI is shown in (b), where in the mixed 
sample only peaks attributable to the 14N or 15N are seen. Spectra of the +13 dimer CSI 
is shown in (c), where in the mixed sample a new, most abundant peak is present, 
attributable to this dimer comprising one 14N subunit and one 15N subunit. This 
indicates that this dimer CSI is dynamic in nature, as the monomeric subunits are in 
exchange. The 2150 - 3000 m/z range is shown in (d), where a variety of low order 
oligomers can be seen. Full subunit exchange was detected for all distinguishable low 
order oligomers in the spectrum, demonstrating that following reconstitution of 
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lyophilised recombinant alpha-synuclein, the low order oligomers detectable by ESI-
MS are dynamic in nature and fully exchange during the time course of the 
experiment. Both the trimer and tetramer higher order oligomers appear to be fully 
exchanged during the time course of the experiment, with broad peaks being observed 
in the mixed 14N and 15N sample. 
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Figure 3.2: ESI-MS analysis of unlabelled and nitrogen labelled alpha-synuclein. Mass 
spectra in the 800 - 3000 range of 14N, 15N and combined proteins (70 µM, 50 mM AA 
pH 7.0) shown in (a). Spectra of the +11 monomer CSI is shown in (b) and the +13 
dimer CSI is shown in (c). Spectra of the +11 and +13 dimer CSIs and +5/+10 and 
+6/+12 monomer/dimer CSIs are shown in (d), with peaks attributable to the 14N 
protein highlighted in blue, 15N protein highlighted in green and mixed 14N and 15N 
highlighted in purple.  
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3.4.3 Structurally comparable species of Type C alpha-synuclein 
oligomers are present in solutions prepared from both unmodified and 
acetylated protein 
As will be discussed in detail in Section 4.1.1 increasing evidence suggests that it is the 
oligomeric species of alpha-synuclein which may be the toxic form of protein, rather 
than mature aggregates. Type C oligomers adapted to be compatible with MS analysis, 
while retaining their cellular effects, have previously been characterised by ESI-IMS-MS 
(Illes-Toth et al., 2015).  
Figure 3.3 shows the drift scope plot (i) and spectra (ii) of Type C alpha-synuclein 
oligomers, adapted for MS analysis, assembled from unmodified (a) and N-terminally 
acetylated (b) protein. Here both low order (dimers, trimers and tetramers) and higher 
order (pentamers and hexamers) oligomeric species can be observed, interspersed 
with peaks that could not be assigned, consistent with the previous report of Illes-Toth 
et al., (2015). In addition to the oligomeric species, a CSD of monomeric CSIs is present, 
despite the use of a 30000 Da MWCO spin concentrator in the Type C preparation 
protocol. This may be a result of the dynamic nature of the oligomers and the re-
establishment of an equilibrium state. Also notable in the spectra is a greater 
proportion of monomeric protein coming from the more compact CSIs (centred on the 
+7 ion) when compared to the spectra of freshly reconstituted alpha-synuclein shown 
in Figure 3.1 and Figure 3.2. Previous work has provided evidence for an increase in the 
compact state of alpha-synuclein, centred on the +7 CSI under conditions which are 
known to increase aggregation of the protein, such as the presence of high 
concentrations of alcohols (Natalello et al., 2011). As accumulation of this compact 
state correlates with increased aggregation, it is plausible that this partially folded 
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form of alpha-synuclein seen here represents an intermediate in conformational 
transitions to oligomeric species of the protein. This shift in CSI intensity was not seen 
in control experiments of the Type C oligomer sample prior to incubation, 
demonstrating that the increase in the more compact CSIs seen following incubation is 
not an artefact of the 10% ethanol used in the oligomerisation protocol. No notable 
differences were observed in the driftscope plot or spectra of Type C oligomers 
prepared from unmodified or N-terminally acetylated alpha-synuclein. This indicates 
that N-terminal acetylation does not affect the assembly of alpha-synuclein into Type C 
oligomers. These results support data shown in Figure 4.4, where N-terminal 
acetylation was found to not alter the ability of Type C oligomers to induce 
intracellular aggregation of alpha-synuclein. 
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Figure 3.3: ESI-IMS-MS analysis of unmodified and N-terminally acetylated alpha-synuclein Type C oligomers. Driftscope plots of unmodified (a) and 
N-terminally acetylated (b) Type C oligomers in the 800 - 5000 m/z range is shown in (i) and corresponding spectra shown in (ii) (inset shows the 
expanded region of 3000 - 5000 m/z). 
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3.4.4 ESI-MS analysis of alpha-synuclein aggregation 
In order to investigate the assembly mechanism of alpha-synuclein into amyloid 
material ESI-MS was used to characterise the transitional species present during the 
early stages of alpha-synuclein aggregation. Incubation of 70 μM alpha-synuclein 
under agitation is known to produce amyloid material that is ThT positive (Figure 2.16). 
Investigations were carried out over a three day time course, as this length of time was 
shown to be adequate for alpha-synuclein to form aggregates in earlier experiments 
using ThT fluorescence, as shown in Figure 2.19. 
Figure 3.4 (a) shows spectra of 0, 3.5, 19.5, 46.5 and 71.5 hour time points of an in 
vitro alpha-synuclein aggregation time course. The 0 hour spectrum displays the same 
characteristics as described in Figure 3.1 of wide CSDs and low order oligomeric 
species present in addition to the monomer. The monomer CSD spans 5 ≤ z ≥ 17 and 
features a predominantly mono-modal distribution centred on the +12 CSI at 0 hour 
incubation. From the 3.5 hour time point the CSDs of the monomeric and oligomeric 
species begin to narrow, with the CSD of the various species at each time point 
summarised in Figure 3.4 (b). The dimer CSD reduced from 10 ≤ z ≥ 23 at 0 h to 11 ≤ z ≥ 
15 at 71.5 h, indicative of a collapse in the conformation of the dimer with time. In 
addition to the alterations in CSD, the Total Ion Chromatogram (TIC) was found to 
decrease at each time point (as highlighted on the spectra of Figure 3.4 (a) in purple), 
as it became increasingly difficult to achieve a stable nESI spray. This would indicate 
that as the time course progresses alpha-synuclein monomers and low order oligomers 
are depleted from the solution, possibly as a result of these species aggregating to 
higher order oligomers beyond the mass range able to be detected in this experiment. 
 137 
 Alpha-synuclein aggregation is a nucleation dependent process, and it has been 
suggested that the dimer acts as the nucleus for aggregation (Roostaee et al., 2013). A 
previous study by Phillips et al., (2015) monitoring the aggregation of alpha-synuclein 
using MS methods found, in contrast to data presented here, that the CSD of the 
dimeric species remained consistent throughout the aggregation experiment (despite a 
reduction in TIC as found here) and a shift in the ratio of dimer to monomer CSIs over 
time. In contrast, the ratio of monomer to dimer was found here to increase over time, 
suggesting a preferential depletion of the dimeric species. This is shown in Table 3.1, 
where the ratio of monomer to dimer, calculated by summing the absolute intensities 
of all monomeric CSIs and all odd dimeric CSIs at each time point, is displayed. This is in 
keeping with the suggestion of the dimer as a nucleus for aggregation, as it is possible 
the dimer CSIs would be depleting at a greater rate than the monomer CSIs if they 
were nucleating the formation of higher order oligomers or fibrils.  
 
Table 3.1: the ratio of monomer to dimer derived from the sum of the intensities of all 
monomer CSIs and all odd dimer CSIs following an aggregation time course.
 Incubation time (hours) 
0 3.5 19.5 46.5 71.5 
Monomer : Dimer  27.4 31.4 59.2 76.1 132.6 
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Figure 3.4: ESI-MS analysis of alpha-synuclein aggregation time course. Spectra 
acquired following 0, 3.5, 19.5, 46.5 and 71.5 hour incubations are shown in (a), with 
the total ion count over 20 scans shown in purple. Table showing the CSD of 
monomeric, dimeric and trimeric species present at corresponding time points shown 
in (b). Spectra of the +13 dimer CSI of 14N and 15N incubated separately and combined 
immediately before acquisition is shown in (c), with peaks attributable to the 14N 
protein highlighted in blue, 15N protein highlighted in green and mixed 14N and 15N 
highlighted in purple. 
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The data presented in this chapter appear to present a paradox in results with 
monomer to hexamers being observed in the Type C oligomer specific protocol yet 
larger species absent during fibril formation. Larger oligomeric species would be 
expected, and results presented in Figure 3.3 demonstrate that species up to at least 
the hexamer are able to be detected under our experimental conditions. The lack of 
higher order oligomers during fibril formation conditions could potentially be due to 
aggregating species of alpha-synuclein quickly reaching a size making them 
undetectable by our MS method due to the increased concentration of the total 
protein 70 μM compared to the 7 μM used in the oligomer protocol. A plausible 
explanation is that the time points selected missed the presence of aggregating species 
or that the absence of either ethanol or a pre-concentration step prevented their 
formation. This could indicate that the low order oligomeric species present 
throughout the aggregation time course experiment may easily form and dissociate, 
but are not part of the fibril formation pathway. It has been demonstrated in the case 
of other proteins that reconstitution of lyophilised protein can result in the formation 
of low order oligomers on short time frames (Smith, Radford and Ashcroft, 2010) and 
the storage conditions of alpha-syncuclein can affect the oligomeric state of the 
protein (Stephens et al., 2018).  
Alternatively the low order oligomers which persist at later time points could 
potentially be an artefact of the electrospray process, however higher order 
pentamers and hexameters were shown to require incubation before being observed. 
The lack of the higher order oligomeric species similar to the Type C preparation found 
during the aggregation time course suggests that these oligomers are either transient 
in nature, only being detectable for a defined period of time before aggregating 
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further and becoming undetectable, or that they are off pathway oligomers not related 
to the eventual formation of amyloid fibrils.  
To address the dynamic nature of the oligomers populated during the early stages of 
aggregation isotopic labelling of proteins was utilised in the manner described in 
Section 3.3.2. This allowed the investigation of the dynamics of alpha-synuclein 
oligomer subunit exchange over the course of the aggregation experiment. Equal 
concentrations of 14N and 15N labelled alpha-synuclein were incubated under 
aggregation conditions separately and mixed immediately prior to ESI-MS analysis at 
discrete time points. Figure 3.4 (c) shows the spectra of the +13 dimer CSI of 14N and 
15N incubated separately and combined immediately before acquisition, with peaks 
attributable to the 14N protein highlighted in blue, 15N protein highlighted in green and 
mixed 14N and 15N highlighted in purple. The presence of a peak attributable to both 
14N and 15N was detected at every time point, demonstrating that this dimer is 
remaining dynamic throughout the aggregation experiment. This pattern was seen 
across all detectable oligomeric species in the spectra, which were found to undergo 
subunit exchange at each time point tested. The finding of all low order oligomers 
remaining dynamic at the end of the aggregation experiment is in contrast to previous 
studies using a similar technique to analyse the aggregation of β2 microglobulin, where 
alterations in dynamics were found for both particular oligomeric CSIs and over the 
time course of an aggregation experiment (Smith et al., 2010, Smith et al., 2011). This 
provides support to the possibilities mentioned above, that low order alpha-synuclein 
oligomers detectable by ESI-MS either easily form and dissociate, but are not a part of 
the aggregation pathway, or are an artefact of the electrospray process. What can be 
determined from ESI-MS is that soluble protein is consumed during the aggregation 
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process and that the oligomeric species become compacted upon incubation.  The 
absence of high order oligomers akin to those observed with the oligomer specific 
protocol raises the possible that the Type C oligomers form on an amyloid independent 
pathway. 
3.4.5 Aggregates of alpha-synuclein are formed over the time course 
utilised for ESI-MS experiments 
Due to the absence of any oligomeric species larger than those present prior to sample 
aggregation, alternate techniques were employed on samples taken at corresponding 
time points to confirm that protein aggregation had occurred on the timescale 
investigated. 
Figure 3.5 (a) shows the result of western blot analysis of the samples using an 
antibody to detect alpha-synuclein. A band corresponding to the monomeric form of 
the protein can be seen at all time points, which correlates to the presence of a 
monomeric CSD at each time point seen with MS analysis. Also detectable is the 
presence of a high molecular weight species of alpha-synuclein at the 19.5 hour, 46.5 
hour and 71.5 hour time points. These aggregates reside at the very top of the sample 
well of the SDS-PAGE gel used to separate out the samples before western blot 
transfer, demonstrating that these aggregates are too large to enter the gel and be 
analysed by SDS-PAGE analysis. Figure 3.5 (b) shows the result of dot blot analysis of 
the samples using the LOC antibody which recognise generic epitopes common to 
amyloid fibrils and fibrillar oligomers. It can be seen that the intensity of fluorescence 
from this antibody increases at each time point, with the most intense fluorescence, 
and therefore the most fibrillar material in the sample, being at the 71.5 hour time 
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point. No signal is detected at the 0 hour time point, demonstrating that the starting 
material is not recognised by this antibody. Figure 3.5 (c) shows the result of ThT 
analysis of the 5 samples. No notable fluorescence above the vehicle control is 
detected in the 0 hour and 3.5 hour samples, indicating that no significant β-sheet 
structure is present in these samples, correlating to both the lack of signal from the 
LOC antibody by dot blot analysis and lack of large aggregates seen through western 
blot analysis. At the later time points (19.5 hour, 46.5 hour and 71.5 hour) an increase 
in ThT fluorescence is seen, indicating that the protein in the sample has assembled 
into a form containing significant β-sheet structure. 
The data presented here confirms that amyloid material has been formed under MS 
compatible conditions during the time course aggregation experiment used for MS 
analysis, despite the lack of larger species seen in the ESI-MS spectra, validating the 
time points chosen for MS experiments. 
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Figure 3.5: Western blot, dot blot and ThT evidence that alpha-synuclein is forming aggregates in the duration of time course experiments. Western 
blot using an antibody to detect alpha-synuclein of samples taken following 0, 3.5, 19.5, 46.5 and 71.5 hour incubations is shown in (a). The same 
samples were subject to dot blot analysis using an antibody to recognise generic epitopes common to amyloid fibrils and fibrillar oligomers shown in 
(b) and ThT assay, shown in (c). 
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3.5 Conclusions and Future Work 
Characterizing prefibrillar oligomers is key to understanding the aberrant aggregation 
of misfolding proteins and provides vital insights which can aid in the design of 
potential therapeutics for protein misfolding diseases. The aim of this chapter was to 
apply MS methods to investigate the species of alpha-synuclein which arise during the 
early stages of its aggregation. 
Data presented in this chapter has characterised the species of low order oligomers 
which are present in non-aggregated samples of both unmodified and N-terminally 
acetylated alpha-synuclein. The same species were present for both forms of the 
protein, indicating that acetylation does not alter the formation of low order alpha-
synuclein oligomers. To investigate the dynamic nature of low order oligomers, the 
rate of subunit exchange was monitored using 14N/15N labelling. The data revealed that 
all oligomer ions present in the non-aggregated samples underwent rapid exchange, 
demonstrating that they are dynamic entities. 
Experiments presented here also confirmed that the species of Type C alpha-synuclein 
oligomers, characterised using MS by Illes-Toth et al., (2015) were also present when 
these oligomers were assembled from the acetylated protein. The dynamics of the 
higher order oligomeric species present in Type C oligomer samples were not able to 
be analysed during the course of this PhD, due to a combination of difficulty in 
obtaining two independent preparations displaying these species at similar intensities 
on the same time scale, and due to broad peaks masking exchange. 
Lastly, the characteristics of ESI-MS spectra acquired over the course of an aggregation 
experiment was assessed. As fibrillar forms of the protein were formed (as confirmed 
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by various biochemical assays) evidence was seen in the spectra for depletion of 
solution phase constituents. It was also notable that the low order oligomers present 
throughout the aggregation time course remained dynamic, continuing to undergo 
subunit exchange. This suggests that these oligomeric species may not be on pathway 
oligomers or that the early stages of aggregation are highly dynamic. What was 
observed was a decrease in the CSD with time, indicative of more compact 
conformation being populated during the aggregation process. An alternative 
explanation is that these oligomers could be an artefact of the electrospray process, 
and not representative of the protein in solution, however further experiments would 
be required to determine this. There are various lines of evidence supporting the idea 
of low order oligomeric forms of the protein (particularly tetramers) in vivo. It may be 
the case that the monomeric protein pool present at the end of the aggregation 
experiment is in equilibrium with large aggregates, and that the low order oligomers 
seen are able to form whenever there is monomer present. 
It is important to note that some variations were found between results presented 
here and previously published work, with one example being the opposite trend in 
monomer to dimer ratio found here compared to that shown in a similar experiment 
by Phillips et al., (2015). One possible explanation for the contrasting results lays in the 
instrumental settings used in each study. While sample preparation conditions were 
virtually identical in both studies, different cone voltages were applied, with 70 V being 
used for spectra presented in this chapter and 165 V being used in the study of Phillips 
et al.. This higher cone voltage could potentially be resulting in the dissociation of 
higher aggregates of alpha-synuclein, resulting in alterations to the spectra seen 
compared to where dissociation was not occurring.   Alpha-synuclein is a notoriously 
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conformational plastic protein, and significant day to day variability in MS spectra 
under near identical conditions has been reported. Also apparent on review of the 
literature is a significant degree of variability in the findings of different research 
groups. For example, when using MS to investigate conformational shifts in response 
to altered pH studies by Bernstein et al., (2004) and Frimpong et al., (2010) found a 
shift to more compact conformations at low pH while Natalello et al., (2011) found a 
shift to the more extended conformations. The known variability of alpha-synuclein 
may also account for the differences in results presented here and previous reports.  
The failure in identifying higher order oligomers than those present at the 0 hour time 
point, or alterations in the dynamics of low order oligomers during the aggregation 
process perhaps goes someway to explain the lack of progress made in characterising 
alpha-synuclein aggregation species by ESI-MS. Much progress has been made in the 
characterisation of other amyloidogenic proteins by the methods employed here, but 
no one has yet successfully applied these techniques to the analysis of alpha-synuclein 
aggregation. It may be the case that alpha-synuclein is not a protein suitable for 
analysis by these methods, or these oligomers are never populated, and consequently 
different approaches may need to be developed to progress the field.
 147 
Chapter 4 - Validation and further characterisation of the 
effect of alpha-synuclein oligomers on SH-SY5Y cells 
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4.1 Introduction 
4.1.1 Oligomeric species of alpha-synuclein have been proposed as the 
toxic form of the protein 
Much research has implicated alpha-synuclein aggregation and, more specifically, the 
generation of prefibrillar oligomeric species, as the toxic form of the protein which 
contributes to the neurodegeneration seen in PD. Key evidence supporting the 
hypothesis of oligomers, rather than the fibrillar aggregates, being the toxic species 
comes from the observation of LBs being present in approximately 10% of 
neurologically normal individuals over the age of 60 (Frigerio et al., 2011), LB load 
correlating poorly to PD symptoms and certain familial forms of the disease presenting 
with neuronal degeneration with the absence of LBs (Cookson, Hardy and Lewis, 2008). 
Further evidence includes increased levels of alpha-synuclein oligomers in brains with 
LB pathology (Paleologou et al., 2009) and in the cerebrospinal fluid (CSF) of PD 
patients (Parnetti et al., 2014). Animal models have provided supporting evidence, 
with 3 month old female Fisher F344 rats (Harlan Laboratories) expressing artificial 
E57K and E53K alpha-synuclein variants, designed to promote ‘off-pathway’ oligomer 
formation, displaying a more severe loss of dopaminergic neurons compared to these 
rats expressing artificial WT alpha-synuclein. Conversely, a peptide encompassing 
amino acid 30 – 110 of alpha-synuclein, designed to have increased aggregation 
propensity, did not induce toxicity in this rat model (Winner et al., 2011). Additionally, 
injection of pre-formed oligomeric species into the SNpc Sprague Dawley rats (300–
350 gram) has been shown to induce nigral degeneration (Dimant et al., 2013). In vitro, 
cell culture studies have demonstrated that exogenously applied pre-formed oligomers 
are capable of inducing cellular pathology in both the SH-SY5Y cell line and neuron-
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enriched cerebral cortical cells prepared from embryonic mice brains (Danzer et al., 
2007), and that inducing intracellular alpha-synuclein oligomerisation in human H4 
neuroglioma cells, Human Embryonic Kidney cells and Chinese Hamster Ovary cells 
results in increased toxicity (Outeiro et al., 2008).  
Despite strong evidence that alpha-synuclein oligomers can be toxic, identifying the 
mechanism of oligomer induced toxicity is hindered by the heterogeneity of its 
aggregation products and the complex interactions which occur between oligomers 
and various cellular pathways implicated in PD. Mechanisms of oligomer induced 
toxicity which have been implicated to date include mitochondrial defects (Parihar et 
al., 2009, Di Maio et al., 2016), endoplasmic reticulum stress (Colla et al., 2012a, Colla 
et al., 2012b), inflammatory response (Zhang et al., 2005, Wilms et al., 2009), synaptic 
dysfunction (Diogenes et al., 2012, Choi et al., 2013, Kaufmann et al., 2016), 
autophagic and lysosomal dysfunction (Klucken et al., 2012, Bliederhaeuser et al., 
2016), membrane disruption (Volles and Lansbury, 2002, Danzer et al. 2007) and cell to 
cell propagation (Kordower et al., 2008, Li et al., 2008, Mendez et al., 2008, Danzer et 
al., 2009, Lee et al., 2010, Danzer et al., 2012). Alpha-synuclein oligomer membrane 
disruption and cell to cell propagation have been investigated in this chapter, and will 
be described in more detail below. 
4.1.1.1 Alpha-synuclein membrane disruption 
One well studied mechanism of alpha-synuclein toxicity is through its interactions with 
cellular membranes. As described in Section 1.3.2 monomeric alpha-synuclein is 
known to be capable of binding to membranes, and it is thought this ability may be 
important for its physiological function, supported by the observation that the six 
known PD causing variants in alpha-synuclein occur within the membrane binding 
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region of the protein. Aside from the physiological membrane binding of alpha-
synuclein, it has been shown that certain oligomeric species of the protein can form 
pores in biological membranes, leading to calcium influx and subsequent cell death 
(Danzer et al., 2007; Feng et al., 2010; E Illes-Toth et al., 2015; Pacheco et al., 2015). It 
has also been demonstrated that alpha-synuclein is able to bind to mitochondrial 
membranes, resulting in the production of ROS and subsequent cellular damage 
(Parihar et al., 2008, 2009; Paillusson et al., 2017; Ludtmann et al., 2018) and that 
targeting the interaction of oligomers and membranes can reduce alpha-synuclein 
toxicity through displacement of the protein from the membrane, interfering with 
membrane-induced self-assembly and vesicle disruption (Wrasidlo et al., 2016).     
4.1.1.2 Alpha-synuclein propagation 
A second potential mechanism of alpha-synuclein oligomer induced toxicity which has 
received much attention in recent years is the possibility of the protein spreading 
pathology in a prion-like manner. This theory originated from the observation that 
upon neuropathological examination, LB pathology tended to follow a stereotypical 
pattern in vivo, undergoing an ascending distribution from the lower brainstem and 
olfactory bulb to the limbic system and, finally, the neocortex (Braak et al., 2003). This 
typical propagation of alpha-synuclein pathology between anatomically 
interconnected brain areas correlates with the characteristic progression of PD 
symptoms observed clinically, as detailed in Figure 4.1, with the Braak model of PD 
proposing that LB pathology spreads over time between axonally connected structures 
(Braak et al., 2006). Moreover it has been proposed that this process is initiated by a 
'causative agent' affecting the olfactory bulb and autonomic nerves before spreading 
pathology through the interconnected neuronal pathways (Hawkes, Del Tredici and 
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Braak, 2007). This hypothesis was supported in 2008 by ground breaking findings of LB 
pathology in foetal dopaminergic neuron grafts which had been transplanted into PD 
subjects 11 – 16 years prior to their death (Kordower et al., 2008; Li et al., 2008); a 
phenomenon which has been successfully replicated in animal models (Angot et al., 
2012). The discovery of LB pathology in these relatively young neurons was strongly 
suggestive of alpha-synuclein pathology spreading from diseased to healthy cells in a 
prion-like manner, a hypothesis with important implications for our understanding of 
PD and the development of potential therapeutics. Consequently, much research has 
been undertaken to attempt to elucidate the mechanism of prion-like alpha-synuclein 
spread. It has been shown that Lewy body extracts derived from PD brains were able 
to trigger alpha-synuclein pathology and neurodegeneration in animal models 
(Recasens and Dehay, 2014), providing further evidence that alpha-synuclein is capable 
of spreading from diseased to healthy cells. Data from in vitro and in vivo models 
suggests that certain oligomeric forms of alpha-synuclein are able to promote cell-to-
cell propagation, aiding in the spread of pathology (for a review see Longhena et al., 
2017). The species of alpha-synuclein oligomer appears to be crucial to its seeding 
capability, as in vitro and in vivo studies have demonstrated that both fully formed 
fibrils (Luk et al., 2012) and certain oligomeric populations (Danzer et al., 2007; 
Fagerqvist et al., 2013) do not have seeding capabilities.  
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Figure 4.1: Braak staging of PD brain pathology. Proposed mechanism of the 
progression of PD brain pathology, showing the initiation sites in the olfactory bulb and 
the medulla oblongata, through to the later infiltration of Lewy pathology into cortical 
regions. Image taken from Doty (2012). 
 
The molecular events at each step of alpha-synuclein propagation (the seeding of 
aggregates, release of aggregates from diseased cells and entry of aggregates into 
healthy cells) have been the subject of intense investigation (reviewed by Brundin and 
Melki, 2017). In order for alpha-synuclein to be capable of seeding aggregates it must 
have the ability to induce conformational change and aggregation in another molecule. 
This property is well established for alpha-synuclein both in vitro (Luk et al., 2009) and 
in vivo (Masuda-Suzukake et al., 2013). One mechanism through which alpha-synuclein 
is thought to be released from cells is via misfolding-associated protein release, which 
occurs under conditions of proteasomal dysfunction and has been repeatedly linked to 
PD (Lee et al., 2016). Other proposed mechanisms of alpha-synuclein release include 
exocytosis (Lee, 2005; Jang et al., 2010) and secretion in exosomes (Danzer et al., 
2012; Fussi et al., 2018). Released alpha-synuclein is thought to be able to enter donor 
cells through several possible mechanisms, such as through endocytosis (Desplats et 
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al., 2009), direct penetration (Jiang et al., 2017), tunnelling nanotubules (Abounit et 
al., 2016) and membrane receptor mediated access (Lee et al., 2008; Mao et al., 2016). 
4.1.2 Oxidative stress is associated with PD 
Strong evidence suggests that OS may play a key role in the cascade of events leading 
to the loss of dopaminergic neurons seen in PD (Gaki and Papavassiliou, 2014). OS is 
the result of an imbalance between ROS and the ability of an organism to counteract 
their action by antioxidative protection systems. At normal physiological levels ROS act 
as signalling molecules which are involved in the regulation of cell proliferation, 
apoptosis and gene expression (Poljsak, Šuput and Milisav, 2013). However ROS which 
are not counteracted by antioxidants can cause damage to many components of the 
cell, including DNA, lipids and proteins. Up until a threshold level the cell is able to 
counteract the OS and promote survival. However, if the balance of ROS to 
antioxidants becomes too dysregulated, cellular damage caused by ROS will eventually 
lead to cell death, which is believed to be one mechanism involved in the development 
of PD (Dias, Junn and Mouradian, 2013). ROS have various intra and extracellular 
origins. The largest source of intracellular oxidants is the mitochondria and its 
respiratory chain. Free radicals of oxygen are generated as a normal result of oxygen 
metabolism as during aerobic respiration mitochondria reduce O2 to H2O and through 
this process produce the superoxide anion radical (O2
-·), hydrogen peroxide (H2O2) and 
the hydroxyl radical (OH·). Other sources of ROS production include microbial 
infections involving phagocyte activation, interactions between redox-active metals 
and oxygen species, the degeneration of fatty acids by peroxisomes and the oxidative 
metabolism of ingested toxins. The human body is equipped with a variety of 
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antioxidants which counteract ROS, including superoxide dismutase, glutathione (GSH) 
and catalase (for a review see Rahal et al., 2014).  
There are several pathways specific to nigrostriatal dopaminergic neurons which leave 
them particularly vulnerable to OS. Firstly, the process of dopamine metabolism is a 
source of ROS. Certain enzymes involved in dopamine metabolism, such as MAO, TH 
and L-amino acid oxidase, produce H2O2 as a by-product of their activity (Segura-
Aguilar et al., 2014). MAO is known to catabolize excess cytosolic dopamine, producing 
ROS (Segura-Aguilar et al., 2014). Excess cytosolic dopamine can occur as a result of 
neuron damage or levodopa treatment (Blesa, Lanciego and Obeso, 2015). 
Mitochondrial impairment is a second mechanism which seems to affect nigrostriatal 
dopaminergic neurons in particular. Impairment or inhibition of mitochondrial complex 
I are known to lead to an increase in ROS production and subsequent apoptosis 
(Franco-Iborra, Vila and Perier, 2015). Studies have shown that mitochondrial complex 
I inhibitors such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Langston et 
al., 1983) and rotenone (Betarbet et al., 2000) result in the highly specific 
degeneration of nigrostriatal dopaminergic neurons, resulting in a Parkinsonian 
phenotype. Mutations in many PD associated genes are known to affect the 
mitochondria, and these changes are associated with an increase in OS in 
dopaminergic SNpc neurons (Blesa, Lanciego and Obeso, 2015). A third source of ROS 
specific to these cells is iron, stored in neuromelanin. Neuromelanin has high affinity 
for transition metals, with both high and low affinity binding sites for iron. At 
physiological iron levels the majority of iron is found bound to the high affinity sites, 
where it is stored in an inactive form. At increased concentrations of iron, 
neuromelanin's high affinity sites are saturated and more iron will bind to the low 
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affinity sites, where it can accumulate in an inactive form and catalyse the Fenton 
reaction (Zucca et al., 2017). Additionally, neuromelanin saturated with iron has been 
shown to oxidise dopamine, exacerbating OS (Zecca et al., 2008).   
Considerable evidence from both PD patients and experimental models supports that 
increased OS is seen in both sporadic and familial cases of PD. Evidence of OS has been 
provided through detection of oxidised DNA, lipids and proteins in the brains of PD 
patients (Bosco et al., 2011). A meta-analysis of studies designed to identify oxidative 
stress markers in PD demonstrated that patients have increased levels of the OS 
damage markers 8-OhdG and malondialdehyde and the reactive nitrogen species 
nitrite in peripheral blood. Conversely, decreased levels of the antioxidants catalase, 
uric acid and glutathione were found (Wei et al., 2018). 
4.1.3 Cell culture models of PD 
Despite advances in PD research, the mechanisms underlying neuronal degeneration 
remain unclear. In vitro cellular models are a useful tool to investigate molecular 
pathologies underlying PD and provide an opportunity to develop therapeutic 
strategies to alter these pathologies. A major challenge of conducting research into 
age-related neurodegenerative disorders is that there are no cellular or animal models 
capable of recapitulating all features of the disease. When attempting to investigate 
the molecular mechanisms underlying complex disorders such as PD it can be useful to 
break down and investigate each pathological disease process individually, which is 
particularly important when there is limited understanding of the pathogenic 
mechanisms underlying the disease. The use of in vitro cellular models can be a helpful 
tool to increase understanding in this area. A range of cell culture models are 
commonly used in PD research, most frequently immortalized human and animal cell 
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lines, primary cells and stem cells. In PD multiple types of neuronal cells are known to 
degenerate. However, due to the importance of motor symptoms in PD there has been 
a focus on the use of dopaminergic cell models to try to recapitulate the mechanisms 
underlying the degeneration of dopaminergic neurons in the SNpc, which gives rise to 
these motor symptoms. SH-SY5Y cells are a popular choice in PD research, and the cell 
model used in this thesis (for a review of the use of SH-SY5Y cells in PD research see 
Xicoy, Wieringa and Martens (2017)). SH-SY5Y cells are a subline of the SK-N-SH line, 
established in 1970 from a bone marrow biopsy of a metastatic neuroblastoma of a 4 
year old female. The SH-SY5Y line undergoes 3 rounds of clonal selection, from SK-N-
SH to SH-SY to SH-SY5 to SH-SY5Y. These cells have many advantages. They are 
inexpensive to obtain and culture and they amplify rapidly, allowing experiments 
requiring large numbers of cells to be performed. These cells are of human origin, and 
so express human specific proteins. SH-SY5Y cells express dopamine receptors and 
transporters, and are vulnerable to oxidative stress. It is important to note that while 
there are genetic alterations in these cells, being from a neuroblastoma, PD related 
pathways which they are commonly used to study (such as the UPS, ROS metabolism 
and DA metabolism) remain unaffected (Krishna et al., 2014). However, SH-SY5Y cells 
are difficult to differentiate into a post-mitotic mature dopaminergic state 
(Constantinescu et al., 2007) and, at present, there is no consensus on many 
fundamental aspects of their use such as culture media composition and 
differentiation protocols (Xicoy, Wieringa and Martens, 2017). 
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4.2 Aims and Objectives 
The purpose of this chapter was to further investigate the calcium influx inducing Type 
A and intracellular aggregation seeding Type C oligomers first characterised by Danzer 
et al. (2007). Previous investigations into these oligomeric species have been 
conducted using oligomers produced from unmodified recombinant alpha-synuclein. 
As discussed in detail in Section 2.1.3.2, alpha-synuclein is known to be constitutively 
acetylated in vivo. In this chapter the SH-SY5Y cell line was used as a model to 
investigate the effect of N-terminal acetylation on the cellular effects of these two 
oligomeric populations. Furthermore, the response of these cells following treatment 
with Type C oligomers was further investigated, with an emphasis on OS. 
The specific aims of this chapter were: 
1. To establish whether N-terminal acetylation affected the cytotoxicity of Type A 
and C oligomers. 
2. To establish whether N-terminal acetylation affected the ability of Type C 
oligomers to induce intracellular aggregation. 
3. To further investigate the effect of Type C oligomers inducing intracellular 
alpha-synuclein aggregation in SH-SY5Y cells. 
4. To establish whether Type C oligomers are able to induce a stress response in 
SH-SY5Y cells. 
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4.3 Methods 
4.3.1 Production of alpha-synuclein oligomers 
Unmodified and N-terminally acetylated alpha-synuclein was produced as described in 
Section 2.3.7/2.3.8. 'Type A' and 'Type C' oligomeric species were prepared as 
described by Danzer et al. (2007), unless otherwise stated. In brief, Type A oligomers 
were prepared by reconstituting lyophilised alpha-synuclein in 50 mM sodium 
phosphate buffer (SPB) (pH 7.0) containing 20% ethanol to a final concentration of 7 
µM. Following a four hour incubation at 21 °C with continuous shaking, solutions were 
lyophilised and resuspended in one half the starting volume in 50 mM SPB (pH 7.0) 
containing 10% ethanol. These solutions were shaken at 21 °C for 24 hours with open 
lids to evaporate residual ethanol, followed by 6 days of shaking at 21 °C with closed 
lids. Type C oligomers were prepared by reconstituting lyophilised protein in 50 mM 
SPB (pH 7) containing 20% ethanol to a final concentration of 7 µM and incubating at 
21 °C overnight with continuous shaking, followed by concentration 1:14 using 
ultracentrifugation (VivaSpin 500 columns, MWCO 30 kDa, GE Healthcare) allowing the 
separation of oligomeric species from monomeric protein. Type A and Type C 
oligomeric species were used for experiments immediately after production. 
4.3.2 Maintenance and cryopreservation of SH-SY5Y neuroblastoma cell 
line 
All cell culture methods were carried out under sterile conditions in a class II laminar 
flow cabinet. SH-SY5Y human neuroblastoma cells were purchased from the European 
Collection of Authenticated Cell Cultures (Cat. No. 94030304, Public Health England, 
Salisbury, UK). Cell cultures were maintained in high glucose Dulbecco's modified 
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Eagle's GLUTAMAXTM medium (DMEM) (Gibco) supplemented with 10% (v/v) foetal 
bovine serum (FBS) and 1% (v/v) penicillin-streptomycin (Invitrogen) at 37 °C in a 
humidified atmosphere containing 5% CO2. Cells were purchased at passage 16 and 
used up to a maximum of passage 25. Stocks of 1x106 cells per cryovial were preserved 
in liquid nitrogen dewars for long-term storage in a solution of 90% FBS/10% dimethyl 
sulfoxide. 
4.3.3 CellTox™ Green Cytotoxicity Assay 
Following manufacturer guidelines the Express, No-Step Addition at Dosing method of 
the CellTox™ Green Cytotoxicity Assay (Promega) was performed on SH-SY5Y cells. 
Briefly, SH-SY5Y cells were seeded at 1x104 cells per well and cultured for 48 hours in 
black-walled 96-well plates before treatment with test compounds. 1 µL of CellTox™ 
Green Dye was added to each 500 µL of test compound diluent and/or vehicle control 
before adding to the cells and incubating at 37 °C/5% CO2 for the desired treatment 
time. Following treatment fluorescence was measured using a CLARIOstar plate reader 
(BMG LABTECH, Buckinghamshire, UK) with excitation at 485 nm and emission at 520 
nm. 
4.3.4 Resazurin reduction assay 
Resazurin sodium salt (Sigma-Aldrich) was dissolved in PBS to 3 mg/mL, sterilised 
through a 0.2 μm filter into a light protected container and stored at 4 °C before use. 
SH-SY5Y cells were seeded at 1x104 cells per well in opaque-walled 96-well plates and 
cultured for 48 hours before treatment with test compounds. Following treatment 
with various alpha-synuclein species and appropriate controls, test medium was 
replaced with growth medium containing 0.03 mg/mL resazurin and the cells 
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incubated for a further two hours at 37 °C/5% CO2. Culture media was incubated with 
resazurin in parallel as a blank control. Fluorescence was then measured using a 
CLARIOstar plate reader with excitation at 560 nm and emission at 590 nm. 
4.3.5 Immunocytochemistry 
For immunofluorescence staining SH-SY5Y cells were seeded at 4x104 cells per well and 
cultured and treated with test compounds in 8 well Lab-Tek II chamber slides (Nunc, 
154534). Following treatment, culture medium was removed from each well and cells 
washed with PBS before fixation and permeabalisation in ice-cold methanol for 15 
minutes at -20 °C. The cells were then washed in PBS containing 0.1% (v/v) Tween-20 
(PBS-T).  Non-specific binding sites were blocked using 1% (w/v) BSA in PBS for one 
hour at room temperature under continuous gentle shaking. After blocking, cells were 
washed three times in PBS-T before incubation with primary antibody (anti-α-synuclein 
syn211 monoclonal antibody (1:2000, Fisher, AFMA112874)) in blocking solution for 1 
hour at room temperature under continuous gentle shaking. Three more PBS-T wash 
steps were performed before cells were incubated with secondary antibody (Texas 
Red® goat anti-mouse polyclonal IgG H+L (1:1000, Invitrogen; T6390)) in blocking 
solution for 1 hour at room temperature under continuous gentle shaking. Cells were 
washed four times with PBS-T before mounting using ProLong™ Diamond Antifade 
Mountant with DAPI (Invitrogen™, ThermoFisher Scientific, Loughborough, UK). To 
assess background fluorescence primary antibody was omitted in a designated 
chamber and all other steps were performed as described above. Slides were left to 
cure overnight at 4 °C in the dark prior to image capture using an Olympus BX60 bright 
field/fluorescence microscope. Evaluation of percentage of cells containing alpha-
synuclein inclusions was performed by counting the number of cells per field of vision 
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containing clear alpha-synuclein immunopositive inclusions, expressed as a percentage 
of total cell count. To quantify total fluorescence per cell, images were analysed using 
the image analysis software ImageJ 1.50i using the corrected total cell fluorescence 
(CTCF) calculation shown below, were the background fluorescence of a selected area 
is subtracted from the fluorescence value of a measured area:  
 
𝐶𝑇𝐶𝐹 =  
𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 − (𝑚𝑒𝑎𝑛 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑥 𝑎𝑟𝑒𝑎)
𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟
 
 
4.3.6 Preparation of conditioned media 
To prepare conditioned cell culture media for dot blot analysis, SH-SY5Y cells were 
cultured and treated with test compounds as described in Section 4.3.5. Following 
treatment, media containing test compounds was removed; the cells washed once 
with PBS-T and then incubated with fresh culture media for one hour. This conditioned 
media was removed from the cells, 2 mM of PMSF added and the media centrifuged at 
16000 x g for 15 minutes at 4 °C. The supernatant was aliquoted and stored at -80 °C 
for future analysis. 
4.3.7 Dot blotting 
0.05% Triton X-100 was added to samples of conditioned media. Nitrocellulose 
membranes (0.45 µM, GE Healthcare, Sweden) were spotted with 1 µL of sample or 
positive/negative control, allowed to dry and blocked for 1 hour in 5% (w/v) non-fat 
milk (NFM) in TBS-T. Primary antibody (anti-α-synuclein syn211 monoclonal antibody 
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(1:2000, Fisher, AFMA112874)/anti-alpha-synuclein phospho S129 antibody (1:2000, 
abcam, ab51253)) was diluted in 1% NFM TBS-T and incubated with the membrane 
overnight under continuous gentle shaking at 4 °C. Three wash steps were performed 
with TBS-T before incubation with secondary antibody (goat anti-mouse IRDye® 800 
nm CW secondary antibody (1:15,000 dilution, Cat. No. 925-32210, LI-COR)/donkey 
anti-rabbit IRDye® 680 nm CW secondary antibody (1:15,000 dilution, Cat. No. 925-
68073, LI-COR) diluted in 1% (w/v) NFM TBS-T for 1 hour under continuous gentle 
shaking at room temperature. Visualisation was performed using the LI-COR Odyssey 
and Odyssey Infrared Imaging software (LI-COR, Nebraska, USA). 
4.3.8 GSH/GSSG-GloTM Assay 
Following manufacturer guidelines (Promega) the Assay Procedure for Measuring 
GSSG and Total Glutathione in Adherent Mammalian Cells was performed. Briefly, SH-
SY5Y cells were seeded at 2x104 cells per well, cultured and treated in white opaque-
walled 96-well plates. Test compounds were 10% (v/v) Type C alpha-synuclein 
oligomers, 10 μM menadione as a positive control and corresponding vehicle controls. 
Test compound and/or vehicle control was removed from the cells and replaced with 
50 µl per well of Total Glutathione Lysis Reagent or Oxidized Glutathione Lysis Reagent 
as appropriate. 50 µL of Total Glutathione Lysis Reagent was also added to no-cell 
controls and wells containing a range of glutathione concentrations to produce a 
standard curve. The plate was then shaken for 5 minutes at room temperature. 50 µL 
per well of Luciferin Generation Reagent was added to all wells and incubated at room 
temperature for 30 minutes. 100 µL per well of Luciferin Detection Reagent was added 
and incubated at room temperature for 15 minutes. Luminescence was recorded using 
a CLARIOstar plate reader. The concentration of total and oxidised glutathione in 
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treated cells was extrapolated from the standard curve and the GSH/GSSG ratio 
calculated. 
4.3.9 CellROX™ Green assay  
Following manufacturer guidelines the assay procedure for measuring oxidative stress 
using CellROX™ Green Reagent was performed on SH-SY5Y cells. Briefly, SH-SY5Y cells 
were cultured and treated with test compounds on coverslips. The CellROX™ Green 
Reagent was then added to a final concentration of 5 μM and the cells incubated for 
30 minutes at 37 °C. Medium was then removed and cells washed with PBS. Cells were 
then fixed with 10% formalin and mounted using ProLong™ Diamond Antifade 
Mountant with DAPI. Slides were left to cure overnight at 4 °C in the dark prior to 
image capture using an Olympus BX60 bright field/fluorescence microscope. Corrected 
total cell fluorescence was calculated as described in Section 4.3.5. 
4.3.10 Polysome profiling 
4.3.10.1 Extract preparation 
SH-SY5Y cells were plated at a density of 4x106 cells per T175 flask and cultured for 48 
hours before treatment. Following treatment cells were incubated with the translation 
inhibitor cycloheximide (100 µg/mL) for five minutes at 37 °C, washed and cells 
scraped in 5 ml of ice-cold  PBS containing 100 µg/mL cycloheximide. Cells were then 
pelleted by centrifugation at 500 x g for 5 min at 4 °C and resuspended in 450 μl of 
hypotonic buffer (20 mM HEPES KOH (pH 7.4), 2 mM Magnesium Acetate, 0.1 M 
Potassium Acetate, 100 µg/mL cycloheximide, 500 μm DTT, 1x protease inhibitor 
cocktail and 100 units RNAse inhibitor in DEPC treated distilled water). The mixture 
was vortexed for five seconds, before the addition of 25 μL of 10% Triton X-100 and 25 
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μl of 10% SDS, and vortexed for five more seconds. Lysates were incubated at 4 °C for 
five minutes before centrifugation at 16000 xg and the supernatant frozen at -80 °C for 
future analysis. 
4.3.10.2 Preparation of sucrose density gradients 
Varied concentrations of sucrose ranging from 15-50 % were prepared from a 60 % 
(w/v) DEPC treated sucrose stock and 10X polysome buffer (100 mM Tris acetate, pH 
7.4, 700 mM NH4OAc, 40 mM MgOAc). To generate a gradient, 2.25 mL of each 
solution was sequentially dispensed into open-top 12.0 mL pollyallomer centrifuge 
tubes (Seton Scientific), starting with the 50% (w/v) sucrose solution and ending with 
the 15% (w/v) solution. Each layer was snap-frozen in liquid nitrogen before the next 
layer was added. Sucrose gradients were stored at -80 °C and thawed overnight at 4 °C 
prior to use. 
4.3.10.3 Sedimentation of extracts on polysome gradients 
The concentration of polysome extracts was determined using a NanoDrop 1000 
spectrophotometer (ThermoFisher Scientific). 2.5 A260 units of extract were layered on 
top of sucrose gradients. Sucrose gradients were centrifuged using a Th-641 swing-out 
rotor in a Sorvall WX Ultracentrifuge for 150 minutes at 4 °C. Polysomes were 
measured by upward displacement using 60% (w/v) sucrose; gradients were displaced 
using a fractionator that was connected to a UV-vis detector which measured 
polysomes at 254nm, producing a polysome trace as shown in the diagram in Figure 
4.2. Monosomes/polysomes were measured and compared using NIH ImageJ software. 
1 mL fractions were collected. 750 µL of Trizol was added to each fraction before being 
frozen at -80 °C. 
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Figure 4.2: Schematic of polysome profiling traces. Following the addition of 
cycloheximide, ribosomes decoding mRNA become stalled. Cell extracts are then 
separated on a sucrose gradient before being passed through a UV detector to 
produce a polysome trace. With the exception of the 40S and 60S peaks, the peaks 
relate to the number of ribosomes attached to any given mRNA. As efficient 
translation can be attributed to multiple ribosomes translating along mRNAs, the area 
underneath the monosome peak can be compared to the polysome peaks to calculate 
a polysome/monosome ratio which can be compared to evaluate translational control 
and translation initiation. 
 
4.3.11 Statistical Analysis 
Statistical analysis was undertaken using StatsDirect version 3.0.126. Data was 
determined to be non-parametric following Shapiro-Wilk test of normality therefore a 
Kruskal-Wallis test was undertaken with post hoc analysis. Dwass-Steel- Critchlow -
Flinger post hoc analysis was undertaken for data points > 6 and Conover-Inman post 
hoc analysis < 6 data points. P value < 0.05 is denoted on graphs by *.  
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4.4 Results and discussion 
Several modes of action have been proposed as to how alpha-synuclein oligomers can 
elicit cytotoxicity and protocols have been established to enable the formation of 
oligomers with known cellular effects. Exogenous application of Type A and Type C 
alpha-synuclein oligomers characterised by Danzer et al. (2007) are known to reduce 
cell viability and increase cytosolic alpha-synuclein aggregation respectively. However, 
oligomers used in these studies were prepared from unmodified, recombinant alpha-
synuclein. As discussed in detail in Chapter 2, in vivo alpha-synuclein is known to be 
constitutively acetylated at its N-terminus. The effect of Type A and Type C oligomers 
prepared from N-terminally acetylated alpha-synuclein on a cell culture model has, to 
the best of our knowledge, not previously been investigated.  
4.4.1 Type A oligomers produced from both unmodified and N-terminally 
acetylated alpha-synuclein reduce the viability of SH-SY5Y cells 
Exogenous application of the Type A pore forming oligomers of alpha-synuclein has 
been shown to result in an influx of calcium into SH-SY5Y cells, leading to reduced cell 
viability (Danzer et al. 2007). In order to assess the effect of N-terminal acetylation on 
alpha-synuclein cytotoxicity the viability of SH-SY5Y cells following 16 hour treatment 
with 10% (v/v) unmodified and N-terminally acetylated forms of monomer, Type A and 
Type C oligomers was assessed using both a CellTox Green Cytotoxicity Assay and a 
resazurin reduction assay, with results displayed in Figure 4.3.  
The CellTox Green Cytotoxicity Assay allows the assessment of cell viability through 
detecting changes in membrane integrity which occur upon cell death. This allows the 
CellTox Green assay dye to enter cells and bind to their DNA, enhancing the dye’s 
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fluorescent properties. Consequently fluorescence is proportional to cytotoxicity, with 
an increase in fluorescence correlating to a decrease in cell viability. Results following 
16 hour incubation with the various treatments are shown in Figure 4.3 (a). Type A 
oligomers were the only treatment found to have a significant effect on cell viability. 
Type A oligomers were significantly cytotoxic to cells when made from both 
unmodified (p = 0.0157) and N-terminally acetylated (p = 0.0035) alpha-synuclein. 
Conversely, monomeric and Type C oligomeric forms of the protein were found not to 
have an effect on cell viability.  
 
Figure 4.3: Cell viability assays of SH-SY5Y cells following 16 hour treatment with 10% 
(v/v) of various forms of unmodified and N-terminally acetylated alpha-synuclein. 
Results of CellTox Green Cytotoxicity Assay shown in a) and results of resazurin 
reduction assay shown in b). Statistical significance determined by Kruskall-Wallis test 
* = P < 0.05. 
 
An alternate approach to assessing cell viability is through monitoring the metabolic 
activity of cells. Resazurin is a cell permeable, redox indicator which can be used to 
assess metabolic activity, and therefore cell viability. Metabolically active cells 
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maintain a reducing environment within their cytoplasm and mitochondria, which 
allows reduction of oxidised resazurin to reduced resorufin, which has detectable 
fluorescence. By monitoring this fluorescence the relative metabolic activity of cells 
can be determined. Resasurin reduction assay results following 16 hour incubation 
with the various treatments are shown in Figure 4.3 (b). The results of this assay are, in 
agreement with the CellTox Green Cytotoxicity Assay. Again, Type A oligomers were 
found to cause a significant decrease in viability when produced from both unmodified 
(p = 0.0256) and N-terminally acetylated (p = 0.0152) alpha-synuclein.  
The results of these two viability assays demonstrate, in agreement with previous 
reports (Danzer et al. 2007, Illes-Toth et al. 2015), that Type A alpha-synuclein 
oligomers have a cytotoxic effect on the SH-SY5Y cell line. Monomeric and Type C 
oligomeric forms of the protein did not display a cytotoxic effect, indicating that this 
cytotoxic property is dependent on the oligomer species, and not a shared feature of 
all forms of alpha-synuclein. The previously unstudied N-terminally acetylated Type A 
oligomers were found to have a comparable effect on cell viability to the unmodified 
species, demonstrating for the first time that N-terminal acetylation does not alter the 
cytotoxic properties of these oligomers.  
4.4.2 Type C oligomers produced from both unmodified and N-terminally 
acetylated alpha-synuclein cause an increase in cytosolic alpha-synuclein 
aggregate formation in SH-SY5Y cells 
While the concept of intracellular propagation of alpha-synuclein has been extensively 
studied over the last decade, the precise mechanisms underlying this process remain 
uncertain. Exogeneous application of Type C oligomers has been shown to cause a 
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reduction in homogeneous, cytoplasmic alpha-synuclein staining and an increase of 
punctate, aggregate formation in the cytosol and near the nucleus in neuronal cultures 
(Danzer et al. 2009).  
The propensity of Type C oligomers, made from either unmodified or N-terminally 
acetylated alpha-synuclein, to induce aggregation when added extracellularly to SH-
SY5Y cells was investigated here using immunocytochemistry. Representative images 
cells treated with Type C oligomers or vehicle control, stained for DAPI (blue) and 
alpha-synuclein (red) are shown in Figure 4.4 (a). In agreement with previous work 
(Danzer et al., 2009) an alteration in alpha-synuclein staining is seen in treated cells. 
The homogenous, cytoplasmic staining seen in the vehicle control (and in untreated 
cells; representative image shown in Appendix Figure 3) is altered upon treatment with 
Type C oligomers, with punctate spots of heightened fluorescence observed, that are 
indicative of intracellular aggregates of the protein. This alteration was specific to Type 
C oligomers, as treatment with the equivalent concentration of monomer did not 
result in significant changes compared to the vehicle control (representative images on 
monomer treated cells shown in Appendix Figure 3). Figure 4.4 (b) shows analysis of 
this experiment, with fold change in CTCF normalised to the vehicle control shown in 
(i) and percentage of cells containing intracellular alpha-synuclein inclusions shown in 
(ii). It was found that the CTCF was significantly higher following treatment with both 
unmodified and N-terminally acetylated Type C oligomers, which could feasibly be due 
to the exogenously added oligomers or due to an increase in endogenous protein of 
the cells. 
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Figure 4.4: Immunocytochemistry of SH-SY5Y cells treated for 16 hours with 10% (v/v) unmodified or N-terminally acetylated Type C oligomers. 
Representative ICC images at 100x magnification of nuclear staining in blue and alpha-synuclein in red shown in (a) (scale bar = 20 µm). CTCF of the 
red channel (alpha-synuclein) shown in (b) i, presented as fold change in fluorescence normalised to vehicle control. Percentage of cells per field of 
view containing alpha-synuclein inclusions shown in (b) ii. Statistical significance determined by Kruskall-Wallis test * = P < 0.05.  
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While a small proportion of vehicle treated cells were found to contain alpha-synuclein 
inclusions, in cells treated with Type C oligomers the percentage of cells containing 
inclusions was significantly increased for both unmodified and N-terminally acetylated 
oligomers. Representative results presented in Figure 4.4 were consistent upon 
biological repeats (n>3). This demonstrates, in agreement with previous reports 
(Danzer at al., 2009), that the localisation of alpha-synuclein is altered in cells following 
treatment with these Type C oligomers. The presence of this protein in inclusions, 
rather than the usual homogenous cytoplasmic distribution is important as it provides 
supportive evidence for certain forms of the protein having the potential to seed fibril 
formation of endogenous alpha-synuclein, which has important implications as one 
potential explanation of the propagation of alpha-synuclein pathology observed in PD.      
These results demonstrate that Type C oligomers are able to induce the formation of 
intracellular aggregates containing alpha-synuclein in SH-SY5Y cells. Assembling these 
oligomers from N-terminally acetylated alpha-synuclein did not alter this function, 
demonstrating for the first time that acetylation does not affect the capability of these 
oligomers to induce this cellular response. Throughout the rest of this chapter results 
presented were obtained following treatment with N-terminally acetylated alpha-
synuclein species, as the more physiologically relevant form of the protein.  
4.4.3 Extracellular alpha-synuclein staining is observed in SH-SY5Y cells 
treated with Type C oligomers and can be detected in conditioned cell 
media 
As shown in Figure 4.4, treatment of SH-SY5Y cells with Type C oligomers results in an 
increase in fluorescence and the presence of punctate alpha-synuclein inclusions in the 
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cytoplasm. It was noted in the analysis of these images that with this treatment 
extracellular fluorescence was also repeatedly present, which was not seen in the 
vehicle control or monomer treated experiments. It was hypothesised that this 
extracellular staining could potentially result from original treatment protein not being 
taken up by the cell, debris from dead cells or secreted alpha-synuclein. To investigate 
this further, SH-SY5Y cell were treated with 10% (v/v) Type C oligomers for varied 
amounts of time.  
Figure 4.5 (a) shows representative images from immunocytochemistry experiments 
performed following 1, 16 and 30 hour treatments with 10% (v/v) Type C oligomers. 
Following 1 hour treatment the extracellular region remains relatively clear of 
fluorescence, comparable with vehicle controls (Appendix Figure 3). In contrast, 
extracellular fluorescence is clearly present at both the 16 and 30 hour time points, 
indicating that an alpha-synuclein species is being secreted from the cells. Figure 4.5 
(b) shows analysis of extracellular fluorescence in the red channel which has been 
quantified using ImageJ. It can be seen that there is no significant difference in 
extracellular fluorescence (compared to the vehicle control) at the 1 hour time point. 
Conversely, extracellular fluorescence significantly increased at the 16 and 30 hour 
time points. If extracellular fluorescence was a result of exogeneous alpha-synuclein 
oligomers not being taken up by cells it would be anticipated that any extracellular 
fluorescence would be detectable immediately following treatment, and stay 
consistent throughout treatment times. As background fluorescence was low at the 
one-hour time point then increased over time, these results support that idea that the 
extracellular fluorescence cannot be singularly attributable to original treatment 
protein.  
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Figure 4.5: ICC and cell viability of SH-SY5Y cells treated with 10% (v/v) Type C 
oligomers for 1, 16 and 30 hours. Representative ICC images at 100x magnification of 
nuclear staining in blue and alpha-synuclein in red shown in (a) (scale bar = 20 µm). 
Quantification of extracellular fluorescence in the red channel normalised to the 
vehicle control shown in (b). CellTox Green Cytotoxicity Assay at corresponding time 
points displayed as fold change, normalised to vehicle control shown in (c). Statistical 
significance determined by Kruskall-Wallis test * = P < 0.05.  
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In order to investigate cell death as a potential cause of extracellular fluorescence cell 
viability was assessed in parallel using the CellTox Green Cytotoxicity Assay, with 
results shown in Figure 4.5 (c). No significant differences in cells treated with Type C 
oligomers were seen compared to the vehicle control at any of the time points tested. 
As the vehicle control contains little extracellular fluorescence this provides evidence 
against the background fluorescence in oligomer treated cells being attributable to 
debris from cell death, as no significant difference in viability was seen. This leaves the 
possibility of the extracellular fluorescence being attributable to alpha-synuclein being 
secreted from the viable, treated cells.  
While alpha-synuclein was originally thought of as an exclusively intracellular protein 
(due to its lack of a signalling sequence), it is now well established that this protein is 
detectable in extracellular fluids including the plasma (El-Agnaf et al., 2003) and CSF 
(Borghi et al., 2000) of both PD patients and unaffected individuals. To investigate 
whether alpha-synuclein was being secreted from SH-SY5Y cells treated with Type C 
oligomers a dot blot assay was performed on conditioned media using antibodies to 
detect both alpha-synuclein and alpha-synuclein phosphorylated specifically at serine 
129 (ps129). The conditioned media was analysed for the presence of ps129 due to the 
known association between this post-translational modification and PD, as discussed in 
Section 1.3.2. Vehicle control, monomeric or Type C oligomeric treatments were 
applied to SH-SY5Y cells for 16 hours in the same manner as for immunocytochemistry 
experiments. Following 16 hour treatment media was removed, cells washed and fresh 
growth media applied. Cells were incubated in this growth media for 1 hour. 
Conditioned media was then collected and subject to dot blot analysis. As shown in 
Figure 4.6, negligible signal was detected from either antibody in conditioned media of 
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cells treated with vehicle control or monomeric alpha-synuclein. This demonstrates 
that these cells do not release alpha-synuclein to a significant degree able to be 
detected by this method, which corresponds to the lack of extracellular fluorescence 
seen in immunocytochemistry images. The lack of signal from the anti-alpha-synuclein 
antibody in the monomeric treatment demonstrates that the removal of treatment 
media and wash steps were sufficient to remove any treatment protein which had not 
been internalised by the cells.  
 
Figure 4.6: Dot blot of conditioned media from SH-SY5Y cells treated for 16 hours with 
10% (v/v) vehicle control, monomeric or Type C oligomeric alpha-synuclein. 
 
On the contrary, cells treated with Type C oligomers display a signal clearly detectable 
from the alpha-synuclein antibody, demonstrating that alpha-synuclein is being 
released into the media by these treated cells. This provides supporting evidence to 
the extracellular fluorescence seen in Figure 4.4 and 4.5 being attributable to treated 
SH-SY5Y cells secreting alpha-synuclein into the culture media. It is plausible that the 
alpha-synuclein detected could be from either the original treatment oligomers, or 
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endogenous alpha-synuclein produced by the cells themselves. More notably signal 
was also detected in the conditioned media of Type C oligomer treated cells from the 
antibody to ps129. Under physiological conditions approximately 4% of alpha-
synuclein is phosphorylated at one or more of its sites (Fujiwara et al, 2002). In 
contrast, approximately 90% of the alpha-synuclein deposited in LBs is ps129 
(Anderson et al., 2006), suggesting phosphorylation at this site may be associated with 
PD. Several lines of evidence point towards phosphorylation of alpha-synuclein being 
associated with its secretion from cells. PD patients have been shown to have 
increased ps129 alpha-synuclein in their blood plasma compared to controls (Foulds et 
al., 2013). It has been demonstrated that ps129 is important for modulating the 
clearance of alpha-synuclein inclusions through autophagy (Tenreiro et al., 2014), and 
moreover it has recently been shown that alpha-synuclein can be secreted in 
exosomes as a compensatory mechanism of clearance when autophagy is impaired 
(Fussi et al., 2018). An increase in alpha-synuclein ps129 has also been associated with 
conditions of cellular stress, with studies demonstrating that conditions which result in 
oxidative stress correlate to an increase in ps129 (Arawaka et al., 2017). 
4.4.4 Type C oligomers evoke a stress response in SH-SY5Y cells 
While no significant effect on cell viability was found in SH-SY5Y cells treated with Type 
C oligomers, due to the finding of ps129 alpha-synuclein in conditioned media of 
treated cells various cellular stress assays were conducted to investigate the possibility 
of these oligomers inducing a stress response. Three cellular stress assays were 
preformed; CellROX green assay, glutathione assay and polysome profiling. 
Menadione, a compound known to generate intracellular ROS (Criddle et al., 2006; 
Loor et al., 2010) was used as a positive control in each experiment at 10 μM, a 
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concentration chosen to induce OS but not significantly reduce cell viability, based on 
IC50 calculations on SH-SY5Y cells under our laboratory conditions (IC50 curve shown 
in Appendix Figure 4).   
4.4.4.1 Treatment of SH-SY5Y cells with Type C oligomers results in an increase in ROS 
CellROX Green Reagent is a cell-permeable fluorogenic probe which exhibits 
fluorescence upon oxidation by ROS and subsequent binding to DNA. Therefore this 
assay directly detects changes in ROS levels. Figure 4.7 displays results from a CellROX 
Green Assay conducted on SH-SY5Y cells treated with 10% (v/v) vehicle control, 
positive control, alpha-synuclein monomer or Type C oligomers following a 2 hour 
incubation. Figure 4.7 (a) shows representative images of DAPI and CellROX Green 
staining under each condition. CTCF was used as a method of analysing experimental 
images, with results displayed in Figure 4.7 (b). Here it can be seen that treatment with 
both Menadione and Type C oligomers resulted in an increase in CTCF, and therefore 
an increase in ROS in these cells, showing that both of these treatments are evoking an 
oxidative stress response from the cells. No increase in CTCF was found following 2 
hour treatment with either vehicle control or alpha-synuclein monomer. This 
demonstrates that the increase in ROS following treatment with Type C oligomers is 
not a general response to the alpha-synuclein protein, but is conformation specific.  
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Figure 4.7: CellROX Green oxidative stress assay of SH-SY5Y cells treated for 2 hours 
with 10% (v/v) vehicle control, positive control (Menadione), monomer or Type C 
oligomer. Representative images at 40x magnification shown in (a) (scale bar = 100 
μm) and CTCF of the green channel shown in (b). Statistical significance determined by 
Kruskall-Wallis test * = P < 0.05.  
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4.4.4.2 Treatment of SH-SY5Y cells with Type C oligomers results in an altered 
GSH/GSSG ratio 
As described in Section 4.1.2, OS can be a result not only of an increase in ROS, but 
also a disruption in the balance of ROS to antioxidants. One important antioxidant is 
glutathione, a tripeptide consisting of glutamate, cysteine and glycine, with the 
reactive thiol group of the cysteine residue acting as an effective antioxidant. 
Glutathione exists in vivo in reduced (GSH) and oxidised (GSSG) forms, with the 
majority found as GSH under normal physiological conditions. During OS a decrease in 
GSH and increase in GSSG is seen, and therefore the ratio of GSH/GSSG decreases. 
Consequently, GSH/GSSG ratio can be used as an indicator of the health of a cell. 
Figure 4.8 shows the results of a glutathione assay on SH-SY5Y cells treated for 2 hours 
with vehicle control, positive control or Type C oligomers. Figure 4.8 shows the 
concentration following treatment of GSH (a) and GSSG (b), the value of which has 
extrapolated from the calibration curve shown in Appendix Figure 5. Following 
treatment with both Type C oligomers and Menadione a reduction in GSH and increase 
in GSSG is seen, indicative of OS. In contrast to the results obtained from the CellROX 
Green assay, this result was more pronounced with menadione treatment than Type C 
oligomer treatment. Nevertheless, Type C oligomer treatment did result in a 
considerable alteration to the concentration of total and reduced glutathione in the 
cells, which is evidenced in Figure 4.8 (c), where GSH/GSSG ratio (normalised to vehicle 
control) is shown. Decreases in GSH/GSSG ratio in the SNpc have also been found in 
the analysis of brain tissue from PD patients compared to controls (Dias, Junn and 
Mouradian, 2013) and results here suggest that the alteration in GSH/GSSG ratio 
observed during PD could be partially due to certain species of alpha-synuclein.  
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Figure 4.8: Glutathione assay of SH-SY5Y cells treated for 2 hours with 10% (v/v) vehicle 
control, positive control (menadione) or Type C oligomers. Concentration of GSH shown 
in (a) and GSSG shown in (b). Ratio of GHS/GSSG (normalised to the vehicle control) 
shown in (c). Statistical significance determined by Kruskall-Wallis test * = P < 0.05. 
 
4.4.4.3 Treatment of SH-SY5Y cells with Type C oligomers results in an altered 
monosome/polysome ratio 
Polysome profiling was used as a third method of investigating cellular stress. 
Eukaryotic cells are able to adapt to environmental changes by modulating the 
expression of specific gene products. The expression of protein-coding genes can be 
regulated by many processes at both the transcriptional and post-transcriptional level. 
Precise regulation of mRNA translation is fundamental for cellular homeostasis, 
particularly for cellular processes which require rapid changes in protein expression 
patterns, such as in response to conditions of physiological and environmental stress. 
Regulation of mRNA translation can alter cellular phenotype, with a decrease in the 
rate of translation causing a predominant loss of short lived proteins, which can affect 
important cellular processes (Johannes et al., 1999). Specific changes in protein 
expression can also occur as cells are able to alter their pool of efficiently translated 
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mRNA in response to stress conditions (Rajasekhar et al., 2003; Thomas and Johannes, 
2007). mRNA translation is a complex process which can be divided into three major 
phases: initiation, elongation and termination. While all phases are highly regulated it 
is the initiation phase which is most controlled, and therefore thought to be the major 
rate limiting step of protein synthesis (Jackson, Hellen and Pestova, 2010). The analysis 
of polysomes - mRNA molecules attached to multiple ribosomes - has been used as an 
approach to analyse the efficiency of translation initiation. Polysome profiling allows 
the determination of translational efficiency of both the whole transcriptome and 
individual mRNAs. It provides information on the transcriptional status of mRNA 
depending on the number of ribosomes that it is associated with. mRNAs associated 
with no or few ribosomes are thought to be translated poorly while those associated 
with many are believed to be actively translated. Under conditions of cellular stress, 
where translation is inhibited, a reduction in polysomes is seen along with an increase 
of 80S monosomes. Thereby the ratio of polysomes to monosomes from a polysome 
profiling experiment can be used as a measure of translational activity, as the 
integrated area under the curve is proportional to the amount of ribosomal RNA, and 
therefore the number of ribosomes.  
SH-SY5Y cells were treated for 2 hours with vehicle control, positive control or Type C 
oligomers, followed by the addition of cyclohexamide to freeze translating ribosomes 
to their mRNA, permitting the measurement of polysomes. Cells were then lysed and 
the RNA separated on a sucrose gradient, allowing the production of a polysome trace 
for each condition. Figure 4.9 displays the results from these experiments, with 
representative polysome traces following each treatment shown in (a) and the 
polysome/monosome ratio shown in (b). It was found that following treatment with 
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both the positive control and Type C oligomers there was a reduction in polysome to 
monosome ratio, indicative of translational stress. Therefore Type C oligomer 
treatment appears to have a major effect on global mRNA translation, providing 
further evidence that these oligomers are causing a stress response in the cells. 
Combined results from these three assays provide strong evidence that treatment of 
SH-SY5Y cells with Type C alpha-synuclein oligomers evokes a stress response from the 
cells.  
 
 
Figure 4.9: Polysome profiling of SH-SY5Y cells treated for 2 hours with 10% (v/v) 
vehicle control, positive control (menadione) or Type C oligomers. Representative 
polysome traces for each condition shown in (a) and calculated polysome/monosome 
ratio shown in (b). Statistical significance determined by Kruskall-Wallis test * = P < 
0.05.  
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4.5 Conclusions and future work 
Results presented in this chapter demonstrate that N-terminal acetylation of alpha-
synuclein does not affect the function of Type A or Type C oligomers, suggesting that 
either N-terminal acetylation of the protein does not affect its oligomerisation, or that 
the N-terminal region is not critical in self-assembly. This is in contrast to the recent 
report of Bu et al. (2017) showing a significant decrease in oligomerisation of the N-
terminally acetylated protein, thought to result from preventing the formation of 
intermolecular hydrogen bonds. One possible explanation for this difference could be 
that the Type A and Type C oligomers investigated in this study may exert their cellular 
effects on different timescales. The Bu et al. (2017) study demonstrated a reduction in 
the rate of oligomer assembly in the acetylated protein, however in this thesis an 
overnight incubation was used for the preparation of Type C oligomers which was 
presumably long enough to allow oligomers formed from both types of the protein to 
reach their endpoint by the time of analysis. In addition, the technique used to 
monitor aggregation in the study of Bu et al. was limited to the detection of small 
oligomers of less than 8 nm. An alternate explanation of the conflicting results found in 
work presented in this chapter is that the biologically active oligomers investigated 
here are larger than can be detected by the method of Bu et al.. Indeed, in the original 
study by Danzer et al. characterising Type A and Type C oligomers, through using AFM 
Type A oligomer preparations were found to contain structures between 2 and 45 nm 
in size, while Type C preparations were between 4 and 10 nm. 
 Results presented here are the first to our knowledge validating the cellular effects of 
Type A and Type C oligomers characterized by Danzer et al. (2007) when produced 
from N-terminally acetylated alpha-synuclein. Findings that acetylation did not appear 
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to perturb the function of these oligomers implies that oligomers made from 
endogenous protein have the potential to induce the same cellular effects as those 
applied externally. Although N-terminal acetylation was not found to affect the 
function of the two oligomeric species investigated here, it would be advisable to use 
the acetylated form of the recombinant protein for future in vitro experiments 
because, as shown by data presented in Chapter 1. In addition, N-terminal acetylation 
of alpha-synuclein does have the potential to modulate the kinetics if not the final 
structure of protein assemblies.  
The response of SH-SY5Y cells to treatment with Type C oligomers was also further 
investigated in this chapter, leading to novel results. It has previously been shown that 
the seeding effect of Type C oligomers occurs in a time dependent manner, and that 
the aggregates are comprised of both exogenous and endogenous alpha-synuclein 
(Danzer et al., 2009). SH-SY5Y cells overexpressing alpha-synuclein have also been 
shown to secrete alpha-synuclein oligomers into the media, both free and in exosomes 
(Danzer et al., 2012). However, the release of alpha-synuclein from cells treated with 
Type C oligomers has not previously been reported, nor has the release of ps129 
alpha-synuclein from these treated cells which indicates that the released material has 
been processed by the cell. Due to the addition of Triton to conditioned media before 
dot blot analysis it is possible that the alpha-synuclein detected in our experiments 
exists freely in the media or in a membrane bound vesicle such as an exosome. It 
would be of interest to clarify this point, which could be achieved by using differential 
ultracentrifugation to separate vesicles from the conditioned media alongside the 
detection of exosomal markers. This would provide additional information on the 
mechanisms by which alpha-synuclein is being secreted within this model, and 
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establish whether unmodified and phosphorylated alpha-synuclein are being secreted 
via the same mechanisms. It would also be worthwhile to confirm whether the 
secreted protein is exogenous or endogenous protein, or a mixture of both. This could 
be achieved for example by using 15N labelled protein when creating the Type C 
oligomers and then analysing the conditioned media using LC-MS. Using this technique 
could also be useful to validate the results presented in Figure 4.5 (b) and Figure 4.6 
giving a fully quantitative output, as opposed to the more qualitative analysis by 
ImageJ and dot blot analysis.  
Alpha-synuclein is known to aggregate under stress conditions and age is the number 
one risk factor for PD. In addition to the presumed decades needed for misfolded 
proteins to reach a critical threshold to induce neuronal damage, age associated 
impairment of mitochondrial function and subsequent increase in ROS are thought to 
be key factors in age related neurodegenerative disorders (Schapira, 2008; Greaves et 
al., 2012). Intracellular generation of free radicals has been shown to induce alpha-
synuclein aggregation, as has exposure of cells in culture to H2O2 and ferrous iron, 
MPP+, NO and superoxide (Ostrerova-Golts et al., 2000; Kakimura et al., 2001; Paxinou 
et al., 2001). The overexpression of alpha-synuclein is also known to increase 
intracellular ROS (Junn and Mouradian, 2002) and cause structural and functional 
alterations to mitochondria (Ingelsson, 2016). Additionally, it has recently been 
described that treatment of iPSC-derived neurons with an oligomeric species first 
described by Hoyer et al. (2002) induced OS through interactions with metal ions (Deas 
et al., 2016). However the oligomers used in this study were assembled through a very 
different method to the Type C oligomers investigated here and, importantly, are not 
known to be associated with intracellular seeding of endogenous alpha-synuclein. 
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Phosphorylation of alpha-synuclein is known to be increased in conditions of stress 
and ps129 alpha-synuclein was detected here in conditioned media from Type C 
treated cells. In addition OS was observed by fluorescence and luminescence based 
assays, and polysome analysis shows a characteristic stress response.  Results 
presented in this chapter therefore provide strong evidence that treatment of SH-SY5Y 
cells with Type C oligomers leads to an increase in OS.  
An interesting extension of work presented here is in relation to the polysome profiling 
experiment shown in Figure 4.9. As mentioned previously, specific changes in protein 
expression can occur in response to different conditions as cells are able to alter their 
pool of efficiently translated mRNA (Rajasekhar et al., 2003; Thomas and Johannes, 
2007). Results presented here demonstrate that, following treatment of SH-SY5Y cells 
with Type C oligomers, a global reduction in mRNA translation occurs. Through 
analysing the mRNA present in the monosome and polysome peaks, the specific 
expression of individual proteins in response to treatment could be investigated to 
determine whether they are up regulated or down regulated under these conditions. 
RT-PCR or northern blot polysome analysis could be used for the targeted analysis of 
specific mRNAs. Alternately, global translational changes occurring following treatment 
with Type C oligomers could be analysed by identifying the translational status of 
polysomal mRNAs through microarray or deep-sequencing analysis, giving a genome-
wide perspective of the mRNA pool being translated following treatment.  
This chapter provides further knowledge of the mechanism of action of Type C 
oligomers, and provides a potential explanation of OS being involved in the ability of 
these oligomers to induce aggregation. While it has previously been hypothesised that 
these oligomers cause intracellular alpha-synuclein aggregation through a self-
 187 
propagation prion-like mechanism, results presented here raise the possibility of OS as 
an additional explanation of the increased aggregation of alpha-synuclein following 
treatment. The concept of alpha-synuclein acting in a prion-like manner is not without 
controversy. One main point of contention is that not all post-mortem analyses of PD 
cases display the typical spread of LB pathology described by the Braak staging scheme 
(Burke, Dauer and Vonsattel, 2008; Brundin and Melki, 2017). Results presented here 
provide evidence that rather than certain oligomeric species of alpha-synuclein directly 
self-propagating aggregation of endogenous protein, OS is playing an important role in 
this process.  
While the cells in our experiments do not display reduced viability in response to Type 
C oligomer treatment, it is important to take into account the treatment time tested 
and, more importantly, the nature of these cells. PD develops gradually over many 
decades, with the cells lost to the disease being post-mitotic neurons. While the SH-
SY5Y cells used in this chapter seem to be able to cope with the OS induced by Type C 
oligomers (on the time scale tested here), the experiments in this chapter were 
conducted on undifferentiated SH-SY5Y cells. These cells are commonly used in PD 
research however, as with all in vitro models, using these cells has disadvantages. One 
of the main disadvantages is that they are an actively dividing cancer cell line. Many 
lines of evidence suggest that a build-up of aberrant proteins in neurons contributes to 
PD, and metabolically active dividing cells are not likely to share this characteristic 
build up over time. Whether oligomer treatment would prove toxic to post-mitotic 
neurons which are potentially already vulnerable to stress due to age, the build-up of 
environmental toxins or genetic alterations which cause vulnerability to PD is open to 
investigation. This highlights the importance of future work being conducted on more 
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representative cell culture models. One possibility would be the use of iPSC derived 
neurons is an exciting, though more technically and financially challenging, alternative. 
Deriving neurons from the somatic cells of patients would provide an excellent 
opportunity to investigate the effect of the oligomeric species investigated here in one 
of the most relevant cell culture models currently available. The use of iPSC models 
also importantly allows the investigation of disease progression, from early progenitor 
cells to aged neurons (McKinney, 2017).  
In conclusion, results presented in this chapter have firstly validated the cellular effects 
of the Type A and Type C alpha-synuclein oligomers first characterised by Danzer et al. 
(2007) when prepared from the N-terminally acetylated protein. To the best of the 
author's knowledge these are the first investigations into these oligomeric species 
using the modified form of the protein which is found in vivo. The effect of Type C 
oligomers on SH-SY5Y cells was then further investigated, with data suggesting that 
this treatment results in an OS response from the cells and subsequent secretion of 
phosphorylated alpha-synuclein into the culture medium. This work provides new 
knowledge on cellular response to exogenously applied alpha-synuclein oligomers and 
raises new avenues of investigation, for example by furthering the polysome profiling 
experiments conducted here to take an untargeted approach to determining the 
translational response of cells to such treatments.  
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Chapter 5 - General discussion 
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PD remains a debilitating disorder with no disease-altering treatments currently 
available. The lack of such treatments is due in part to incomplete knowledge of the 
molecular mechanisms involved in the disease. Alpha-synuclein has been irrefutably 
linked to PD through genetic and pathological evidence, with data pointing towards 
oligomeric forms as the toxic species (for a review see Bengoa-Vergniory et al. 2017). 
As such, increasing knowledge of both the normal cellular function of the protein and 
its potentially pathogenic forms could conceivably enhance preclinical therapeutic 
development for PD.  
The overall aim of this thesis was to investigate the structural and functional aspects of 
alpha-synuclein and its oligomers. Chapter 2 presents data from investigations into the 
copper binding and subsequent alterations to conformation and aggregation 
propensity of alpha-synuclein. Specifically, the effects of a familial PD mutation and a 
physiologically relevant modification on these factors were characterised, with the 
importance of N-terminal acetylation in metal binding being determined. Chapter 3 
investigated the aggregation of alpha-synuclein, both into specific oligomers of known 
function and into amyloid fibrils. The focus of this section of work was on the various 
oligomeric species present in solutions of alpha-synuclein at different stages of 
aggregation, and the dynamics of these species. Data demonstrated that N-terminal 
acetylation has little effect on oligomer assembly and final structural state. Chapter 4 
set out to further characterise the effect of alpha-synuclein oligomers with the ability 
to seed intracellular aggregation on an SH-SY5Y cell culture model. A summary of key 
findings from this body of work is provided below. 
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5.1 H50Q mutation of N-terminally acetylated alpha-synuclein 
results in a loss of the proteins ability to bind to copper. 
Investigations of alpha-synuclein containing familial PD causing mutations have been 
intensely studied, as alterations in the structure or function of these mutants may 
provide insights into how this protein is associated with the disease (for a review see 
Sahay, Ghosh and Maji, 2017). However, a large body of this work was conducted 
before the realisation that alpha-synuclein is constitutively acetylated in vivo 
(Anderson et al., 2006). Therefore, the effects of PD associated mutations on the 
physiologically relevant N-terminally acetylated form of alpha-synuclein are not well 
characterised. In Chapter 2 the effect of the familial H50Q mutation on N-terminally 
acetylated alpha-synuclein's copper binding and subsequent conformation and 
aggregation propensity were investigated. This previously unstudied form of the 
protein was found to have drastically impaired copper binding (Mason et al., 2016), a 
finding of potential significance as it has been suggested that alpha-synuclein's ability 
to bind copper is important for its proposed physiological function as a ferrireductase 
(Davies, Moualla and Brown, 2011). Results presented here imply that the H50Q 
mutation may leave alpha-synuclein impaired in its ability to act as a ferrireductase. 
Therefore, it would be of great interest to assess the ability of N-terminally acetylated 
H50Q alpha-synuclein to act as a ferrireductase, and if alterations were found, assess 
resulting metal homeostasis and ROS levels.  
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5.2 N-terminal acetylation of alpha-synuclein was found to not 
alter the formation of oligomeric species or their function. 
Characterising prefibrillar oligomers is key to understanding the aberrant aggregation 
of misfolding proteins, with the potential to support the design of therapeutics for 
protein misfolding diseases. MS methods were applied to investigate the species and 
dynamics of alpha-synuclein that arise during the early stages of its aggregation. 
Data presented in Chapter 3 demonstrated that N-terminal acetylation does not alter 
the oligomeric alpha-synuclein species detectable by ESI-IMS-MS. In samples of protein 
prior to aggregation a range of dimers, trimers and tetramers were detected. In 
samples of MS compatible Type C oligomers (a specific form of the protein known to 
inducing intracellular alpha-synuclein aggregation), pentamers and hexamers were 
additionally observed. These oligomeric species were detected in preparations made 
from both unmodified and N-terminally acetylated protein. These results indicated 
that this post translational modification has little effect on the final structure of type-C 
oligomers. However, N-terminal acetylation does alter the rate of aggregation, as 
demonstrated in Chapter 2. The data presented here highlights the importance of 
using disease relevant versions of key proteins when investigating mechanistic actions. 
In Chapter 4 the effect of N-terminal acetylation on oligomeric species of known 
cellular function was investigated. Two species were investigated: 'Type A' oligomers, 
known to decrease cell viability and 'Type C' oligomers, known to induce intracellular 
aggregation of alpha-synuclein (Danzer et al., 2007). Results demonstrated that N-
terminal acetylation did not affect the cellular function of Type A or Type C oligomers. 
This constitutes, to the best of the author's knowledge, the first study validating the 
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cellular effects of the Type A and Type C oligomers characterized by Danzer et al. 
(2007) when produced from the physiologically relevant, N-terminally acetylated form 
of alpha-synuclein.  
5.3 Treatment of SH-SY5Y cells with Type C alpha-synuclein 
oligomers inducing a stress response.  
Type C oligomers of alpha-synuclein are known to induce intracellular aggregation of 
endogenous protein and it has been proposed that this represents a 'seeding 
mechanism', providing evidence towards the hypothesis of alpha-synuclein pathology 
propagating from cell-to-cell in a prion-like manner (Danzer et al., 2009). In Chapter 4 
the response of SH-SY5Y cells to treatment with Type C oligomers was further 
investigated. The data provides strong evidence that this treatment results in a stress 
response from these cells, with an increase in ROS, a decrease in GSH:GSSG ratio and a 
reduction in global translation being detected. As an increase in OS has been well 
documented to increase intracellular aggregation of alpha-synuclein (Scudamore and 
Ciossek, 2018), these results imply that OS may have a role in the apparent seeding 
effect of Type C oligomers. It has recently been described that treatment of iPSC-
derived neurons with an oligomeric species of alpha-synuclein induced OS in the cells 
(Deas et al., 2016), setting a precedent for the results found in this chapter. However, 
the oligomers used by Deas et al., unlike the Type C oligomers investigated here, are 
not known to be associated with seeding intracellular aggregation of endogenous 
alpha-synuclein. Results presented in this thesis provide evidence that treatment of 
SH-SY5Y cells with Type C oligomers evokes a stress response and this may well be the 
trigger for further aggregation of the protein. This furthers knowledge of the 
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mechanism of action of these oligomers and, importantly, provides an alternate 
explanation of their ability to 'seed' aggregation. The data also offer a potential target 
for further therapy through decreasing the protein's ability to transfer pathology by 
damping its redox abilities. It is however important to note that the work in Chapter 4 
details the response of a neuroblastoma cell line to treatment with Type C alpha-
synuclein oligomers. Whether a similar response would be seen in the dopaminergic 
neurons of the SNpc affected in PD cannot be inferred from the experiments 
conducted here. To extend this work, it would be important to determine whether a 
stress response to Type C oligomer treatment is seen in either a more biologically 
relevant in vitro model or an in vivo model of PD.    
5.4 Concluding remarks 
It has been 200 years since Dr James Parkinson published 'An Essay on the Shaking 
Palsy', describing for the first time the signs and symptoms of PD. Despite the 
development of many treatment options to ameliorate PD symptoms, there are 
currently no disease-modifying treatments to slow down or reverse disease 
progression. Irrefutable evidence points to alpha-synuclein as a key contributor to the 
neurodegeneration seen in PD and, as such, much research is being carried out on this 
protein. Areas of interest include the use of alpha-synuclein as a biomarker of PD 
(Paciotti et al., 2018), the use of immunotherapy to reduce levels of the protein 
(Weihofen et al., 2018) and the use of small molecules to stabilise non-toxic forms of 
the protein (Price et al., 2018). Whether the findings of this research will translate to 
clinical use remains to be seen. What is clear however is that increased understanding 
of the alpha-synuclein protein is of great importance to enable the development of 
new candidate PD therapies which target this protein.    
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Together, data presented in this thesis have contributed novel findings and furthered 
knowledge in the field of alpha-synuclein research. Results have highlighted the 
importance of using the biologically relevant form of a protein when performing in 
vitro experiments, identified a loss of copper binding function resulting from the H50Q 
familial mutation, validated the cellular effects of previously characterised alpha-
synuclein oligomers when produced from N-terminally acetylated protein and 
extended knowledge of the cellular response of the SH-SY5Y cell line to treatment with 
Type C oligomers. In addition, the PhD project has raised new avenues for future study, 
which have the potential to extend knowledge of alpha-synuclein's role in PD.  
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Appendix Figure 1: Typical column chromatography UV chromatograms and SDS-
PAGE analysis of alpha-synuclein purification  
SDS-PAGE was performed at each stage of the protein purification process. (a) Shows 
the chromatogram obtained from running crude lysate through a 50 mL Q-Sepharose 
anion exchange column and (b) shows corresponding SDS-PAGE of protein containing 
eluted fractions. Fractions containing overexpressed alpha-synuclein are present in 
lanes 6 - 16. The band corresponding to alpha-synuclein has a molecular weight 
between the markers at 17 and 22 kDa, consistent with previous reports of this protein 
running on SDS-PAGE at slightly larger than its true size of 14 kDa (Moussa et al, 2004). 
Lanes 2 - 4 represent samples from the crude purification process prior to anion 
exchange, with the lysate immediately upon lysis in lane 2, the lysate after an initial 
centrifugation in lane 3 and the lysate following acid precipitation and centrifugation in 
lane 4.  (c) Shows the chromatogram obtained from running pooled anion exchange 
fractions containing alpha-synuclein through a HiLoad® 26/600 SuperdexTM 200 size 
exclusion column size exclusion column and (d) shows corresponding SDS-PAGE of 
alpha-synuclein containing eluted fractions. Here the band corresponding to 
overexpressed alpha-synuclein is seen in lanes 2-11 with no other visible contaminant.
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Appendix Figure 2: Arrival time distribution and Gaussian fitting of each charge state 
distribution of all alpha-synuclein species studied in Chapter 2.  
Experimental collisional cross sections of all charge state of unmodified and acetylated 
WT and H50Q alpha-synuclein. Apo and Cu2+ bound forms resulting from mixing a 50 
mM aqueous ammonium acetate solution of 10 µM alpha-synuclein with 10µM CuCl2. 
The percentages of alternate populations of differing CCS were calculated using 
Gaussian fitting. The raw ATD is displayed in pink and the sum of the fitted Gaussians is 
shown as a black broken line. The area under the curve of each Gaussian was used to 
calculate the percentage of protein in each conformational family under different 
conditions, presented in the main text in Figure 2.10, Figure 2.14 and Figure 2.17. 
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Appendix Figure 3: Immunocytochemistry images of SH-SY5Y control experiments for 
the data presented in Figures 4.4 and 4.5 
Representative ICC images at 100x magnification of nuclear DAPI staining in blue and 
alpha-synuclein in red (scale bar = 20 µm). Untreated control represents cells without 
the addition of any treatment, stained with both primary and secondary antibodies. 
Secondary only control represents cells treated with 10% (v/v) Type C oligomers for 16 
hours, stained with the emission of the primary antibody. The lack of fluorescence 
compared to the images of treated cells stained with both antibodies demonstrates 
the specificity of the secondary antibody for the primary antibody. Monomer treated 
control represents cells treated for 16 hours with 10% (v/v) 98 μM alpha-synuclein 
monomer, demonstrating that the alterations in alpha-synuclein staining seen 
following Type C oligomer treatment is not a general response to all conformations of 
the protein.  
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Appendix Figure 4: Nonlinear transform plot displaying amount of Menadione 
required to reduce SH-SY5Y cell activity by 50% (IC50) following 2 hour treatment.  
IC50 was calculated to aid in the selection of a concentration of Menadione to use as a 
positive control in stress experiments, the results of which as shown in Figures 4.7, 4.8 
and 4.9. Based on the IC50 value of 17.54 μM found here, a Menadione concentration 
of 10 μM was used in these experiments. 
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Appendix Figure 5: Total and oxidised glutathione calibration curves.  
A calibration curve of total and oxidised glutathione was produced using the 
GSH/GSSG-GloTM Assay following manufacturer guidelines to enable the calculation of 
glutathione concentration in SH-SY5Y cells following treatment as displayed in Figure 
4.8. 
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